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 “Why do individuals respond differently to infection 
with the same pathogen?” “Why is the response to 
vaccination with the same vaccine so different per person?” 
“Why do patients react differently to the same treatment?” 
Possible explanations for these differences are variable 
environmental factors, differences in immune status, 
or pathogen variation. Another likely answer to these 
questions is the topic of this thesis: 
“individuals are different” and in particular: 
“they carry different genetic factors”. 
In this thesis we examine these genetic differences 
to learn more about pertussis.
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 1.1 Introduction 
Whooping cough is a highly contagious infectious disease caused by the 
airway pathogen Bordetella pertussis. Since the introduction of the vaccine 
against pertussis in the 50’s, morbidity and mortality have decreased 
drastically but the incidence has increased during the last decennia in most 
countries, including the Netherlands(20,21). In spite of world wide 
vaccination against pertussis, whooping cough is still endemic in most 
countries, causing 297,000 deaths annually(62). Especially young non-
vaccinated children are at risk for major symptoms such cyanosis or even 
fatalities (62).  
 
1.1.1 Symptoms 
After a 7-10 days incubation period, the first characteristics of the disease 
manifest themselves by symptoms like a common cold, malaise, low grade 
fever and progressive cough. This first stage (catarrhal phase) lasts 1 to 2 
weeks and is followed by the paroxysmal phase, characterized by the typical 
‘whooping’ paroxysms often with cyanosis and vomiting. The paroxysmal 
phase begins gradually with prolonged and paroxysmal coughing that often 
ends in a characteristic inspiratory gasp (whoop). After 2-4 weeks the final 
convalescent period dawns, typified by diminished frequency and duration of 
the coughing periods (17,45,59).  
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Figure 1: The number of reported cases (legal notifications) of Pertussis in the 
Netherlands (19). 
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1.1.2 Incidence 
Despite high vaccination coverage pertussis is still endemic in The 
Netherlands with epidemic peaks every 2 to 3 years during the last decade. 
Since 1996 a large increase in the number of notifications, positive cultures, 
positive serologic diagnoses, and hospital admissions was observed (20,21). 
The incidence of pertussis rose suddenly from 1996 onwards to reach 58,3 
reported cases per 100 000 population in 2004, compared with 2.3/100 000 
on average from 1989 to 1995 (52,53). Also in several other European 
countries, as well as Canada, The United States and Australia, a re-
emergence of pertussis has been observed as is illustrated in figure 1 
(18,19).   
Waning immunity, increased reporting, improved diagnosis, and adaptation 
of the bacterium have been proposed to explain this re-emergence. While 
pertussis is commonly known as a childhood disease, nowadays there has 
been an increase in the incidence of pertussis in adolescents and adults 
(3,59). 
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1.2  Bordetella pertussis 
The genus Bordetella encompasses nine known species which vary in the 
ability of infecting different hosts, and by the expression of different 
virulence factors (23,24). Besides B. pertussis only Bordetella parapertussis, 
Bordetella bronchiseptica and Bordetella holmesii have been associated with 
respiratory infections in humans and other mammals (30). The primary 
focus of this thesis is B. pertussis, and other Bordetellae are therefore left 
aside. 
 
1.2.1 The BvgAS system. 
B. pertussis can express a wide variety of virulence factors, controlled by the 
Bordetella virulence genes (Bvg) control system. This system consists of two 
components, a DNA-binding response regulator (BvgA) and a 
transmembrane sensor kinase (BvgS). The BvgAS system responds to 
environmental stimuli by controlling the expression of the virulence factors. 
B. pertussis can exist in three different phenotypes, Bvg+, Bvgi and Bvg- 
respectively. Bvg+ is the virulent stage of B. pertussis, in which several 
virulence factors are expressed by which the bacteria can colonize the 
respiratory tract of the host. The Bvg- is the a-virulent phase, known as the 
starvation mode. In this stage the majority of the virulence factors are 
down-regulated, whereas other genes (e.g. motility genes) are up-
regulated.  
 The Bvg intermediate phase (Bvgi) is hypothesized to be important for 
respiratory transmission and is characterized by the expression of a subset 
of Bvg+ phase-specific factors (30,45,46). The different virulence factors will 
be addressed in the next paragraph.  
 
 
1.2.2 Virulence factors 
B. pertussis expresses various virulence factors (Figure 2) with different 
functions to facilitate infection and to induce pathology of the host. The most 
important virulence factors are summarized below.  
The exotoxin Pertussis toxin (PT) is the primary component of acellular 
pertussis vaccines (ACV). PT is a member of the A-B (A, active domain; B, 
binding) bacterial toxin superfamily and consists of five different subunits 
(S1 to S5) with different functions. The S1 protein is the A subunit which has 
ADP ribosyltransferase activity. Together, the subunits S2-S5 constitute the 
B subunit which facilitates the attachment and entry of pertussis toxin into 
host cells (30,61).  
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Filamentous hemagglutinin (FHA) is a surface-associated and secreted 
protein required for tracheal colonization. FHA binds to galactose residues on 
a sulfated glycolipid called sulfatide which is very common on the surface of 
ciliated cells. FHA is highly immunogenic and one of the main components of 
acellular pertussis vaccines (ACV) (45,61).  
Figure 2: Virulence factors of Bordetella pertussis (Adapted from A.Weiss) 
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Fimbriae (FIM) are long filamentous polymeric proteins on the surface of the 
bacterium which have been proposed to mediate attachment of Bordetella to 
respiratory epithelium required for persistent tracheal colonization. FIM is 
one of the components of some ACV’s for its ability to induce protective 
immunity to infection (45,61). The surface protein Pertactin (PRN) belongs 
to a class of auto transporter proteins that undergo autoproteolytic 
processing. PRN has been shown to play a role in adhesion of the bacterium 
to monocytes. Antibodies against PRN have been shown to correlate with 
clinical protection against pertussis. PRN is one of the components of some 
ACVs (35).  
The endotoxin Lipopolysaccharide (LPS) is the main component of the outer 
leaflet of the outer membrane of B. pertussis. By activating Toll-like receptor 
4 (Tlr4) signaling pathway, LPS promotes the secretion of pro-inflammatory 
cytokines, such as  tumor necrosis factor in many cell types, but especially 
in macrophages. LPS is very reactogenic and pyrogenic, and is therefore 
unwanted in vaccines (30). 
 
1.2.3 Pathogenesis 
Pathogenesis of B. pertussis infection is characterized by colonization and 
proliferation of bacteria on the ciliated mucosal cells, resulting in damage of 
the respiratory epithelium, and an acute increase in the levels of 
inflammatory cytokines resulting in cellular infiltrate in the alveolar spaces 
(45,49,51).  
Circulating polymorphonuclear leukocytes (PMN’s) are rapidly recruited to 
the lungs to bind and ingest B. pertussis, subsequently killing the bacteria 
by a combination of reactive oxygen and granule components. Finally, the 
PMN’s undergo apoptosis (44). Toll-like receptor (TLR, §1.3.2) ligands such 
as bacterial lipopolysaccharide (LPS) are critical components for the 
recruitment and activation of PMN’s (43). Serum antibody–mediated 
clearance of B. pertussis also requires a TLR-induced early recruitment of 
PMN’s. However, in mice it was shown that pertussis toxin limits this rapid 
serum antibody–mediated clearance by inhibiting PMN recruitment (43) 
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Figure 3: Toll-like receptor 4 signalling.  
1.3  Immunity 
1.3.1 Innate and adaptive immunity 
The immune system can roughly be divided in two types, the innate and the 
adaptive immune system. The adaptive or acquired immune system evolves 
during the multiple infections in life, and develops epitope-specific antibodies 
and the B- and T-cell memory systems. The innate immune system (or first-
line defense) responds more quickly compared to the adaptive immune 
response, but does not develop a memory response as the adaptive 
response does. The innate immune system responds to pathogens in stead 
of specific epitopes. These pathogens are recognized by receptors with a 
broad specificity that can recognize pathogen-associated molecular patterns 
(PAMS).  The major class of receptors that recognizes these PAMPS are Toll-
like receptors. 
 
1.3.2 Toll-like receptors 
There are different Toll-like receptors (TLR), with an identical intracellular 
domain known as Toll/IL-1R (TIR) domain (47,48). The TLRs differ especially 
in their ligand specificity:  Lipoprotein is recognized by TLR1 or TLR6, 
Peptidoglycan is the agonist for TLR2, Flagellin are recognized by TLR5, 
Imidazoquinolines (anti-viral compounds) can activate TLR7, TLR9 
recognizes CpG DNA,  dsRNA is the ligand for TLR3 and Lipopolysaccharide 
(LPS) is recognized by TLR4 (1). 
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1.3.3 Toll-like receptor 4 
Toll-like receptor 4 (TLR4) was the first TLR to be described and was 
originally designated human Toll (47,48). It was shown that TLR4 directly 
influences innate immunity by studies in Tlr4 defective mice (12,50). 
The innate receptor for LPS is situated on the outer membrane of antigen 
presenting cells and B-cells (Figure 3, macrophages, dendritic cells and 
natural killer cells). LPS binds to the LPS-binding protein (LPB) that 
circulates in blood. This complex binds to the co receptor of Tlr4, cluster of 
differentiation 14 (CD14). When this complex binds to the MD2-Tlr4 
complex, Tlr4 is activated, triggering a down-stream signaling (29,32,39).  
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1.4  Vaccination 
The reasons to vaccinate against pertussis are prevention of the disease 
(especially children younger than 1 year of age are at risk for developing 
major symptoms such cyanosis or even fatalities), prevention of infection of 
idividuals and decreasing the number of carriers to prevent the spreading of 
bacteria. 
Since the introduction of the whole cell pertussis vaccination in the 
Netherlands, mortality reduced drastically. Since January 1999 the primary 
vaccination for pertussis has been advanced and children are vaccinated at 
the age of 2, 3, 4 and 11 months, instead of 3, 4, 5 and 11 months from 
that time. Since the whole cell pertussis vaccines contain strong 
immunogens like Ptx and LPS, they are rather reactogenic, and several side-
effects were reported. During the last decades, the incidence of pertussis 
increased, the public opinion changed, and the Dutch government decided to 
switch from whole-cell pertussis vaccine (WCV) to acellular pertussis vaccine 
in 2005 (ACV) (34,62). 
 
1.4.1 WCV 
In 1952, whole cell pertussis vaccination was included in the Dutch 
vaccination program. Whole cell pertussis vaccine consists of heat-killed B. 
pertussis, and thus contains all epitopes of the bacterium, thereby inducing 
a broad immune response (34). Antigens are especially directed at the 
surface antigens PT, PRN, FIM. The serum titers of PT-IgG have been shown 
to correlate with protection against pertussis. Although LPS or endotoxin has 
adjuvant effects, also on other simultaneously administered vaccines (such 
as diphtheria), it can also induce strong side-effects (30).  
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1.4.2 ACV 
As a result of these side-effects, children in the Netherlands are vaccinated 
with accellar vaccines since 2005 (21). ACV contains purified proteins of B. 
pertussis, by which a stronger, but narrower immune response is induced 
(15,16). There are several ACV’s registered which differ in their composition 
of virulence factors, PT, FHA, PRN and FIM. The Dutch ACV comprises 3 
components, PT, FHA and PRN. ACV induces less side-effects (less 
reactogenic) compare to WCV while the vaccine efficacy (induced protective 
antibody-titers against the specific epitopes) is good. However, although the 
vaccination coverage in the Netherlands is very good (approximately 95%), 
pertussis is still endemic in the Netherlands. Several approaches to reduce 
disease incidence and severity have been suggested, one of them being the 
improvement of existing aP. 
 
1.4.3 Adjuvant   
To enhance the effectiveness of vaccination, the vaccines are complimented 
with immune-stimulating agents known as adjuvants. An adjuvant is an 
agent that stimulates the immune system without having any specific 
antigenic effects itself. Adjuvants are important for enhancing the primary 
response and for inducing long-term memory. The Dutch wP is adjuvated 
with aluminium phosphate, the aP is adjuvated with aluminium hydroxide. 
When the vaccine combined with the adjuvant is administered, one of the 
functions of the adjuvant is that a granuloma is formed (11,27), out of which 
the vaccine-antigens are slowly released. This results in a prolonged 
stimulus. The use of adjuvants also reduces the amount of purified antigen 
required for successful immunization, thus making vaccine production more 
economical and more feasible (26). The use of aluminum as adjuvant is 
associated with local reactions in young children (38).  
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1.5  Susceptibility to infectious diseases 
As described in the previous paragraphs, B. pertussis can express different 
virulence factors that have functions in establishing infection and disease. 
The success of infection also depends on different environmental factors, 
such as population density, as well as host factors such as immune status 
and host genetics.  The genetic variability of the host plays a role in 
processes such as adhesion, specific and non-specific immunity, antigen 
presentation, and inflammation. The susceptibility or resistance to infectious 
diseases can be exploited to gain knowledge of infectious diseases and 
improve their treatment and prevention (13,41,42).  
Generally, there are two approaches for the identification of host genetic 
factors that influence the course of an infectious disease: with or without a 
priori assumptions. In humans the identification of host genetic factors that 
play a role in complex diseases is difficult because of the small individual 
effects and the genetic heterogeneity of the population, therefore an 
approach without a priori assumptions is very difficult. Biological processes 
of health and disease are nowadays often characterized by the involvement 
of biological pathways. A ‘pathway’ is defined as the mutual coherence of 
factors (such as proteins, DNA) and the sequence of communication 
between these factors. Most studies in humans focus on a specific pathway 
and study the association between single nucleotide polymorphisms (SNPs) 
of specific genes within such a pathway and a phenotypic parameter (42). In 
contrast, the mouse offers significant advantages as a model to study the 
effects of host genetics on infectious diseases without a priori assumptions, 
but the path from susceptibility locus to susceptibility genes requires 
intensive study and many animals (10,54). Further, established 
susceptibility genes in mice, should be extrapolated to the human 
homologues. Only recently new techniques have been developed by which 
host genetics can be studied in man by whole genome analysis using an 
array-based SNP assay with up to one million SNP’s that are analyzed 
simultaneously. Excessive costs, multiple testing problems and the 
requirement of large cohorts are limiting factors at this moment, but these 
techniques will be more easily available in the near future (60).  
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1.5.1 Mouse models 
To define the numerous susceptibility genes that have small but cumulative 
effects on a specific phenotype, an appropriate approach is to first identify 
them in a mouse model, and subsequently to study the role of their human 
homologues in humans (25,54).  To map susceptibility genes in mice, 
several different strategies are available encompassing different mouse 
models as ´genetic tool´ to facilitate linkage studies (22).  Different mouse 
models have a similar approach: by series of crossings between different 
parental strains of mice (the so-called background strain and the so-called 
donor strain), an offspring is generated containing specific chromosomal 
regions from the donor strain across the donor genome. The genome is 
genotyped with microsatelite markers or single nucleotide markers to locate 
the donor regions across the background genome. Examples of different 
mouse models are congenic inbred strains (CIS), chromosome-substitution 
strains (CSS), genome tagged mice (GTM) or recombinant congenic mice 
(RCS).  
CIS are ´ordinary´ homozygous strains that are derived by series of 
crossings between two parental inbred strains (background strain and donor 
strain), with donor regions randomly spread across the background genome. 
CSS strains contain one chromosome from the donor strain, the remainder 
originates from the background strain (Figure 4a) (58). GTM can be 
considered as partial CSS. Each GTM line differs from the background strain 
only in a relatively short segment of one chromosome. Phenotypic 
differences between a GTM line and the background strain can be attributed 
to one or more genes on the differential segment of the chromosome (Figure 
4b). RCS are homozygous strains that are derived from two parental inbred 
strains. Each RC strain (in a usual set of 20 or more) is homozygous, and 
contains a randomly spread set of ~12.5% genes from strain S and 87.5% 
genes from strain C (Figure 4c) (22,54).  In this thesis CIS and RCS 
strategies were used for the identification of B. pertussis susceptibility loci in 
mice.  
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Figure 4: Tools to map 
Mouse susceptibility loci. 
 a | Chromosome 
substitution (consomic) 
strains. 
Each consomic strain 
contains one differential 
chromosome from the 
‘donor’ strain; the 
remainder 
originate from the 
‘background’ strain. 
Phenotypic differences 
between a consomic strain 
and 
the background strain can 
be attributed to one or 
more genes on the 
differential chromosome. 
b | Genome-tagged mice 
(GTM). Each GTM line 
differs from the background 
strain only in a 
relatively short segment of 
one chromosome. 
Phenotypic differences 
between a GTM line and 
the background strain can 
be attributed to one or 
more genes on the 
differential segment of the 
chromosome.  
c | Composition of 
recombinant congenic 
strains. Recombinant 
congenic (RC) strains are 
homozygous strains that 
are derived from two 
parental inbred strains. 
Each RC strain (in a 
usual set of 20 or more) is 
homozygous, and contains 
a random different set of 
~12.5% genes from the 
donor strain  and 87.5% 
genes 
from the background 
strain. Sex chromosomes 
are not shown in this 
example. 
Modified from Demant, 
2003(22) 
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To map individual susceptibility loci, mice are infected, and the relevant 
phenotypic parameter is determined (for instance colony forming units). 
Subsequently the mice are genotyped at marker loci (microsatellites or single 
nucleotide polymorphisms) that are polymorphic between the two parental 
strains. The correlation between the distribution of marker alleles and the 
susceptibility phenotype(s) allows susceptibility loci to be mapped to 
chromosomal locations (2,22,28,57).  
 
1.5.2 Human studies 
There is substantial evidence that host genetic factors play a major role in 
determining the outcome of infection with many pathogens (36). Genetic control 
of susceptibility to infectious diseases provides new tools for prevention and 
control of these diseases. Whole genome-based genetic approaches have the 
major advantage that no a priori assumptions about mechanisms of 
pathogenesis need to be made in these studies, and thus previously 
unrecognized pathways of disease susceptibility can be detected (55).   
The classical approach for a human association study is the case-control study 
which is used to identify factors that may contribute to a medical condition by 
comparing the genotypes of a group of patients who have that condition with the 
genotypes of a group of control persons. For this approach, certain genetic 
variants of genes are selected a priori, usually from the disease pathway. This a 
priori selection is often called a hypothesis-based approach. The most frequently 
occurring form of genetic variation in the human genome is the single nucleotide 
polymorphism (SNP).  SNPs are chromosomal positions at which more than one 
nucleotide can occur when genomes of different individuals are compared and 
that are present by definition in 1% or more in the population (note: when this 
chromosomal nucleotide variation is present in less than 1% of the population, it 
is called ‘mutation’ by definition). Most SNPs are located in non-coding regions 
(with little evolutionary pressure) such as intronic regions (between exons), in 
the non-coding regions between genes, or in 5’ and 3’ regulatory regions. SNPs 
in coding region (exons) can cause an amino acid substitution, or, despite the 
change in codon, encode the same amino acid, resulting in an unchanged 
protein. Although the functional relevance of non-coding SNPs is limited or 
unknown, it could still be very useful for the identification of susceptibility alleles 
in association studies, acting as a marker through linkage to another causal 
variant (haplotype analysis) (56) .  
At this moment, array-based whole-genome genotyping assays are developed 
covering over one million SNPs to interrogate human genetic variation 
(33,37,40).  Such assays make whole-genome association studies more feasible 
and have good prospects for dissecting the genetics of common diseases. They 
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currently face a number of challenges, including problems with multiple testing 
and study design, definition of intermediate phenotypes and interaction between 
polymorphisms (14).  
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1.6  Aims and outline of this thesis 
The objective of this thesis is to acquire knowledge of genetic host factors that 
influence the pathogenesis of B. pertussis as well as host factors that influence 
the vaccination response against pertussis. By increasing these insights in host 
factors, new methods can be developed for treatment or prevention of whooping 
cough. Eventually, such insights may provide novel concepts in infectious 
disease control by extrapolation of the knowledge acquired for B. pertussis to 
other infectious diseases. This thesis can be divided in two parts, the first part 
describes the role of host genetic factors in the pathobiology of pertussis 
disease, and the second part focuses on the role of toll-like receptor 4 in the 
pathogenesis of, and the vaccination against pertussis.  
In Chapter 2 we describe the identification of three novel susceptibility loci in 
mice. We designate these loci Bordetella pertussis susceptibility loci-1, -2 and -
3. We identify these loci by using recombinant congenic strains of mice (7).  In 
Chapter 3 we describe the expression profiles of pertussis infected mice. In this 
chapter we demonstrate that the expression of 1,841 genes is significantly 
changed upon B. pertussis infection. These genes are involved in various 
immune-related processes, such as the acute-phase response, antigen 
presentation, cytokine production, inflammation, and apoptosis (5). Chapter 4 
describes differential gene expression between the C3H and HcB strains, the two 
strains of mice in which we identified the Bps-1 locus. By this approach, we 
narrow down the number of susceptibility genes within this locus(8).  
Toll-like receptor 4 is the receptor for lipopolysaccharide, one of the major 
components of the cell-membrane of B. pertussis. In Chapter 5 we demonstrate 
the significance of Tlr4 in genetic susceptibility and pathobiology of pertussis in 
mice. We show that functional Tlr4 is essential for an efficient (pro) 
inflammatory response; efficient clearance of bacteria from the lung; and 
reduced lung pathology. (9).  
The role of Tlr4 in vaccination response to Bordetella pertussis in a murine 
model is demonstrated in chapter 6 (6) and in chapter 7 we show that TLR4 also 
plays an important role in the vaccine-induced immunity in children (4). We 
show that a Toll-like receptor 4 polymorphism is associated with the response to 
whole-cell pertussis vaccination in children (4). Chapter 8 gives an application of 
the acquired knowledge of the role of Tlr4 in pertussis vaccination. Here we 
describe that LPS analogs improve acellular pertussis vaccine (31). 
Finally, in Chapter 9 the findings of the preceding chapters are summarized and 
discussed and future perspectives are presented.  
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Abstract 
Susceptibility to and severity of Bordetella pertussis infection in infants and 
children varies widely. The spectrum of clinical symptoms ranges from 
subclinical infection, mild disease, severe whooping cough, and death. The aims 
of this study were to examine genetic susceptibility in mice to B.pertussis,  and 
to identify genetic loci in the mouse genome that are involved in susceptibility to 
B.pertussis infection. To this purpose we screened two sets of recombinant 
congenic strains (RCS) of mice, HcB and CcS, for differences in the numbers of 
bacteria in the lung seven days after inoculation. In both CcS and in HcB mice, a 
wide range in numbers of bacteria in the lung was found, suggesting that the 
course of infection is under multigenic control. From both RCS sets of mice, we 
selected one strain to identify possible susceptibility loci in F2 hybrid mice. The 
degree of lung colonization seven days post-inoculation in these F2 mice was 
compared with genetic markers by linkage analysis. We found three novel loci 
that are involved in the control of B.pertussis infection. One locus, designated 
B.pertussis susceptibility locus 1 (Bps-1), was identified on chromosome 12. The 
presence of C57BL/10 genome on this locus in stead of C3H genome 
significantly decreased the number of B.pertussis bacteria in the lung. Bps-1 has 
a dominant positive effect on the clearance of B.pertussis from the lung.  The 
function of most genes in this region is unknown. Two other loci, Bps-2 and Bps-
3 showed genetic interaction and are located on chromosome 5 and 11.  We aim 
to identify the gene(s) in these regions which modify the susceptibility to 
B.pertussis. 
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Introduction 
Bordetella pertussis is a gram-negative bacterium that causes the respiratory 
disease known as whooping cough or pertussis. Worldwide, this bacterial agent 
causes some 20–40 million cases of pertussis and an estimated 300.000 deaths 
each year (35). 
The bacterium enters the airways via aerosol droplets and attaches to the 
epithelium of the upper respiratory tract.  After a 7-10 days incubation period 
the first symptoms of the disease, which are  similar to the common cold, may 
be observed. One to two weeks later more serious symptoms can occur, such as 
the typical 'whooping cough' (23). In spite of worldwide vaccination since the 
50's, the incidence of pertussis is increasing again (4). Several causes have 
been suggested for the resurgence of pertussis, including improved diagnostics 
and surveillance, waning immunity, and the emergence of escape variants 
(27,28). 
The clinical course of B.pertussis infection varies widely. Knowledge about host 
genetic and immunological factors that influence susceptibility and severity of 
the infection, may lead to the identification of new approaches for prevention or 
treatment of infectious diseases (14). Yet, knowledge about human genetic 
factors that influence B.pertussis infection is still very limited. A number of 
studies provides clues for the role of host genes in susceptibility to B.pertussis 
infection. The genetic make-up of mouse strains effected the immune response 
against B.pertussis (2,21,25).  This was also confirmed in studies using the 
respiratory B.pertussis infection model in knock-out mice, where numerous 
genes, such as CR3,CD32,CD32,FcR, IFN-, IL-4 and Ig, have been knocked-
out to establish their involvement in the pathogenesis of B.pertussis infection. 
(12,25). Recently a mutation in the Toll Like Receptor 4 (Tlr-4) was identified as 
a major factor that influences the course of B.pertussis infection in mice (13,22). 
In human cell lines, differences in expression between B.pertussis-treated and 
untreated cells have been found for a number of genes. Upregulated genes 
encoded cytokines, chemokines, anti-apoptotic factors, and Nuclear factor of  B 
(NF-B), whereas  downregulated genes encoded DNA-binding proteins and 
cellular adhesin molecules (3,30).  
In general, to identify unknown genes involved in the course of complex 
diseases, quantitative trait loci (QTL) mapping studies in humans or animals 
have been used (7). A QTL is a polymorphic locus which contains alleles that 
differentially affect the expression of a continuously distributed phenotypic trait. 
QTL mapping is a phenotype-driven approach to identify genes affecting a 
phenotype. As such it permits the discovery of new genes and contrasts with 
gene-driven approaches, such as knock-out mice, which allow the study of 
genes with known function (5,9). 
There are several ways to map a QTL. One approach, which reduces the genetic 
complexity of the mouse genome by ~90%, uses so called Recombinant 
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Congenic Strains (RCS) of mice (8). This approach also enables the identification 
of possible low-penetrance genes and their interactions (7,10,29). RCS are 
derived from two different inbred strains, the so called background and donor 
strain. After two backcrosses and intercrossing, a set of RCS is created, with 
each strain containing 12.5% of the donor genome differently distributed across 
the background genome (8). The approximate distribution of these chromosomal 
regions of the donor strain is called strain distribution pattern (SDP).  A more 
detailed description, including an example of such an SDP was provided by P. 
Demant and coworkers(11,31). 
The aims of this study were, first, to examine whether RCS of mice show genetic 
differences in susceptibility to B.pertussis, and, second, whether we could 
identify one or more genetic loci responsible for such differences. We used the 
number of bacteria in the lung one week after inoculation to define the 
phenotype, and microsatelite markers to define the genotype. Using this 
approach we identified a locus on chromosome 12, designated B.pertussis 
susceptibility locus 1 (Bps-1),  and 2 interacting loci on chromosome 5 and 11, 
designated Bps-2 and 3, which influence the number of bacteria in the lung one 
week after inoculation.  
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Materials and Methods 
Experimental design 
We examined the course of B.pertussis infection in twelve different CcS/Dem 
strains and twenty-one HcB/Dem strains. Approximately ten mice of each strain, 
i.e. 145 CcS and 170 HcB mice, were tested for the number of bacteria in the 
lung one week post-inoculation. Two F2 hybrid generations of mice generated 
from two different recombinant congenic strains, 211 (CcS4 x BALB/c) F2 mice 
and 230 (HcB28 x C3H) F2 mice, were subsequently phenotyped as described 
below.  
Due to logistical limitations we inoculated maximally 100 mice per day and 
combined the results. To test the reproducibility of the infection model, on 
several days the experimental groups  contained BALB/c control mice that were 
inoculated in the same way.   The original RCS mice were examined in four 
experiments, the F2 hybrid mice were examined in eight experiments. 
 
Animals.  
Only female mice were used for the infection experiments to increase the 
reproducibility. The RCS of mice were derived as described in previous 
publications (6,10). HcB/Dem (referred to as HcB) strains are derived from the 
mouse strains C3H/DISnA (referred to as C3H) as background and 
C57Black/10ScSnA (referred to as C57BL/10) as donor. The CcS/Dem (referred 
to as CcS) strains are derived form the mouse strains BALB/cHeJ (referred to as 
BALB/c) as background and STS/A (referred to as STS) as donor as described 
previously (6,10). 
232 Hcb28 F2 hybrid mice were generated by crossing HcB28 to C3H and 
subsequently intercrossing their F1 progeny. Similarly, 211 Ccs4 F2 hybrid mice 
were generated by crossing CcS4 and BALB/c mice and intercrossing their F1 
progeny. All mice were acclimatized at our animal testing facility for at least one 
week after transport before the start of the experiments. Mice received a 
standard laboratory chow (SRM-A, Hope Farms, Woerden, the Netherlands) and 
tap water ad libitum. All animal experiments were approved by the Institute’s 
Animal Ethics Committee. 
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Figure 1: Strain distribution pattern (SDP) of two 
Recombinant Congenic Strains (RCS). The CcS4 strain (above) 
was derived from the mouse strains BALB/c as background 
(displayed in grey) and STS as donor (displayed in black). The 
HcB28 (below) was derived by crossings between mouse strains 
C3H as background (displayed in grey) and C57BL/10 as donor 
(displayed in black). 
Ccs4/Dem
1 2 4 5 6 7 8 9 10
11 12 13 14 15 16 17 18 19 X
3
Background Strain: BALB/cHeA
Donor Strain (12.5%): STS/A
Hcb28/Dem
1 2 4 5 6 7 8 9 10
11 12 13 14 15 16 17 18 19 X
3
Background Strain: C3H/HeASn
Donor Strain (12.5%): C57Black/10ScSnA
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Infection experiments.  
In this study, we used the number of viable B.pertussis bacteria in the lung one 
week after inoculation to define the phenotype. This infection protocol was 
described previously(15,36). Briefly, female mice were intranasally inoculated 
with 2.107 colony forming units (CFU) of B.pertussis strain B213 after being 
anaesthetized with diethyl ether or enflurane. Seven days after inoculation, mice 
were sacrificed and the lungs were collected in Verwey medium(33). The lungs 
were homogenized in Verwey medium and diluted 10 and 1,000 times. The 
number of CFU in these dilutions was determined by plating on Bordet Genou 
agar substituted with 15% sheep blood and 30g/ml streptomycin. Plates were 
incubated for 3 days at 35°C  
 
Genotyping.  
Microsatelite markers that have been used to construct the strain distribution 
patterns (SDP) were also applied to define the genotypes of the F2 hybrid mice.  
A selection of these SDP’s is presented by Jackson Laboratories (24). A more 
detailed SDP for the HcB series of mice was recently obtained (Demant 
unpublished work). A schematic representation of SDP’s of the two RCS of mice 
used in this study is presented in Figure 1. In a F2 generation constructed of 
RCS, only markers present in regions in which the parental strain contains donor 
genome are informative.  
Genomic DNA was isolated from mice tails using the DNeasy Tissue kit (Qiagen). 
Strain CcS4 carries the genetic material of STS origin on 8 segments on 7 
chromosomes as described(11,31). For genotyping, we selected 17 microsatelite 
markers in these donor regions, D5Mit179, D6Mit109, D11Mit151, D11Mit51, 
D11Mit139, D11Mit28, D11Mit36, D11Mit122, D11Mit61, D11Mit49, D12Mit37, 
D15Mit121, D15Mit1, D15Mit3 and D15Mit37. Strain HcB28 carries the genetic 
material of C57BL/10 origin also on 8 segments on 7 chromosomes (11,11,31). 
We genotyped these segments using 13 microsatelite markers: D7Mit294, 
D7Mit350, D7Mit330, D8Rivm46, D9Mit260, D9Mit182, D9Mit82, D11Rivm263, 
D12Mit167, D12Mit263, D15Mit68, D15Mit107, D17Mit64. Six additional flanking 
markers were selected round a region of special interest:  3 microsatelite 
markers, D12Mit53, D12Mit133 and D12Rivm144, and 3 Single Nucleotide 
Polymorphism (SNP)-markers, S12Rivm101, S12Rivm102, and S12Rivm104. 
The sequences of all primers except the RIVM-markers (Table 1) were obtained 
from the mouse genome database of the Massachusetts Institute of Technology 
(MIT) (26). 
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DNA was amplified in a 10μl PCR-reaction using 5μl hotstar 5x Mastermix 
(Qiagen), 1.0μM of each primer and approximately 2mM tail-DNA. Amplification 
was performed on a GeneAmp PCR System 9700 (Applied Biosystems), 
according to the following scheme:  an initial 15 minutes at 95°C to denaturize 
the DNA and to activate the Hotstar Taq, followed by 30 cycles of 45 seconds at 
94°C for denaturizing, 45 seconds at 57°C for annealing, 1 minute at 70°C for 
elongation and finally 10 minutes at 72°C for elongation, PCR-products were 
stored until further use at 4°C. 6-Carboxyfluorescein (FAM)-labeled microsatelite 
primer-sets were used (Isogen Life science, Maarssen, the Netherlands) and 
fragment-sizes were determined on a 3700 Capillary DNA Sequencer/Genotyper 
system (Applied Biosystems) using Genotyper software (Applied Biosystems).  
The 3 SNP-markers were analyzed by Restriction Fragment Length 
Polymorphism (RFLP)-assay on a 2.5% agarose gel (Table 1). Reaction-
conditions were used according to the manufacturer’s instructions (New England 
Biolabs).  
 
Assaya Forward primer Reverse primer C3H C57Bl/10 Enzyme NCBI accessnr. 
D8Rivm46 CAGCCTGGGCTACATGAGA TCCTGAGGGAAAATCACACA 164 bpb 190 bp   
D11Rivm263 CATGCTAAGCAATGCAGCTC ACACACAGACCGAGTGACCA 269 bp 252 bp   
D12Rivm144 AGGGAGTCTGAGGCCATCTT TGCTTCCTTCAGGAACTATTTTT 229 bp 202 bp   
S12Rivm101 GCCATGGGGGAAGATAATTT CAGAGTGAGGATGGCAGAGG A G SfaN I rs3685115 
S12Rivm102 TGCAGTCGGAGAGAAGGTTT GCTGGTTCTTCGATCTCCAG C T Tsp45 I rs3697423 
S12Rivm104 GGTGAGAAGTTGGGGACTCA CCTCCCTTCCTGGATCTCTC C G Bpu10 I rs4229572 
  
Table 1:  Markers used for genotyping.  
a Top 3 markers are microsatelite-markers(MS), bottom 3 are SNP markers.  
b For MS-markers, fragment length was used as parameter to genotype the F2 back-cross 
generation.  
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Statistical analysis.  
The statistical differences in phenotypes (number of CFU in the lung) between 
the different RCS of mice were examined by Analysis of Variance (ANOVA, SPSS) 
and tested with the Student-Newman-Keuls test for multiple comparisons. To 
stabilize variances and to obtain approximately normal distributions, the colony 
forming units were square root (sqrt) transformed. For the F2 mice, linkage 
between the CFU in the lung and the genotypes, and their effect on the total 
phenotypic variation, were calculated by an ANOVA with genotypes as fixed 
factor, and CFU as dependent variable. To correct for the influence of 
experiment, experiment was included as random factor. All single markers and 
all pairs of non-linked markers were tested for linkage with a marker or 
interaction between markers. Interaction, or epistasis, is defined as the 
combined effect of two or more genes on a phenotype that could not have been 
predicted as the sum of their separate effects (10). Linkage is presented as p-
value and Log of the odds (LOD) score, which was calculated as –log of the 
significance (p-value).  
All markers and interactions were tested at the level of 0.05 (p<0.05). p-values 
were corrected for multiple comparisons using the formula:  
 
μ(T) = [C+2GT2]T (18,19) 
 
Where μ(T) is the desired corrected p-value, C is the number of chromosomes 
segregating in the cross (For Hcb28 and Ccs4 C=7, Figure 1),  is the crossover 
rate (1.5 for a F2 hybrid generation), G is the genome length of the segregating 
part of the donor genome in Morgans (12,5 % of the whole mouse genome of  
16M is 2). T2 is the threshold, the F-value from ANOVA for the observed p-value 
is used as T2 , T is the observed uncorrected p-value. 
The estimated effect of a linked locus on the total of the observed phenotypic 
variation was presented as R2. To test the reproducibility of the infection 
protocol, we performed a T-test between the CFU’s of the control-mice 
inoculated in different experiments. 
To test a normal distribution of genotypes per experiments, we used a 2-test. 
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Figure 2. CFU’s in 
the lungs of the CcS 
Recombinant 
Congenic Strains 
(RCS) (Top) and 
the HcB RCS 
(Bottom). Seven 
days after inoculation 
with B.pertussis lungs 
were removed, and 
the number of viable 
B.pertussis was 
determined. Bars 
indicate the group 
average of the 
number of bacteria in 
the lung (average of 
10 mice per group) 
Horizontal Lines 
connect groups of 
mice who are 
mutually not 
significantly different 
according to the 
Student Neuman 
Keuls test. From 
these strains Ccs4 
and HcB28 were 
selected for 
generating F2 hybrid 
generations. 
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Results  
Reproducibility of the infection model 
To test the reproducibility of the infection model, we performed several 
experiments with BALB/c mice. The number of bacteria in the lungs of the 
control mice, one week post-inoculation, was similar regardless of the day the 
experiment was performed (data not shown).  Because there was no significant 
difference between any of the control groups (p>0.05), we combined the results 
of all experiments.  
 
Differences between the congenic strains in B.pertussis infection of the 
lung. 
We tested twelve different CcS strains for the number of viable bacteria (CFU) in 
the lung one week post-inoculation. Both in CcS and in HcB mice a wide range in 
bacterial numbers was found. Results are shown in Figure 2. Significant 
differences in lung colonization were observed between the strains of mice. 
Horizontal lines connect groups of mice who are mutually not significantly 
different according to the Student Neuman Keuls test. The number of CFU varied 
from 1.6*106 to 9.0*106  CFU per lung (Figure 2).  From these strains we 
selected CcS4 as most representative strain for further breeding. 
Similar experiments were performed with twenty-one different HcB strains 
(Figure 2). The differences in lung colonization in Hcb mice were more 
pronounced compared to the CcS mice and ranged from 1.4*105 to 6.8*106 CFU 
per lung.  From these strains we selected HcB28 as most resistant strain (HcB29 
was not  a suitable strain for breeding). We also observed pathologic differences 
in the lungs, ranging from macroscopically healthy lungs to severe lung edema 
(data not shown).  
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8 Figure 3: CFU’s in the 
lungs of (CcS4 x 
BALB/c) F2 and 
(HcB28 x C57BL/10) 
F2 mice 7 days after 
infection with 
B.pertussis. Lungs were 
removed, and the 
number of viable 
B.pertussis was 
determined by counting 
CFU’s in the 
homogenized lungs. 
Approximately 200 mice 
per F2 strain were used. 
Each dot represents the 
number of CFU of 
individual mice. 
Identification of new susceptibility loci 
Based on the data presented above, we selected the CcS4 and HcB28 strain for 
subsequent F2 hybrid experiments to identify susceptibility loci. Both strains 
were used to generate an F2 hybrid generation of approximately 200 mice. F2 
mice were inoculated with B.pertussis and the number of CFU in the lung was 
determined after 7 days (Figure 3). The CFU per lung in the F2 hybrid 
generation from (CcS4 x BALB/c) ranged from 1.0*102 (detection limit) to 
1.8*107, and the average of this group was 3.7*106. The CFU’s per lung in the 
F2 hybrid generation from (Hcb28 x C3H) ranged from 1.0*102 to 3.4*106, and 
the average of this group was 5.0*105 CFU’s per lung.  All mice were individually 
genotyped, and we compared genotypes with phenotypes to identify possible 
QTL’s by linkage analysis.  
In the F2 mice,  generated by crossing HcB28 and C3H mice, we  found linkage  
between the number of CFU and a region on chromosome 12. In Figure 4 the 
LOD-diagram is shown for the telomere-region of this chromosome. We found 
maximum linkage between the number of CFU  
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Figure 4: Linkage (LOD-
score) between lung 
colonization by 
B.pertussis (phenotype) 
and donor chromosomal 
loci (genotype).  The 
association was calculated 
by ANOVA with genotypes 
as fixed factor, and sqrt CFU 
as dependent variable. The 
LOD score is plotted as -log 
p against the physical 
distance of chromosome 12. 
The region, designated as 
B.pertussis susceptibilty 
locus 1 (Bps-1), has a LOD-
score of 4,6 (p=0,0000251 , 
R2 = 0,09728) 
and the locus defined by S12Rivm102 (102.4Mb) with a LOD-score of 4.6. This 
LOD-score, and corresponding p-value (p=0.000025) is statistically significant, 
also after correction for multiple comparisons as described in the statistical 
section (p=0.0019). However this result does not withstand correction for 
experiment as random factor (p=0.36). Although the experimental conditions 
are highly reproducible and the distribution of genotypes per experiment 
appeared to be normal according to the 2-test (p=0.489),  the day of the 
experiment, has influence on the established linkage. We therefore consider 
these results suggestive linkage instead of significant linkage,  and they warrant 
further investigation. Almost 10  percent (9.7%) of the  variation in the number 
of bacteria in the experiments could be ascribed to the found locus (R2 = 0.097).  
We propose to call the locus B.pertussis susceptibility locus 1 (Bps-1). In table 2 
means of CFU’s in F2 mice are displayed per genotype. The mean differences are 
significantly different at the 0.05 level between C3H and heterozygotes, and 
between C3H and C57BL/10, but there is no significant difference between 
heterozygotes and C57BL/10. This indicates that the presence of C57BL/10 DNA 
has a dominant positive effect on the clearance of B.pertussis from the lung. 
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Table 3: Genetic interaction between D5Mit179 and D11Mit122a.  
a Means of CFU’s in F2 mice per genotype of two interacting markers. 
BALB/c Heterozygote STS
D5Mit179 BALB/c 3,98E+06 2,31E+06 2,28E+06
Heterozygote 2,95E+06 2,32E+06 3,36E+06
STS 1,35E+06 3,67E+06 2,22E+06
D11Mit122
a The association was calculated by ANOVA with genotype(s) as fixed factor and sqrt CFU as 
dependent variable. 
b The association was calculated as above but with experiment included as random factor. 
c p-value corrected for multiple comparisons according to Lander and Kruglyak (18) 
d LOD-score was presented as  –log (p) 
e Means of CFU’s in F2 mice per genotype.  
f Loci with highest linkage are presented in bold.  
g Individual markers showed no significant linkage,  but linkage was found between the number of 
CFU’s and the interacting markers D5Mit179 and D11Mit122. 
Table 2: Linkage between lung colonization by B.pertussis  and donor chromosomal loci. 
a
Marker Locus Strain
Chromosome (cM) p-value Corrected p LOD-score p-value Corrected p C3H Heterozygote C57Bl/10
D12Mit167 12 47,0 0,065865 1,549407 1,2 0,129824 2,673846 4,91E+05 3,08E+05 3,83E+05 Hcb28
S12Rivm101 12 47,0 0,000503 0,027409 3,3 0,011481 0,434292 6,26E+05 2,79E+05 3,19E+05 Hcb28
D12Mit53 12 47,0 0,000203 0,012282 3,7 0,002499 0,125222 6,27E+05 2,72E+05 2,61E+05 Hcb28
S12Rivm102 12 50,0 0,000025 0,001855 4,6 0,008272 0,359418 7,21E+05 2,77E+05 3,41E+05 Bps-1 Hcb28
S12Rivm104 12 52,0 0,001226 0,059666 2,9 0,014378 0,518711 6,20E+05 2,93E+05 3,20E+05 Hcb28
D12Mit133 12 52,5 0,000181 0,011023 3,7 0,033071 0,836288 5,97E+05 2,63E+05 4,14E+05 Hcb28
D12Mit263 12 56,8 0,000705 0,036669 3,2 0,008690 0,365544 6,14E+05 2,92E+05 3,42E+05 Hcb28
D12Rivm144 12 56,8 0,000705 0,036669 3,2 0,008690 0,365544 4,01E+05 3,10E+05 2,39E+05 Hcb28
D5Mit179 5 4,4 2,68E+06 2,70E+06 2,79E+06 Bps-2 Ccs4
D11Mit122 11 50,3 2,76E+06 2,68E+06 2,78E+06 Bps-3 Ccs4
D5Mit179    x D11Mit122 0,010250 0,281342 2,660718 0,002184 0,089410 Ccs4Please see table 3
Position Experiment not included as factor Exp. incl. as random factor Mean CFU
b
c d
e
c
f
Not significant
Not significant
g
g
g
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In the F2 mice generated by crossing CcS4 with BALB/c, we did not find any 
linkage between individual markers and the number of CFU’s. However, we 
found linkage between the number of CFU’s and the interacting markers 
D5Mit179 (chromosome 5) and D11Mit122 (chromosome 11) with a LOD-score 
of 2.92 (Figure 5). This LOD-score, and corresponding p-value (p=0.010), are 
statistically significant, but not after correction for multiple comparisons as 
described in the statistical section (p=0.28). However when the experiment is 
included as random factor the significance increases (p=0.089). We therefore 
consider these results suggestive linkage, instead of significant linkage,  and 
they warrant further investigation. 
Seven percent (7.0%) of the variation in the number of bacteria in the 
experiments could be ascribed to these interacting loci (R2 = 0.070).  We 
propose to call these loci Bps-2 and Bps-3. In table 3 means of CFU’s in F2 mice 
are displayed per interaction of D5Mit179 and D11Mit122 (the marker-
combination with the highest linkage) genotypes. When both markers carry the 
BALB/c allele in stead of STS, the CFU’s in the lung is relatively high. 
Chapter 2 
 
 
 
47 
47,0cM
56,8cM
59cM
0,0
20,0
40,0
60,0
80,0
100,0
120,0
0,0 0,5 1,0 1,5 2,0 2,5 3,0
Association (LOD-score)
P
h
y
s
ic
a
l 
d
is
ta
n
c
e
 (
M
b
)
(telomere)
BALB/c
STS
D11Mit151
D11Mit51
D11Mit28
D11Mit41
D11Mit139
D11Mit67
D11Mit36
D11Mit180
50,3cM
Bps-3 D11Mit122
D11Mit70
D11Mit49
D11Mit61
D5Mit179
Chromosome 5
22,4Mb, 4,4cM
Chromosome 11
 
 
Bps-2
Figure 5: Linkage (LOD-score) 
between lung colonization by 
B.pertussis (phenotype) and an 
interaction between two donor 
chromosomal loci (genotype).  
The association was calculated by 
ANOVA with the interaction of 2 
genotypes as fixed factor, 
experiment as random factor and 
sqrt CFU as dependent variable. 
Individual markers showed no 
linkage with the phenotype, but an 
interaction was found between 
chromosome 11 and an locus on 
chromosome 5 (4.4cM). The LOD 
score is plotted as -log p against 
the physical distance of 
chromosome 11. These regions 
designated as B.pertussis 
susceptibilty locus 2(chromosome 
5) and 3 (chromosome 11) (Bps-2, 
Bps-3), has a LOD-score of 2.7 
(p=0,002184 , R2 = 0,070) 
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Discussion 
Pertussis is re-emerging, despite high vaccination coverage’s (27). Further, 
pertussis morbidity and mortality is especially high in baby’s that are too young 
to be vaccinated (32). Treatment of pertussis with antibiotics is only effective if 
initiated early during infection. Thus new novel therapeutic or preventive 
treatments of pertussis are required. 
Elucidation of genetic differences in susceptibility to complex diseases can result 
in improved knowledge of pathways involved in the pathogenesis of these 
diseases. Identification of genes which affect susceptibility to infectious diseases 
is important to unravel pathogen-host interactions. Furthermore, identification of 
such genes may lead to novel therapeutics. Novel therapeutics are especially 
important for infectious diseases which are difficult to control by vaccination 
such as tuberculosis, pertussis and Aids, and/or antibiotics such as multi-
resistant bacteria.  
To identify genes that affect the course of B.pertussis infection we tested 2 sets 
of recombinant congenic strains, STS and HcB sets. This approach has been 
applied successfully before in identifying Sst1 as one of the loci in mice affecting 
susceptibility to Mycobacterium tuberculosis (16,17). The same approach was 
also successful in identifying a series of loci (Lmr), each associated with a 
different combination of pathological and immunological reactions, to Leishmania 
major (1,20,34).  
In this study we studied the effect of genetic differences in the mouse on lung 
colonization by B.pertussis. Recently a mutation in the Toll Like Receptor 4 (Tlr-
4) was identified as a major factor that influences the course of B.pertussis 
infection in mice (13,22).  The gene coding for Tlr4 is positioned on mouse 
chromosome 4 (33cM). The strains of mice we applied here do not have 
documented mutations in Tlr4, and this gene therefore did not influence the 
variation observed in our experiments. 
We tested two sets of RCS of mice, and selected one strain of each set for 
generating F2 hybrid generations to identify susceptibility loci. For both sets of 
RCS, a wide range was observed in the number of CFU recovered from the 
lungs. The phenotypic variation in these strains of mice, which only differ in 
12.5% of their genome, indicates that genetic factors do influence B.pertussis 
pathogenesis. In addition, the range of variation between these strains suggests 
that the course of pertussis is controlled by multiple genes, and that the 
genetics of B.pertussis infection is complex and controlled by multiple QTL’s.  
To identify loci potentially responsible for the observed differences in lung 
colonization, we generated F2 hybrid generations of approximately 200 mice. As 
shown in Figure 3, the phenotypic differences of the F2 mice generated from the 
CcS4 were approximately similar compared to the F2 generated from the HcB28. 
Based on the SDP’s we genotyped all mice from both F2 hybrids, and compared 
the genotypes with the degree of lung colonization. For a classical mouse F2 
intercross generation(whole genome segregating)  the following critical values 
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for establishing linkage are used: a LOD-score below 2.8 argues against linkage, 
while a LOD-score of 4.3 or higher indicates linkage (18,19). For a RCS F2 
hybrid generation, the critical values are lower because only 12.5% of the 
genome is segregating. Therefore all p-values are corrected for multiple 
comparisons as described in the statistical analysis section.  
In the F2 mice generated from the HcB28 mice, we initially found linkage 
between lung colonization and one marker D12Mit133 (chromosome 12) with a 
LOD-score of 2.7. We subsequently tested several flanking markers and found a 
maximum linkage between CFU and S12Rivm102 with a LOD-score of 4.6. This 
finding could explain almost 10% of the variation in CFU observed in the F2 mice 
generated from the HcB28 (Figure 4).  This locus, which we propose to 
designate as B.pertussis susceptibility locus 1 (Bps-1), is positioned near the 
telomere on chromosome 12 (approximately 102Mb), and influences the number 
of bacteria present in the lung one week after inoculation.  As is shown in Table 
2, the presence of C57BL/10 DNA on this allele in stead of C3H DNA has a 
dominant positive effect on the clearance of bacteria from the lung.   
In the F2 mice generated by crossing CcS4 with BALB/c, we did not find any 
linkage between individual markers and the number of CFU’s. However, we 
found linkage between the number of CFU and the interacting markers D5Mit179 
(chromosome 5) and D11Mit122 (chromosome 11) with a LOD-score of 2.92 
(Figure 5). Seven percent (7.0%) of the  variation in the number of bacteria in 
this experiment could be ascribed to these interacting loci (R2 = 0.070).  We 
propose to call these loci Bps-2 and Bps-3. In table 3 means of CFU’s in F2 mice 
are displayed per interaction of D5Mit179 and D11Mit122 (the marker-
combination with the highest linkage) genotypes. These linked regions are 
homologous to the human loci 7q21-q22 (D5Mit179) and 17p11-q12 
(D11Mit122). These regions contain numerous genes, including genes encoding 
with immunological functions, but the regions must be narrowed down before 
focusing on individual genes is possible. 
The significance of the results described may not withstand all statistical 
corrections, but nevertheless the results are promising enough for future 
investigation. We consider the 3 novel loci to be in suggestive linkage. Because, 
according to the 2-test, the genotypes on the Bps-1 locus are normally 
distributed (p=0.489) the relevance of the Bps-1 locus is underlined.  
Because the wide range of variation found in the RCS mice suggests a multigenic 
control of B.pertussis infection, we did not expect to find only three loci 
influencing our phenotype. It is therefore likely that the combined effect of other 
loci on this phenotype is too subtle to detect in these experiments. Presumably, 
because B.pertussis infection is controlled by multiple genes, the extremes in 
phenotypes must be larger to identify subtle genetic effects. Although all mice 
were raised and housed in the same facility under carefully controlled conditions,  
the contribution of other factors, besides genetics,  can not be excluded 
completely as complicating factors in the differences in bacterial load between 
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mice. In addition it would probably be necessary to increase the number of F2 
animals to detect significant QTLs. 
Based on the data presented in Figure 4, we selected the region between 100 
and 108Mb around Bps-1 on chromosome 12 for future analysis. This region is 
similar to the human locus 14q32. It contains 84 different genes, including 
genes involved in immunity such as tumor necrosis factor-associated factor 3, 
and microtubule affinity-regulating kinase 3. However the majority of genes in 
this region has an unknown function (RIKEN cDNA). In future experiments we 
aim to identify the gene(s) that modifies the susceptibility to B.pertussis by a 
combination of positional cloning and  expression analysis.   
In conclusion,  we screened two sets of RCS of mice for susceptibility to 
B.pertussis infection, and found a wide range in bacterial numbers in the lung at 
one week post inoculation. This indicates a multigenic control of the B.pertussis 
infection.  We identified one locus located on chromosome 12, which we 
designated as Bps-1, and 2 interacting loci on chromosome 5 and 11, 
designated Bps-2 and 3, which influence the number of bacteria in the lung one 
week after inoculation. The presence of C57BL/10 DNA on Bps-1 in stead of C3H 
DNA has a dominant positive effect on the clearance of bacteria from the lung. 
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Abstract 
Host genetics determines the course of Bordetella pertussis infection in mice. 
Previously we found four loci, Tlr4 and three novel loci, designated Bps 1-3, that 
are involved in the control of B. pertussis infection. The purpose of the present 
study was to identify candidate genes that could explain genetic differences in 
the course of B. pertussis infection assuming that such genes are differentially 
regulated upon infection. We therefore studied the course of mRNA expression in 
the lungs after B. pertussis infection. Of the 22,000 genes investigated, 1,841 
were significantly differentially expressed, with 1,182 genes up- and 659 genes 
down-regulated. Up-regulated genes were involved in immune-related 
processes, such as the acute phase response, antigen presentation, cytokine 
production, inflammation, and apoptosis, while down-regulated genes were 
mainly involved in non-immune processes, such as development and muscle 
contraction. Pathway analysis revealed the involvement of granulocyte function, 
Toll-like receptor signaling pathway, and  apoptosis. Nine of the differentially 
expressed genes were located in Bps-1, 13 were located in Bps-2 and 62 were 
located in Bps-3. We conclude that B. pertussis infection induces a wide and 
complex response, which appears to be partly specific for B. pertussis and partly 
non-specific. We envisage that these data will be helpful in identifying 
polymorphic genes that affect the susceptibility and course of B. pertussis 
infection in humans. 
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Introduction 
The airway pathogen Bordetella pertussis can cause the disease known as 
whooping cough. Despite high vaccination coverage, pertussis is still an endemic 
disease with peaks in incidence every two to three years during the last decade 
(10-12).  Susceptibility to and severity of B. pertussis infection in infants and 
children vary widely (22). The spectrum of clinical symptoms ranges from 
subclinical infection to mild disease, severe whooping cough, and death. In 
previous studies we examined genetic susceptibility of mice to B. pertussis, and 
identified loci in the mouse genome that are involved in restriction of 
colonization and / or clearance of B. pertussis. We and others have provided 
indications for the role of several polymorphic host genes in the course of B. 
pertussis infection, including the interferon gamma receptor (27), toll-like 
receptor 4 (Tlr4) (15,28,29), and three putative disease loci, B. pertussis 
susceptibility locus 1, 2 and 3 (Bps-1, 2 and 3) (3). Tlr4 is a major host factor 
involved in the course of B. pertussis infection. C3H/HeJ mice, which cary a non 
functional Tlr4 gene, exhibit an aberant course of infection. Functional Tlr4 is 
essential for an efficient IL1-, TNF- and IFN- response,  efficient clearance of 
bacteria from the lung, and therewith reduced lung pathology (4). The Bps-1 
locus is located on chromosome 12, spanning a region of 185 genes and has a 
dominant positive effect on the clearance of B. pertussis from the lung. The 
function of most genes in this locus is unknown. Two other loci, Bps-2 and Bps-
3, showed genetic interaction and are located on chromosomes 5 and 11, 
respectively (3).  
The highest linkage between the number of CFU and the Bps-1 locus that we 
observed showed a LOD score of 4.6. This LOD score and the corresponding P 
value (P = 0.000025) are statistically significant, also after correction for 
multiple comparisons (P = 0.0019). We interpreted these data as suggestive for 
linkage warranting further investigation (3).In the present study we aimed to 
enhance the insight in the host response and pathogenesis of B. pertussis 
infection by identifying genes that are differentially expressed upon infection. In 
particular we were interested in identifying candidate genes that could explain 
genetic differences in the course of B. pertussis infection, assuming that such 
genes are differentially regulated upon infection. For this purpose we infected 
mice and analyzed gene-expression profiles in the lungs on days one, three and 
five after inoculation using microarrays. We were especially interested if genes, 
located in the Bps-1, 2 and 3 loci, were differentially expressed after B. pertussis 
infection or that the susceptibility of these loci was regulated alternately.  
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Materials and Methods 
Experimental design 
Female C3H/DISnA mice (eight mice per group, total 48) were intranasally 
inoculated with 2*107 colony forming units (CFU) of the streptomycin-resistant 
Tohama strain of B. pertussis (B213) in 40 μl Verwey medium (The Netherlands 
Vaccine institute, Bilthoven, the Netherlands), or as a control with Verwey 
Medium only.  One, three and five days after inoculation, mice were euthanized. 
To remove blood cells from the lungs, mice were perfused with PBS, and the 
lungs and trachea were collected (23,44).  For the extraction of RNA, the right 
lung was collected in RNA stabilization reagent (RNAlater, Qiagen, Venlo, The 
Netherlands). The left lung was fixed intratracheally using 4% formalin for 
histological examination.  
The number of viable B. pertussis bacteria was determined in the trachea to 
confirm a proper infection (42). Therefore, approximately one centimeter of the 
trachea was collected in 500 μl Verwey medium. Bacterial suspensions were 
diluted in Verwey medium and the number of CFU was determined by plating on 
Bordet Gengou agar supplemented with 15% sheep blood and 30 g/ml 
streptomycin (Tritium Microbiology, Veldhoven, the Netherlands). Plates were 
incubated for 4 days at 35°C before counting the number of CFU’s using a 
ProtoCOL Colony counter (Synbiosis, Cambridge, United Kingdom.). 
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Animals 
Female C3H/DISnA mice were kindly supplied by Dr. Peter Demant (Department 
of Molecular and Cellular Biology, Roswell Park Cancer Institute, Buffalo, New 
York). Mice were bred to the appropriate numbers at our animal testing facility 
in Bilthoven, The Netherlands. Mice were acclimatized for at least one week 
before the start of the experiments. Mice received standard laboratory food 
(SRM-A, Hope Farms, Woerden, the Netherlands) and tap water ad libitum. All 
animal experiments were approved by the Institute’s Animal Ethics Committee 
and were performed according to NIH guidelines (32) .  
 
Clinical and pathological examinations 
Mice were weighed before inoculation, and subsequently every day after 
inoculation to determine the relative change in weight. Lung weights were 
determined post mortem as a parameter for lung inflammation. Formalin-fixed 
lungs were embedded in paraplast (Monoject Inc., St Louis, Missouri). Sections 
(5 m) were stained with hematoxylin-eosin. Lung lesions were examined for 
infiltration of inflammatory cells in the peribronchiolar space (peribronchiolitis), 
infiltration of inflammatory cells in the alveoli (alveolitis), infiltration of 
inflammatory cells in the perivascular space (perivasculitis), hypertrophy of 
mucus-producing glands, free protein (exudate), and eosinophilia. Lung lesions 
were scored semi-quantitatively as absent, minimal, slight, moderate, marked, 
or strong,  as previously described (5). 
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Transcription profiling 
Lungs were incubated in RNAlater (Qiagen, Venlo, The Netherlands) at 4°C for 
one day, after which the tissues were transferred to a fresh tube, and stored at -
80°C.  RNA was extracted by using the midi-RNA isolation kit (Qiagen, Venlo, 
The Netherlands). RNA concentrations were measured using a NanoDrop 
Spectrophotometer (NanoDrop Technologies, Wilmington, Delaware). RNA 
quality was determined using the 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, California), and was expressed as the RNA Integrity Number (RIN) as 
defined by the manufacturer. Only samples with a RIN score of at least eight (on 
a 1-10 scale) were used for expression profiling. 
Microarray slides were spotted at the Microarray Department of the University of 
Amsterdam. The slides contain 21,997 65-mer oligo nucleotides from the Sigma-
Compugen Mouse oligonucleotide library, 192 additional 65-mer oligo 
nucleotides of genes of which 185 were located in the Bps-1 region spotted in 
duplicate (Isogen Life science, IJsselstein, the Netherlands), as well as 
appropriate controls and blank spots.  
Based on RNA quality and yield, RNA isolated from six mice per group was 
selected for amplification and labeling. RNA amplification and labeling was 
carried out using the Amino Allyl MessageAmp II aRNA kit (Ambion Inc., Austin, 
Texas), using 1 g of total RNA as starting material. RNA samples from 
individual mice were labeled with Cy3. A common reference containing a RNA 
pool of all samples isolated was labeled with Cy5. After hybridization and 
washing, the arrays were scanned using a ScanArray 4000XL microarray 
scanner (Perkin-Elmer, Wellesley, Massachusetts). 
Median Cy3 and Cy5 spot signals were determined using ArrayVision (Imaging 
Research, St. Catharines, Ontario, Canada). Quality control was performed by 
means of visual inspection of the scanned images, raw data scatter, and MA 
plots (M is a mnemonic for the log-ratios of expression, A is a mnemonic for the 
log-intensity of each spot) (39), as well as a normal probability plot to assess 
signal distribution (34). If more than 10% of the spots were flagged as missing 
data, slides were excluded from data-analysis. At least 5 slides per group were 
used for further analysis. 
Raw microarray signal data were normalized in the R statistical software 
environment (37),  using a four-step approach of (1) natural log-transformation, 
(2) quantile normalization of all scans, (3) correcting for differences in the 
reference signal, and (4) averaging replicate spot data.  
Significance of differences in gene-expression  between the experimental groups 
was calculated in R with ANOVA. The false discovery rate (FDR) was calculated 
according to Benjamini and Hochberg (8). The FDR is the expected proportion of 
false positives among the genes considered significantly differentially expressed 
(7,8). Gene-expression  data were visualized by hierarchical clustering (using 
Euclidian distance and Ward linkage) using GeneMaths (Applied Maths, St-
Martens-Latem, Belgium). For this purpose, gene-expression values were 
Host genetics and genomics of Bordetella pertussis infection and vaccination 
 
 
 
62 
corrected for the overall average to allow a neutral comparison between all B. 
pertussis- and mock-inoculated groups. Gene categories were defined by Gene 
Ontology (GO, http://www.geneontology.org). Classification and enrichment 
according to GO categories were determined using DAVID/EASE (13,16), using 
EASE-scores as P-value for enrichment. Additional pathway analysis was 
performed using MetaCore™ (GeneGo Inc., http://www.genego.com). 
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Figure 1: gain of body weight after infection 
Relative gain of body weight at different days post inoculation with medium (mock) or 
B. pertussis. Boxes represent the mean of the relative weights of B. pertussis infected mice, 
diamonds represent the mean of the relative weights of mock inoculated mice. 
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Results  
Bacteriologic and pathologic findings 
All B. pertussis-inoculated mice had between 102 and 105 CFU’s in the trachea 
during the first five days after inoculation thereby confirming a proper infection. 
A statistically significant decrease in the number of bacteria in the trachea was 
observed over time during the first five days post inoculation (P=0.022, linear 
regression, SPSS, data not shown). 
Infected mice lost up to four percent of their body weight during the first five 
days post inoculation, while all mock-inoculated mice gained weight up to four 
percent during these five days. This difference in relative gain of weight between 
mock- and B. pertussis-inoculated mice is significant from day one till day five 
post inoculation (Figure 1).   
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Figure 2: Lung weight after infection 
Relative lung weight of mice after infection with B. pertussis at several days post inoculation. Solid 
bars represent the mean relative weight of B. pertussis infected mice, grey bars  represent the 
mean relative lung weight of mock inoculated mice. 
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We determined lung weights in relation to body weight, as a marker for 
inflammation. All mock-inoculated mice had relative lung weights of 
approximately one percent during the first five days after inoculation, while B. 
pertussis-infected mice had relative lung weights of up to three percent of their 
total body weight. This difference in relative lung weights between mock- and B. 
pertussis-inoculated mice is significant from day one till day five post inoculation 
(Figure 2).   
A summary of histopathological findings is presented in Table 1.  Intranasal 
inoculation of B. pertussis causes an acute inflammatory response that is 
characterized by influx of polymorphonuclear leukocytes (PMNs) and 
macrophages, starting in perivascular and peribronchiolar areas on day one, and 
extending to alveolar walls and lumina on days three and five.  
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Table 1: Histological evaluation of lung changes after B. pertussis inoculation.    
Parameter and grade 
 
Number of Animals a 
  
    Mock      B.pertussis    
    Day 1 Day 3 Day 5   Day 1 Day 3 Day 5   
Peribrochiolitis b Minimal 2  3  4 2 2  
 Slight     1 2 5  
 Moderate      3   
  Total c (25%) (0%) (38%)   (63%) (88%) (88%)   
Perivasculitis Minimal 2 2 2  2 1   
 Slight     4 3 3  
 Moderate      3 5  
 Marked      1   
  Total (25%) (25%) (25%)   (75%) (100%) (100%)  
Hypertrophy Minimal 1  1  1 2   
 Slight       1  
 Moderate      3 1  
 Marked      2 4  
 Strong       1  
  Total (13%) (0%) (13%)   (13%) (88%) (88%)   
Alveolitis Minimal     2 1   
 Slight     4  2  
 Moderate      3 1  
 Marked      1 3  
 Strong      3 1  
  Total (0%) (0%) (0%)   (75%) (100%) (88%)   
Exudate Minimal      2 2  
 Slight      2 2  
 Moderate      1 1  
 Marked      1   
 Strong      1   
  Total (0%) (0%) (0%)   (0%) (100%) (63%)   
a Eight mice per group were inoculated with medium (mock) or B. pertussis   
b 
Hematoxylin-eosin-stained  slides were examined for 
peribronchiolitis,      
  
alveolitis, perivasculitis, hypertrophy of mucus-producing glands 
and     
  
free protein(exudate). Lung lesions were scored semi-
quantitatively as     
  absent (not included in table), minimal, slight, moderate, marked, or strong    
c 
Total percentage of animals with at least minimal scoring in the specified 
category   
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Figure 3: representation of microarray data from mock- and B. pertussis-inoculated mice.  
Analysis was performed on 1,841 genes whose expression was found to be significant at an FDR < 
0.05 (a) Hierarchical clustering shows the segmentation of the genes clustered by gene-expression.  
Relatively increased gene-expression is presented in red while relatively decreased gene-expression 
is presented in green. The color scale shows log(2) ratios of gene-expression levels compared to 
the global average.  
(b) Course of B. pertussis regulated gene-expression, diamonds represent the average of 1,182 up-
regulated genes and squares represent the average of 659 down-regulated genes. Error bars show 
the standard deviation (SD) of the average gene-expression.  
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Expression profiling 
Gene-expression profiles were determined in at least five animals per group. The 
three mock-inoculated groups, euthanized at days one, three and five, were 
statistically indistinguishable (i.e. there were no genes with FDR < 0.6). Of the 
approximately 22,000 genes tested, 1,841 genes, were significantly differentially 
expressed in B. pertussis-inoculated lungs (FDR <0.05, corresponding to 
P<0.0042). Expression levels of all 1,841 genes as well as comparisons to other 
studies are presented in the supplementary data Table 5.   
Hierarchical clustering showed time-dependent changes in gene-expression with 
1,182 up-regulated genes and 659 down-regulated genes. Of these genes, 439 
were more than two-fold up-regulated and 134 were more than two-fold 
repressed. All genes followed a similar trend in time. One day post inoculation 
differential gene-expression was already observed, but the effect was larger on 
days three and five post inoculation (Figure 3). There was no identifiable subset 
of genes that displayed a different kinetic trend in gene-expression. 
To assign functions to differentially expressed genes, we classified them 
according to Gene Ontology (GO) categories. In addition, we determined 
enrichment for GO-categories to identify pathophysiological processes involved 
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in the response to B. pertussis. The most important GO categories, i.e. with the 
highest percentage differentially expressed genes, are summarized in Table 2. 
Most up-regulated genes are involved in immune-response-related processes, 
such as the acute phase response, antigen presentation, cytokine activity, 
inflammation and apoptosis, whereas down-regulated genes are involved in non-
immune processes, such as development, muscle-contraction, cytoskeleton and 
general processes like metabolism.  
 
Table 2: Classification of genes induced upon B. pertussis infectiona 
  Up Downb Total on array P-valuec 
Acute-phase responsed 12 (55%) 0 (0%) 22 2.4*10-7 (up) 
Antigen presentation 21 (66%) 0 (0%) 32 7.7*10-15 (up) 
Apoptosis 47 (15%) 6 (2%) 324 8.0*10-5 (up) 
Cell cycle 43 (8%) 22 (4%) 510 4.3*10-1 (up) 
Chemokine Activity 21 (58%) 0 (0%) 36 1.2*10-13 (up) 
Complement activation 8 (26%) 1 (3%) 31 9.7*10-3 (up) 
Cytokine Activity 48 (25%) 6 (3%) 192 7.8*10-13 (up) 
Cytoskeleton 31 (6%) 40 (8%) 531 2.0*10-3 (down) 
Development 96 (7%) 94 (7%) 1433 9.8*10-1 (down) 
Immune response 162 (40%) 3 (1%) 408 6.3*10-75 (up) 
Inflammatory response 46 (38%) 2 (2%) 121 1.1*10-19 (up) 
Metabolism 353 (7%) 220 (5%) 4771 1.8*10-1 (down) 
Muscle contraction 0 (0%) 12 (24%) 49 6.7*10-6 (down) 
Listed in any of the above 576 (9%) 318 (5%) 6574  
Other 328 (6%) 204 (4%) 5639  
Unannotated 278 (3%) 137 (1%) 9744  
Total 1182 (5%) 659 (3%) 21957   
aClassification according to Gene-Ontology (GO) categories  
bAnalysis was performed on 1841 regulated genes   
c Ease Score for GO category enrichment in the specified set of genes  
dNote:some genes are classified into multiple categories.   
 
To reveal inter-gene relationships, we performed MetaCoreTM analysis on the 
1,841 regulated genes in addition to the GO-based analysis presented above. 
The most significant pathways are presented in Table 3. This analysis revealed 
the significance of several pathways, such as regulation of granulocyte function, 
the Toll-like receptor (TLR) signaling pathway, the classic complement pathway 
and apoptosis. 
Genes located in Bps-1 that were differentially regulated upon B. pertussis 
inoculation and their function according to the GO database are presented in 
Table 4. Bps-1 contains 185 genes, of which nine were differentially expressed. 
The strongest up-regulated genes in this locus were tryptophanyl-tRNA 
synthetase (Wars, 4-fold),  and tumor necrosis factor alpha-induced protein 2 
(Tnfaip2, 5.4-fold). Zinc finger FYVE domain containing 21 (Zfyve21, 1.5-fold)  
and kinesin family member 26A (Kif26a, 1.7-fold) were the strongest down-
regulated genes.  
Genes located in Bps-2 and -3 that were differentially regulated upon B. 
pertussis inoculation are presented in Supplementary data Table 6. Bps-2 is 
located on chromosome 5 and contains 262 genes of which 13 were differentially 
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expressed. Interleukin-6 (IL-6) was the strongest up-regulated gene (4.7-fold) 
in this locus and general transcription factor IIIC, polypeptide 2, beta was the 
strongest down-regulated gene (2-fold) in this locus. Bps-3 is located on 
chromosome 11 and contains 922 genes of which 62 were differentially 
expressed. Chemokine (C-C motif) ligand 8 was the strongest up-regulated gene 
(15.3-fold) in this locus and RIKEN cDNA 9530033F24 gene was the strongest 
down-regulated gene (2.3-fold) in this locus. 
 
Table 3: Pathway Analysis of genes induced upon B. pertussis infectiona       
Name of  Pathway involvedb Main processc P-Valued 
Number of genes in 
Pathway 
      Expressed Total 
Transcription regulation of granulocyte 
development Immune response 0.000001925 17 (38%) 45 
TLR ligands and common TLR signalling 
pathway Immune response 0.00001814 16 (34%) 47 
ECM remodeling Metabolism 0.00003906 18 (30%) 60 
Role of IAP-proteins in apoptosis Apoptosis 0.00005458 13 (36%) 36 
HETE and HPETE diosynthesis and 
metabolism Metabolism 0.0003249 13 (31%) 42 
TPO signaling via JAK-STAT pathway Cell cycle 0.0003893 9 (39%) 23 
Leukotriene 4 biosynthesis and metabolism Metabolism 0.0004655 16 (27%) 60 
RhoA regulation pathway (extension, 
GEFs/GAPs) Immune response 0.002412 10 (29%) 34 
MIF in innate immunity response Immune response 0.002435 14 (25%) 57 
Retinol metabolism Metabolism 0.002842 12 (26%) 46 
Classic complement pathway Complement activation 0.002842 12 (26%) 46 
Putative Erythropoietin Signaling Pathway 
(part 1) Immune response 0.002905 13 (25%) 52 
MAPK cascade Cell cycle 0.004975 12 (24%) 49 
Ceramide-dependent NO antiapoptotic 
action Apoptosis 0.006738 13 (23%) 57 
IL9 signaling pathway Cytokine activity 0.006809 9 (27%) 33 
Ephrins signaling Other 0.007847 13 (22%) 58 
Polyamine metabolism Metabolism 0.008731 7 (30%) 23 
Integrin outside-in signaling Cell cycle 0.009444 16 (20%) 79 
Chemokines and adhesion Chemokine activity 0.009657 34 (16%) 209 
Definition of abbreviations: Extracellular matrix (ECM), GTPase-accelerating protein (GAP), guanine nucleotide exchange 
factor (GEF), 
hydroperoxyeicosatetraenoic acid (HPETE), hydroxyeicosatetraenoic acid (HETE), inhibitor of apoptosis (IAP), interleukin 
9 (IL9), 
Janus tyrosine kinase (JAK), macrophage migration inhibitory factor (MIF), mitogen-activated protein kinase (MAPK), 
nitric oxide (NO), 
ras homolog gene family, member A (RhoA), signal transducers and activators of transcription (STAT) 
aAnalysis was performed on 1841 genes whose expression was found to be significant at an FDR < 0.05, The list is 
presented by descending p-value.  
bClassification according to main Gene-Ontology (GO) categories 
c P-Value  represent the probability of particular mapping arising by chance, given the numbers of genes in  all Metacore 
pathways,
 genes involved in the specified pathway and genes regulated upon B. pertussis inoculation. 
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Discussion 
We have recently shown that genetic differences of the host play an important 
role in the restriction of colonization and /or clearance of B. pertussis from the 
lungs of mice (3,4). In the present study we wanted to extend the 
understanding of the host response to B. pertussis, and identify genes and 
pathways that play a role in the pathophysiological response to B. pertussis 
infection. In particular we were interested in identifying candidate genes that 
could explain genetic differences in the course of B. pertussis infection, 
assuming that such genes are differentially regulated upon infection. For these 
purposes we studied the time course of mRNA-expression in the lungs of mice 
after a B. pertussis infection by microarray analysis. We were especially 
interested if genes, located in the Bps-1, 2 and 3 loci, were differentially 
expressed after B. pertussis infection or that the susceptibility conferred by 
these loci was regulated alternately.  
Of the approximately 22,000 genes investigated, we found 1,841 (8.4%) genes 
to be significantly differentially expressed. Differential gene-expression was 
already observed on day one post inoculation, but the maximum effect was 
observed on day three post inoculation. This effect remained constant till at least 
day five post inoculation. The observed course in gene-expression after B. 
pertussis inoculation was similar to that induced by another gram-negative lung 
pathogen, Francisella tularensis (2). In a study of expression profiles in the 
lungs of F. tularensis-infected C57BL/6 mice, 424 (2.3%) genes out of the 
18,500 genes investigated were up-regulated. Genes involved in immune 
responses were activated strongly on day four post inoculation, but hardly or not 
at all on days one and two (2).  
As expected, most up-regulated genes are involved in immune and 
inflammation-related processes, such as antigen presentation, complement, 
cytokine and chemokine activity. Other processes involved include the acute 
phase response and metabolism. Most down-regulated genes are involved in 
non-immune processes, such as metabolism, development, cell-cycle or muscle 
contraction. We speculate that by down-regulating these genes, the energy 
balance is shifted in favor of  the immune response. Evidently, cellular influx in 
the lungs is likely to influence the gene-expression profile.  
Our data provide more detailed information on the central role of PMN’s in the 
pathogenesis of B. pertussis infection. Pathogenesis of B. pertussis infection is 
characterized by colonization and proliferation of the ciliated mucosal cells, 
resulting in damage of the respiratory epithelium, and an acute increase in the 
levels of inflammatory cytokines resulting in cellular infiltrate in the alveolar 
spaces (30,31,35). Circulating PMN’s are rapidly recruited to the lungs to bind 
and ingest B. pertussis, subsequently killing the bacteria by a combination of 
reactive oxygen and granule components. Finally, the PMN’s undergo apoptosis 
(25). TLR ligands such as LPS are critical components for the recruitment and 
priming of PMN’s. Serum antibody–mediated clearance of B. pertussis also 
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requires a TLR-induced early recruitment of PMN’s. However, pertussis toxin  
limits this rapid serum antibody–mediated clearance by inhibiting PMN 
recruitment (24). As determined by pathway analysis in this study, the most 
significant pathways involved in the response to B. pertussis infection are 
regulation of PMN function, TLR signaling pathway, extracellular matrix 
remodeling, and apoptosis. It has been described that apoptosis of PMNs in 
which TLR2 plays an important role (18), is accelerated following phagocytosis of 
bacteria (25,26). So, the involvement of three out of four pathways may, at 
least partly, be explained by the influx of PMNs.  Our data thus further illustrate 
the central role of PMN’s in the course of B. pertussis infection and the involved 
mechanisms in PMN function.  
We found the response to B. pertussis to be wide and complex. Some 
remarkable findings were the involvement of mucin genes, Intracellular 
pathogen resistance gene, and the excessive up-regulation of Serum amyloid A 
genes. We found the mucin (Muc) genes Muc4 and Muc5b to be significantly 
upregulated. Expression of mucin in the respiratory tract is one important innate 
host defense mechanism that respiratory pathogens must overcome (6). Muc4, 
which encodes a respiratory tract mucin glycoprotein, was expressed 3.3-fold at 
day five upon B. pertussis  inoculation. Muc5b, which encodes mucin 5, subtype 
B protein, in  tracheobronchial epithelial cells, was expressed 1.8-fold three days 
upon inoculation. Belcher et al. (6) describe that B. pertussis induces mucin 
gene transcription by BEAS-2B cells. Evidently gene-expression studies do not 
allow to define the functional role of regulated genes. Further studies should 
define whether the mucin response is favorable to the host, the pathogen, or 
both.  
In our study we found a 3-fold upregulation of the Intracellular pathogen 
resistance gene 1 (Ipr1). Ipr1 mediates innate immunity to Mycobacterium 
tuberculosis (33). Pan et al. (33) speculated that the Ipr1 gene product might 
function in integrating signals generated by intracellular pathogens with 
mechanisms controlling innate immunity, cell death, and pathogenesis. Our data 
therefore suggest that Ipr1 may be involved in intracellular presence of B. 
pertussis. Interestingly, B. pertussis was shown to survive intracellularly  in 
macrophages, PMN’s and broncho-alveolar lavage (BAL) cells of mice (14,31).  
Among the upregulated genes upon B. pertussis inoculation, Serum amyloid A 
(SAA) genes were upregulated to a remarkably high extent. SAA is an acute 
phase protein whose expression is markedly up-regulated during inflammation 
and infection (40). Among other functions, this protein plays an important role 
in HDL cholesterol metabolism by promoting cellular cholesterol efflux through a 
number of different efflux pathways (41). In our study, SAA1, 2 and 3 were 
induced 14-, 54- and 44-fold respectively after B. pertussis infection, again 
underlining the important role for the acute phase response after B. pertussis 
infection. 
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Although strongly upregulated, it is clear that the acute-phase response is not 
specific for B. pertussis infection.  
In a previous study we observed a 1.5 fold up-regulation of the membrane-
receptor Tlr4 and a 5-fold up-regulation of the downstream cytokine gene Tnf- 
three days post B. pertussis inoculation by means of quantitative real-time PCR. 
Thus, a slight upregulation (1.5-fold) of this receptor induces a more 
pronounced (5-fold) induction of this downstream pro-inflammatory cytokine 
(4). In the present study we obtained similar results by using microarray 
analysis. Tlr4 expression was increased 1.6-fold, while the expression of Tnfaip 
was increased 4.5-fold 3 days post inoculation. The results of the present study 
hereby confirm our previous observations. In a recent study a high correlation 
between gene-expression values determined by quantitative real-time PCR and 
microarray was observed (9). Given these results and our observations, we 
conclude that the results, at least for the two given genes, are similar for both 
techniques. 
It is very likely that the expression profile to B. pertussis is partly unique to B. 
pertussis, and partly non-specific. To examine the specificity of B. pertussis-
regulated gene-expression, we compared our data to other studies. In a recent 
review by Jenner & Young (19), a comparison was made between published 
transcriptional profiling data from 32 studies that involved 77 different host-
pathogen interactions. A set of 417 genes that comprise a common host 
transcriptional response was defined. We found that 122 genes affected by B. 
pertussis infection were listed in this common host pathogen response, further 
illustrating that many genes regulated by B. pertussis are indeed not specific for 
B. pertussis infection, but are involved in a common response to pathogens. One 
explanation for the broad response in expression profiles is the complexity of the 
bacterium. It is, for instance, known that lipopolysaccharide (LPS) is a very 
potent immune stimulus, which induces a strong inflammatory response 
(21,36,43). Transcriptional profiling of LPS-induced acute lung injury in mice 
resulted in 71 immune-related up-regulated genes (20). 43 of these 71 genes 
were also regulated upon B. pertussis inoculation in this study.  
Previously we have demonstrated that the Bps-1 locus has a dominant positive 
effect on the clearance of B. pertussis from the lung. Of the 185 genes in this 
locus, nine were differentially expressed. Some of these genes could explain the 
linkage of this locus with susceptibility to B. pertussis infection. Tumor necrosis 
factor, alpha-induced protein 2 (Tnfaip2) has been described as a tumor necrosis 
factor-alpha-inducible primary response gene in endothelial cells (38). 
Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA with their 
cognate amino acid. Tryptophanyl-tRNA synthetase (Wars) catalyzes the 
aminoacylation of tRNA(trp) with tryptophan and is induced by interferon 
(17).The role of the nine genes in the B. pertussis infection process is unknown, 
and will be investigated in future experiments.  Thus, by using a microarray 
approach, we selected nine possible candidate genes from the 185 present in 
Chapter 3 
 
 
 
73 
Bps-1. However, by this approach, we focussed on transcriptionally regulated 
genes, and the possibility remains that susceptibility to B. pertussis  is regulated 
in a different way, such as phosphorylation or protein binding.  
In comparison to the Bps-1 region, the Bps-2 and -3 regions contain 
considerably more genes, namely 262 and 922 genes, respectively, of which 13 
and 62 were differentially expressed post B. pertussis inoculation. Among these 
differentially expressed genes are several interesting candidate genes that may 
explain the linkage of these loci with susceptibility to B. pertussis infection. IL-6 
was the most  strongly induced gene in the Bps-2 region (4.7-fold). IL-6 is a 
pro-inflammatory cytokine that can be secreted by macrophages after Tlr4 
activation (1). Among the genes differentially expressed in the Bps-3 region was 
a large group of chemokines of which Chemokine (C-C motif) ligand 8 was the 
strongest up-regulated gene (15.3-fold). Upon B. pertussis infection this large 
group of chemokines is induced to promote immune cells to migrate to the site 
of infection. The role of the other B. pertussis-induced genes in these loci is still 
unknown, and will be investigated in future experiments.   
In conclusion, we found 1,841 genes in the lungs of mice that are differentially 
expressed after B. pertussis inoculation. Most up-regulated genes are involved in 
immune and inflammation related processes or in non-specific processes.  Most 
down-regulated genes are involved in non-immune processes.  A substantial 
number of genes and pathways provide more detailed information on the central 
role of PMN’s in the pathogenesis of B. pertussis. In particular the transcriptional 
profiles indicate the significance of genes involved in TLR activation, the 
recruitment and activation of PMN’s, and apoptosis.  
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Supplementary data 
Raw data as well as the detailed description of the experiment will be uploaded 
to the freely accessible online database ArrayExpress  
http://www.ebi.ac.uk/arrayexpress/  upon acceptance of the manuscript. 
Expression levels of all 1,841 genes as well as comparisons to other studies are 
presented in the supplementary data Table 5.   
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Abstract 
Susceptibility to Bordetella pertussis infection varies widely. These differences 
can partly be explained by genetic host factors. HcB-28 mice are more resistant 
to B. pertussis infection than C3H mice, which could partially be ascribed to the 
B. pertussis susceptibility locus-1 (Bps1) on chromosome 12. The presence of 
C57BL/10 genome on this locus instead of C3H genome resulted in a decreased 
number of bacteria in the lung.  
To further elucidate the role of host genetic factors, in particular in the Bps1 
locus, in B. pertussis infection, and to identify candidate genes within in this 
region, we compared expression profiles in the lungs of the C3H and HcB-28 
mouse strains following B. pertussis inoculation. Twelve and a half percent of the 
genomes of these mice are from a different genetic background.  
Upon B. pertussis inoculation 2,353 genes were differentially expressed in the 
lungs of both mouse strains. Two hundred and six genes were differentially 
expressed between the two mouse strains, but, remarkably, none of these were 
up- or down-regulated upon B. pertussis infection. Of these 206 genes, 17 were 
located in the Bps1 region. Eight of these genes, which showed a strong 
difference in gene expression between the two mouse strains, map to the 
immunoglobulin heavy chain complex (Igh).  
Gene expression changes upon B. pertussis infection are highly identical 
between the two mouse strains despite the differences in the course of B. 
pertussis infection. Because the genes that were differentially regulated between 
the mouse strains only showed differences in expression before infection, it 
appears likely that such intrinsic differences in gene regulation are involved in 
determining differences in susceptibility to B. pertussis infection. Alternatively, 
such genetic differences in susceptibility may be explained by genes that are not 
differentially regulated between these two mouse strains. Genes in the Igh 
complex, among which Igh-1a/b, are likely candidates to explain differences in 
susceptibility to B. pertussis. Thus, by microarray analysis we significantly 
reduced the number of candidate susceptibility genes within the Bps1 locus. 
Further work should establish the role of the Igh complex in B. pertussis 
infection.  
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Figure 1: Differences between C3H/DISnA and HcB-28/Dem mice. 
a) Illustration of the distribution pattern of B10 genome across the background genome of the C3H 
strain of the Recombinant Congenic Strain HcB-28/Dem. The HcB-28 strain was derived by 
crossings between mouse strains C3H/DISnA as background (displayed in grey) and C57BL/10 as 
donor (displayed in black). b) Mice (C3H/DISnA) were infected intranasally with B. pertussis strain 
B213. The lungs were removed seven days after inoculation, and the number of viable B. pertussis 
was determined. Bars represent the average number of bacteria in the lungs. Horizontal line 
indicates the significant difference between groups. Error bars indicate the Standard Deviation 
(SD). 
C3H/DISnA HcB28/Dem
5
CF
U 
(lo
g 1
0)
pe
r l
un
g
P=0.0405
6
7
1 2 4 5 6 7 8 9 10
11 12 13 14 15 16 17 18 19 X
3
Bps-1
Background 
Bordetella pertussis is a gram-negative bacterium that can cause the respiratory 
disease known as pertussis or whooping cough in humans. Susceptibility to this 
disease and its course vary widely between individuals (7). We have previously 
shown that genetically divergent mouse strains differ in their response to B. 
pertussis infection, underlining that infection is influenced by host genetic 
factors(3,4). In addition, a role of several host genetic loci in the course of B. 
pertussis infection has been indicated, such as the toll-like receptor 4 (Tlr4) 
gene (3,4,17,18), the interferon gamma receptor gene (16), and three novel 
loci, B. pertussis susceptibility locus 1, 2, and 3 (Bps1, 2, and 3) (3) that 
showed linkage with the severity of infection.  
We have used recombinant congenic mouse strains (RCS) as a tool to facilitate 
the mapping of low-penetrance quantitative trait loci that control complex traits 
such as a B. pertussis infection (8). RCS are derived from two different inbred 
strains, the so-called background and donor strain. After two backcrosses and 
subsequent brother-sister mating, a set of RCS is created, with each strain 
containing 12.5% of the donor genome differently distributed across the 
background genome (9). HcB/Dem RCS of mice are derived from two 
backcrosses of the inbred mouse strains C3H/DISnA (C3H) as background and 
C57BL/10ScSnA (B10) as donor strain, resulting in 12.5% B10 genome across 
the C3H genome. The genome of each HcB/Dem strain, thus, differs maximally 
12.5% compared to the background strain (C3H) (Figure 1a) (12,31).  
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HcB-28 mice contained lower numbers of bacteria in their lungs seven days 
post-inoculation compared to C3H mice. Subsequent genotyping led to the 
identification of the three susceptibility loci, Bps1, 2, and 3. Especially Bps1 
displayed strong linkage with susceptibility to B. pertussis infection.  The Bps1 
locus is located on chromosome 12, spanning a region of 185 genes, of which 
one or more genes have a dominant positive effect on the clearance of B. 
pertussis in the lung, and/or the reduction of bacterial multiplication. However, 
the mechanism by which genes within this region influence the course of 
infection is not clear. Two other loci, Bps-2 and Bps-3, showed genetic 
interaction and are located on chromosomes 5 and 11, respectively (3).  
Although Bps-1 has not yet been validated, we believe that the significance of 
this locus warrants further study. To further elucidate the role of host genetic 
factors, in particular the Bps1 locus, in B. pertussis infection, and to identify 
candidate genes within this region, we studied expression profiles in the lungs of 
mice following B. pertussis inoculation. The traditional approach for mapping 
genes in susceptibility loci is a combination of positional cloning and linkage 
analysis (26,28). Although this strategy has proven to be effective (8,27), the 
approach is quite costly and animal-consuming. Previously we identified changes 
in gene expression in the lungs of C3H/DISnA mice after B. pertussis infection, 
and we especially focused on differentially expressed genes in the lungs of 
infected and non-infected mice located in Bps1,-2, and -3 (2). We found that the 
expression of 1,841 genes was significantly changed upon B. pertussis infection. 
These genes are involved in various immune-related processes, such as the 
acute-phase response, antigen presentation, cytokine production, inflammation, 
and apoptosis. Nine of the differentially expressed genes are located in Bps1, 13 
are located in Bps-2, and 62 are located in Bps-3.   
In the present study we compared the gene expression profiles in the lungs of 
two mouse strains, i.e. HcB-28/Dem and C3H, which showed a different course 
of B. pertussis infection, in order to further identify candidate susceptibility 
genes without the need for positional cloning. We hypothesized that the 
phenotypic differences displayed by these mice in the response to B. pertussis 
can partly be explained by a different gene expression profile between the 
mouse strains, and that this approach could lead to the identification of 
candidate genes affecting the course of infection. Using this approach we 
reduced the number of candidate susceptibility genes within the Bps1 locus. 
Host genetics and genomics of Bordetella pertussis infection and vaccination 
 
 
 
86 
Methods 
Experimental design 
Forty-eight female HcB-28/Dem and 48 female C3H/DISnA (the background 
strain of the HcB-28/Dem) mice were intranasally inoculated with 2*107 colony 
forming units (CFU) of the streptomycin-resistant Tohama strain of B. pertussis 
(B213) in 40 μl Verwey medium (The Netherlands Vaccine Institute, Bilthoven, 
the Netherlands), or as a control with Verwey Medium only (total of 96 mice).  
One, three, and five days after inoculation, 8 infected and 8 control mice were 
euthanized. To remove blood from the lungs, mice were perfused with 
phosphate-buffered saline (PBS, Tritium Microbiology, Veldhoven, the 
Netherlands). Subsequently, the lungs and trachea were collected (14,35). For 
RNA extraction, the right lung was collected in RNA stabilization reagent 
(RNAlater, Qiagen, Venlo, the Netherlands). For histological examination, the left 
lung was fixed intratracheally using 4% formalin.  
The number of viable B. pertussis bacteria was determined in the trachea to 
confirm a proper infection (33) (Note that tracheal counts are not representative 
for bacterial clearance from the lungs.) To this end, approximately one 
centimeter of the trachea was collected in 500 μl Verwey medium. Bacterial 
suspensions were diluted in Verwey medium and the number of CFU was 
determined by plating on Bordet Gengou agar supplemented with 15% sheep 
blood and 30 g/ml streptomycin (Tritium Microbiology). Plates were incubated 
for 4 days at 35°C and the resulting colonies were counted using a ProtoCOL 
Colony counter (Synbiosis, Cambridge, United Kingdom). 
All B. pertussis-infected mice had between 102 and 105 CFU in the trachea 
during the first five days after inoculation, confirming an actual infection (data 
not shown). 
For the analysis of intrinsic immunological and cellular differences between the 
two mouse strains, independent from infection, blood and spleen samples were 
collected from five untreated female mice of both strains. 
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Animals 
Breeding pairs of C3H/DISnA and HcB-28/Dem were supplied by the Department 
of Molecular and Cellular Biology, Roswell Park Cancer Institute, Buffalo, New 
York. Female mice were bred to the appropriate numbers at our animal testing 
facility in Bilthoven, the Netherlands. Mice were acclimatized for at least one 
week before the start of the experiments. Mice received standard laboratory 
food (SRM-A, Hope Farms, Woerden, the Netherlands) and tap water ad libitum. 
All animal experiments were approved by the Institute’s Animal Ethics 
Committee and were performed according to NIH guidelines (21) and Dutch 
legislation.  
 
Clinical and pathological examinations 
Mice were weighed before inoculation, and subsequently every day after 
inoculation to determine the relative change in weight. Lung weights were 
determined post mortem as quantitative parameter for lung inflammation. 
Formalin-fixed lungs were embedded in paraplast (Monoject Inc., St Louis, MO). 
Sections (5 m) were stained with hematoxylin-eosin. Lung lesions were 
examined for infiltration of inflammatory cells in the peribronchiolar space 
(peribronchiolitis), infiltration of inflammatory cells in the alveoli (alveolitis), 
infiltration of inflammatory cells in the perivascular space (perivasculitis), 
hypertrophy of mucus-producing glands, free protein (exudate), and 
eosinophilia. Lung lesions were scored semi-quantitatively as absent, minimal, 
slight, moderate, marked, or strong, as previously described (5). 
 
Enumeration of cellular subsets 
Spleens were harvested and weighed. Cell suspensions were prepared and the 
number of nucleated cells per spleen was determined using a Coulter Counter Z2 
(Beckman Coulter, Mijdrecht, the Netherlands). The percentage of B- and T-
cells, as well as T-cell subsets were determined using a fluorescence-activated 
cell sorter (FACS-Calibur, BD Biosciences, Alphen aan den Rijn, the 
Netherlands). T-cells were detected with phycoerythrin-labeled (PE) anti-CD3 
antibodies (Molecular probes, Invitrogen, Breda, the Netherlands). CD4+ T-cells 
were determined using allophycocyanin-labeled (APC) antibodies (Molecular 
probes) and CD8+T-cells were determined using fluorescein isothiocyanate-
labeled (FITC) antibodies (Molecular probes). B-cells were determined using PE-
labeled anti-CD19 antibodies (Molecular probes). 
 
Splenocyte proliferation test 
The cell suspensions were used to measure the spontaneous (medium only) or 
stimulus-induced 3H-thymidine uptake. The cells were stimulated by adding 10 
g/ml Concavalin A (Con A, T-cell stimulus), 70 g/ml lipopolysacharide (LPS, B-
cell stimulus) or 15 g/ml Lectin (B- and T-cell stimulus) to the culture medium. 
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Cells were incubated for 72hr at 37°C. 3H-thymidine was present during the final 
24hr of culture. See (34) for details. 
 
Hematology 
The morphologic hemogram was determined using an ADVIA 120 Hematology 
system (Multispecies analyzer, Bayer, Mijdrecht, the Netherlands). 
 
Immunoglobulin quantification 
Blood was collected in Vacuette Minicollect tubes (Greiner bio-one, Alphen a/d 
Rijn, the Netherlands), and serum was removed by centrifugation. 
Immunoglobulins were determined using the multiplex Beadlyte Mouse 
Immunoglobulin Isotyping Kit (Millipore, Billerica, MA) for the Luminex platform 
(Luminex, Oosterhoud, the Netherlands), as prescribed by the manufacturer.  
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Transcription profiling 
Microarray analysis experiments were performed as described previously (2). 
Briefly, total RNA was extracted from lungs and amplified using the Amino Allyl 
MessageAmp II aRNA kit (Ambion Inc., Austin, TX). RNA amplification was 
performed to obtain more nucleic acid for labeling. This results in a stronger 
fluorescence signal and a better signal/noise ratio. Because of this, less 
experimental samples (and therefore animals) are needed to obtain sufficient 
statistical power. RNA samples from individual mice were labeled with Cy3. A 
common reference containing a RNA pool of all samples isolated was labeled 
with Cy5.  
Microarray slides were spotted at the Microarray Department of the University of 
Amsterdam. The slides contain 21,997 65-mer oligonucleotides from the Sigma-
Compugen Mouse oligonucleotide library, 192 additional 65-mer oligonucleotides 
of genes of which 185 are located in the Bps1 region spotted in duplicate 
(Isogen Life science, IJsselstein, the Netherlands), as well as appropriate 
controls and blank spots. The Bps-1 oligonucleotides were annotated according 
to NCBI mouse genome build 34.1; all other oligonucleotides were annotated 
according to the Sigma-Compugen Mouse oligonucleotide library. 
At least 5 slides per group were used. Raw microarray signal data were 
normalized and analyzed in the R statistical software environment (24,25,29). 
Significance of differences in gene expression between the experimental groups 
was calculated in R with ANOVA. The false discovery rate (FDR) was calculated 
according to Benjamini and Hochberg (6). Gene expression data were visualized 
by hierarchical clustering (using Euclidian distance and Ward linkage) using 
GeneMaths (Applied Maths, St-Martens-Latem, Belgium). Gene categories were 
defined by Gene Ontology (GO, http://www.geneontology.org). Classification 
and enrichment according to GO categories or location were determined using 
DAVID/EASE (10,13), using EASE-scores as P-value for enrichment.  
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mock     infection       mock      infection
Day   1    3    5    1    3    5    1    3    5    1    3    5
3
0
-3
C3H/DISnA                 HcB28/Dem
Group A: 107 genes
Group B: 99 genes
Group C: 963 genes
Group D: 1,390 genes
Figure 2: Presentation of microarray data from mock- and B. pertussis-inoculated mice. 
Analysis was performed on 2,559 genes whose expression was found to be significantly up- or 
down-regulated at an FDR < 0.05. Relatively increased gene-expression is presented in red while 
relatively decreased gene-expression is presented in green. The color scale shows log(2) ratios of 
gene-expression levels compared to the global average. ANOVA analysis identified 206 genes that 
were differentially expressed between the two mouse strains and 2,353 genes that were 
differentially expressed after infection. Hierarchical clustering of the 2,559 regulated genes results 
in four distinct groups, higher in C3H (A), higher in HcB-28 (B), down-regulated after infection in 
both strains (C) and up-regulated after infection in both strains (D). 
Chapter 4 
 
 
 
91 
Results  
Response of C3H and HcB mice to infection 
We have previously examined clearance of B. pertussis from the lungs of 
infected RCS mice, and established that HcB-28 mice contained lower numbers 
of bacteria in their lungs seven days post inoculation compared to C3H mice 
(Figure 1b) (3). To examine whether the genetic differences between “resistant” 
HcB-28 mice and “susceptible” C3H mice also result in a different transcriptional 
response to B. pertussis infection, we compared gene expression profiles of the 
lungs of infected and uninfected HcB-28 and C3H mice (2,3). mRNA transcription 
profiles were determined in at least five animals per group.  
The three mock-inoculated groups of each mouse strain, euthanized at days 
one, three and five, were found to be statistically indistinguishable from each 
other, i.e. both within the same strain and between strains (i.e. there were no 
genes with FDR < 0.6). Of the approximately 22k genes tested, 2,559 genes 
were significantly differentially expressed either in the two mouse strains or 
upon B. pertussis-inoculation (FDR <0.05, corresponding to P<0.0058). The 
gene expression levels of all 2,559 genes are presented in the supplementary 
data Table 3.  The expression profiles of all genes are illustrated by hierarchical 
clustering in Figure 2. ANOVA analysis identified 206 genes (groups A and B) 
that were differentially expressed between the two mouse strains before 
inoculation, and 2,353 genes (groups C and D) that were differentially expressed 
in both strains after infection. Remarkably, there were no genes that were 
differentially expressed between the two mouse strains following inoculation. 
Thus, genes up- or down-regulated upon infection were identically regulated in 
both mouse strains despite their clear genetic differences and differences in B. 
pertussis susceptibility.  
The 206 genes that were differentially expressed between the two strains were 
all unaffected by infection, but displayed a difference in basal expression level. 
Of the 206 strain-dependent genes, 107 genes were expressed at a higher level 
in C3H/DISnA mice (group A) and 99 genes were expressed at a higher level in 
the HcB-28/Dem mice (group B). Of the 2,353 infection-regulated genes, 963 
were down-regulated upon infection (group C), and 1,390 were up-regulated 
upon infection (group D). All genes that were affected by B. pertussis infection 
followed a similar trend in time. One day post-inoculation differential gene 
expression was already observed, but the effect was stronger on days three and 
five post-inoculation. Thus there was no identifiable subset of genes that 
displayed a different kinetic trend in gene expression.  
To assign functions to the differentially expressed genes, we classified them 
according to Gene Ontology (GO) categories. In addition, we determined 
enrichment for location and biological functions to identify pathophysiological 
processes involved in the response to B. pertussis inoculation. The most 
important GO categories, i.e. with the highest percentage differentially 
expressed genes, are summarized in Table 1. Many genes that were 
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differentially regulated between the two strains of mice (groups A and B) are 
located on chromosome 12, predominantly in Bps1 (8 in group A and  9 in group 
B) (3). All the 17 genes that were differentially expressed in the mouse strains 
C3H and HcB-28 and that are located in Bps1 are presented in Table 2, and may 
be considered as candidate susceptibility genes. Of these genes, the strongest 
differences in gene expression between the mouse strains were found for a 
cDNA sequence in group A (BC022687, up to 3.7-fold higher in C3H mice) and 
for Immunoglobulin heavy chain 1 in group B (Igh-1, up to 3.6-fold higher 
expression in HcB-28 mice). Eight genes within Bps1 (6 in group A and 2 in 
group B) showed a strong difference (i.e. at least two-fold) in gene expression 
between the two mouse strains, and map to the immunoglobulin heavy chain 
complex (Igh).   
Of the 2,353 genes that were differentially expressed after B. pertussis infection, 
1,702 genes were identical to the genes we have described previously to be 
regulated upon B. pertussis infection (2). Thus by examining additional mice, we 
identified approximately 650 additional genes regulated by B. pertussis, most of 
which were weakly up- or down-regulated. Most up-regulated genes upon B. 
pertussis infection (group D) are involved in immune- and inflammation-related 
processes or in generic processes, while most down-regulated genes (group C) 
are involved in non-immune processes such as muscle contraction.  
 
 
gy g p
Total on array
Acute-phase response 0 (0%) 0 (0%) 0 (0%) 0 (0%) 13 (59%) 13 (59%) 22
Antigen presentation 0 (0%) 0 (0%) 0 (0%) 0 (0%) 23 (72%) 23 (72%) 32
Apoptosis 0 (0%) 3 (1%) 3 (1%) 9 (3%) 50 (15%) 59 (18%) 324
Cell cycle 0 (0%) 1 (0%) 1 (0%) 30 (6%) 59 (12%) 89 (17%) 510
Chemokine Activity 0 (0%) 0 (0%) 0 (0%) 1 (3%) 24 (67%) 25 (69%) 36
Mus musculus 12 12 (2%) 11 (2%) 23 (4%) 34 (6%) 38 (7%) 72 (13%) 560
Bps-1  (Mus musculus 12) 8 (4%) 9 (5%) 17 (9%) 6 (3%) 8 (4%) 14 (8%) 185
Complement activation 0 (0%) 1 (3%) 1 (3%) 1 (3%) 8 (26%) 9 (29%) 31
Cytokine Activity 0 (0%) 0 (0%) 0 (0%) 8 (4%) 56 (29%) 64 (33%) 192
Cytoskeleton 0 (0%) 2 (0%) 2 (0%) 48 (9%) 45 (8%) 93 (18%) 531
Development 5 (0%) 9 (1%) 14 (1%) 137 (10%) 118 (8%) 255 (18%) 1433
Immune response 1 (0%) 2 (0%) 3 (1%) 6 (1%) 176 (43%) 182 (45%) 408
Inflammatory response 0 (0%) 1 (1%) 1 (1%) 5 (4%) 52 (43%) 57 (47%) 121
Metabolism 3 (0%) 20 (0%) 23 (0%) 300 (6%) 405 (8%) 705 (15%) 4771
Muscle contraction 0 (0%) 0 (0%) 0 (0%) 14 (29%) 2 (4%) 16 (33%) 49
Listed in any of the above 19 29 48 453 656 1109 6574
Other 3 22 25 383 513 896 5639
Unannotated 85 48 133 127 221 348 9744
Total 107 99 206 963 1390 2353 21957
Infection (C+D)Group C Group DGroup A Group B Genotype (A+B)Category
a
Table 1: Gene-ontology based classification of genes with different expression 
aGenes located on chromosome 12 
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Hematologic and immunologic analyses in non-infected C3H and HcB-28 
mice 
To investigate possible differences in the basal immunological parameters 
between the two strains, we analyzed hematologic parameters, mitogen-induced 
splenocyte proliferation, and lymphocyte subset distributions. Because the two 
mouse strains displayed clear differences in basal gene expression, we wanted 
to examine if these differences led to alterations in blood cell composition or 
basal immune status. We observed a slightly higher number of platelets 
(P=0.0003) in the C3H/DISnA mice (1.1*1012/l) compared to the HcB-28/Dem 
mice (9.6*1011/l), and a slightly higher number of white blood cells (P=0.006) in 
the C3H/DISnA mice (7.3*109/l) compared to the HcB-28/Dem mice (6.5*109/l), 
but no differences in the numbers of red blood cells, reticulocytes, lymphocytes, 
neutrophils, eosinophils, and basophils (data not shown). 
Splenocyte proliferation was determined by mitogen-induced 3H-thymidine 
uptake. There was no difference in proliferation between the two strains after ex 
vivo stimulation with Con A (T-cell stimulus), LPS (B-cell stimulus) or Lectin (B- 
and T-cell stimulus) (data not shown). We observed no differences in the 
number of CD19+ (B), CD3+ (T), CD4+ (Th) and CD8+ (CTL) cells (data not 
shown). 
immunoglobulin heavy chain 1a (serum IgG2a)0.00000003.6Igh-1a
expressed sequence AI4509480.00483161.5AI450948
thymoma viral proto-oncogene 10.00002061.8Akt1
adenylosuccinate synthetase like 10.00015181.5Adssl1
protein phosphatase 1, regulatory (inhibitor) subunit 13B0.00000192.2Ppp1r13b
amnionless0.00029301.7Amn
RIKEN cDNA 1700001K19 gene0.00020851.61700001K19Rik
LOC432692
B
0.00051471.4LOC432692
similar to Ig heavy chain V region VH558 A1/A4 precursor0.00003102.1LOC544911
similar to Igh-VJ558 protein0.00008683.2LOC238448
similar to IgE antibody heavy chain (VDJ)0.00160352.7LOC238440
similar to Ig H-chain0.00024822.7LOC211331
similar to immunoglobulin heavy chain0.00438212.8LOC382694
similar to monoclonal antibody heavy chain0.00246272.6LOC544906
cDNA sequence BC0226870.00054533.7BC022687
RIKEN cDNA 2610204M08 gene
A
0.00000001.52610204M08Rik
DescriptionGroupMax. foldSymbol P-value
a
similar to Ig heavy chain variable region precursor0.00000503.5LOC544805
c, d
c
c
c
c
c
c
c
b
Table 2: Candidate susceptibility genes.
aMaximum fold-change between genes that are located in Bps1 and that are significantly 
differentially expressed between C3H and HcB-28 mice.  
bHierarchical clustering as presented in figure 02, higher in C3H (A) or  higher in HcB-28 (B). 
cIn the most recent annotation of the murine genome, eight probes map to the Immunoglobulin 
heavy chain complex (Igh) similar to Ig heavy chain variable region precursor.  
dThe oligo was designed based on accession number XM_484178 annotated as Igh-1a. Because this 
annotation is based on the reference C57BL/6 mice, the oligo can be considered as Igh-1b 
annotated.  
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Figure 3: Serum levels of immunoglobulin classes after B. pertussis infection. 
Twenty-four mice per group were inoculated with either B. pertussis or with culture medium only 
(Mock), mice were subsequently euthanized at one, three or five days post inoculation. Blood was 
collected for the measurement of serum levels of immunoglobulin classes. C3H mice are presented 
in red and HcB mice are presented in green. Dashed lines represent mock-inoculated mice and 
continuous lines represent B. pertussis-inoculated mice. Error bars represent the standard 
deviation. No significant difference (P>0.05, Bonferoni, ANOVA) was found between mock- or B. 
pertussis-inoculated mice of the same mouse strain, except for IgM at day 5 in C3H mice, IgG2a at 
day 5 in C3H mice, IgG2b at day 3 in HcB mice, IgG3 at day 1 in C3H mice and IgG3 at day 3 in 
HcB mice.All serum levels were significantly different (P<0.05, Bonferoni, ANOVA) between the two 
strains of mice except for IgM at day 5, IgG1 at day 1 and IgG2b at all days for B. pertussis 
infected HcB mice compared to C3H mice .   
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Finally we determined levels of IgM and subclasses of IgG in the sera of the 
mock- and B. pertussis-inoculated mice (Figure 3). Infection did not affect Ig 
levels compared to mock-infected mice of the same strain. We did, however, 
observe a significant difference in the Ig subset distribution between the two 
mouse strains (either mock- or B. pertussis-inoculated). C3H mice had 
significantly higher serum levels of IgM, IgG1, IgG2a and IgG3, while HcB-28 
mice had significantly higher IgG2b levels compared to C3H mice. Importantly, 
HcB-28 mice had no detectable levels of IgG2a in the serum at all, which is 
consistent with the difference in gene expression at the Igh-1 locus between the 
two mouse strains.  
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Figure 4: Relative gain or loss of weight after inoculation. 
Twenty-four mice per group were inoculated with either B. pertussis or culture medium only (Mock) 
and body weights were measured daily.  
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Figure 5: Summary of lung pathology post mock- or B. pertussis-inoculation. 
H&E stained slides were examined for alveolitis, perivasculitis and hypertrophy of mucus-producing 
glands. Lung lesions were scored semi-quantitatively as absent (0), minimal (1), slight (2), 
moderate (3), marked (4), or severe (5) per type of lesion and added up to calculate the 
pathology-score (range 0-15). Dots represent the pathology score per individual mouse, horizontal 
lines represent the groups median.  
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Figure 6: Examples of lung pathology post B. pertussis inoculation. 
Lung sections (H&E, obj x 20) from B. pertussis infected mice. A: HcB28 day 1, mild alveolitis (grade 
2 on scale from 1-5), as seen by inflammatory cells in alveolar septa and spaces. B: C3H day 3, 
alveolitis and thickened septa (pneumonia) varying from grade 3 (upper, right) to 5 (bottom). C: 
C3H day 3, asterix: perivasculitis grade 5, and arrow: hypertrophy bronchiolar epithelium, grade 3. 
D: HcB28 day 3, no major differences in pathology compared to C3H (B and C). 
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Clinical and pathological findings in B. pertussis-infected C3H and HcB-
28 mice 
To examine whether the two mouse strains differed in weight loss after 
infection, we determined their body weights after infection. Infected mice lost 
three to four percent of their body weight during the first five days post-
inoculation, while all mock-inoculated mice gained weight during these five days 
(Figure 4). No significant differences in the gain or loss of weight were observed 
between the two strains, irrespective whether they were infected or not.  
As a quantitative endpoint for inflammation, we determined lung weights 
relative to body weight. All mock-inoculated mice had relative lung weights of 
approximately one percent five days after inoculation, while B. pertussis-infected 
mice had relative lung weights of up to three percent. This difference in relative 
lung weights due to B. pertussis infection is significant from day one till day five 
post-inoculation, but was similar in both mouse strains (data not shown).    
Histopathological evaluation of lung sections was performed as a second 
parameter of lung inflammation.  Intranasal inoculation of B. pertussis causes an 
acute inflammatory response that is characterized by influx of 
polymorphonuclear leukocytes (PMNs) and macrophages, starting in the 
perivascular and peribronchiolar areas on day one, and extending to alveolar 
walls and lumina on days three and five. No differences were observed in the 
histopathological lesions findings between the two mouse strains (Figure 5 and 
6).    
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Discussion 
Studying genetic differences in susceptibility to B. pertussis infection may point 
to novel insights in the pathogenesis of this infection. We have previously 
identified B. pertussis susceptibility locus-1 (Bps1) in HcB-28 mice (3). The Bps1 
locus is located on chromosome 12, spanning a region of 185 genes and has a 
dominant positive effect on the clearance of B. pertussis from the lung. In this 
study we examined gene expression profiles in HcB-28 and C3H mice, which 
differ in their susceptibility to B. pertussis. Twelve and a half percent of the 
genomes of these mice are from a different genetic background (12,31). The 
traditional approach for identification of relevant genes in susceptibility loci is a 
combination of positional cloning and linkage analysis (26,28). This method has 
proven to be effective (8,27), but has disadvantages. We have therefore chosen 
for an alternative strategy. Using this approach we attempted to identify 
candidate susceptibility genes that control the difference between these two 
mouse strains. We hypothesized that the difference in susceptibility to B. 
pertussis infection could (partly) be explained by a different gene expression 
profile between the mouse strains.  
We have previously shown that B. pertussis infection in C3H mice induces a wide 
transcriptional response, which appears to be partly specific for B. pertussis and 
partly non-specific (2). This study revealed that 1,841 genes are differentially 
expressed in the lungs of mice after B. pertussis inoculation, and most up-
regulated genes are involved in immune- and inflammation-related processes or 
in generic processes, while most down-regulated genes are involved in non-
immune processes. In the present study, we found that HcB-28 and C3H mice 
showed a similar gene expression profile upon infection and identified 
approximately 650 additional genes regulated by B. pertussis, most of which 
were weakly up- or down-regulated. However, the gene expression profiles and 
enrichment for GO categories were identical as described in the previous study. 
A substantial number of genes and pathways suggest a central role of PMN 
recruitment and activation in the pathogenesis of B. pertussis infection. The 
transcriptional profiles further indicate in particular the significance of TLR 
activation and apoptosis (2). The reason for the detection of the 650 additional 
genes, besides the strain differences, is that by adding an extra mouse strain 
the number of samples doubled increasing the power of detection. Hundred and 
thirty-nine genes which we have described previously to be regulated upon B. 
pertussis infection were not detected in the present study. These genes were 
borderline significantly regulated (median FDR of 0.03) and only slightly induced 
(median 1.4-fold). These genes are therefore probably less important in the host 
response to B. pertussis infection. The finding that this list of 139 genes does 
not show significant enrichment for any GO-term, including immunological 
terms, corroborates this.  
Although the two mouse strains differ in 12.5% of their genome (12.5% of the 
genomes of these mice are from a different genetic background), we observed 
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no marked differences in their phenotypical characteristics other than the 
previously observed difference in bacterial numbers in the lungs after infection 
(Figure 1b). C3H mice did have slightly higher numbers of circulating platelets 
and white blood cells compared to the HcB mice, but the cellular proportions, as 
well as the proliferation of splenocytes was identical for both strains. There was 
also no significant difference observed in body weight, lung weight and 
histopathological findings in response to B. pertussis infection between the two 
mouse strains. The major difference is that HcB-28 mice did not have detectable 
IgG2a serum levels.  
We observed 206 genes that were differentially expressed between the two 
mouse strains, but these genes were identically expressed in mock- or B. 
pertussis-inoculated mice. The majority of these genes (65%) are unannotated. 
These unannotated genes tend to have no GO functional annotation, because 
they are not "regular" protein-coding genes and many of them are not 
(sufficiently) mapped to a chromosomal locus to warrant including them under 
chromosome 12 or Bps-1. The mentioned 23 genes, which were mapped to 
chromosome 12, are significant at P = 5.29e-014 (Fisher exact probability, 
Bonferroni correction for multiple testing). The same test applied to all other 
mouse chromosomes yielded P values > 0.05. Twenty-three out of the 206 
genes were located on chromosome 12, which can be explained by the fact that 
approximately one fifth of the genetic variation between the two mouse strains 
is due to variation on chromosome 12 (3). Because the genes that were 
differentially regulated between the two mouse strains only showed differences 
in expression before infection, it appears likely that such intrinsic differences in 
gene regulation are involved in determining differences in susceptibility to B. 
pertussis infection. Alternatively, such genetic differences may be explained by 
genes that are not differentially regulated between these two strains of mice, or 
by processes at present not fully characterized and possibly involving differential 
expression of genes by mechanisms such as microRNA’s. Remarkably, 17 of 
these genes were located in the Bps1 region, 8 of which mapped to the Igh 
complex. Among these 8 genes were the Igh-1 gene and genes that encode for 
Ig heavy chain variable regions. We observed a significantly higher expression 
(up to 2.8-fold) of the gene variant of Igh-1 isotype b in HcB mice compared to 
C3H mice. The Igh locus is genetically polymorphic and very complex (30). The 
Igh-1 gene exists in 2 major genetic variants (Igh-1a and Igh-1b) with 83.8% 
similarity (20). The Igh-1a allele codes for the heavy chain of IgG2a while the 
Igh-1b allele codes for the heavy chain of IgG2c (19). Mouse strains such as 
C57BL/6 and C57BL/10 (the donor strain of the HcB mice) only contain the gene 
variant Igh-1b  and are therefore incapable of producing IgG2a, while mouse 
strains such as BALB/c only contain the gene variant of Igh-1a and are therefore 
incapable of producing IgG2c (19,20). The oligo for Igh-1 spotted on the 
microarray, was designed based on accession number XM_484178 annotated as 
Igh-1a. Because this annotation is based on the reference C57BL/6 mice, this 
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oligo can be considered as Igh-1b annotated. In the sera of HcB mice we 
detected no IgG2a while C3H mice had significant titers of IgG2a, thereby 
confirming the expression results. It is tempting to speculate if and how genes 
within the Igh complex may affect differences early in the course of B. pertussis 
infection. Possible mechanisms may include differences in transcriptional gene 
regulation affecting immune responsiveness, different function of the IgG2a or c 
isotypes, or different usage of V chains. This latter possibility might imply the 
existence of “natural antibodies” reacting with B. pertussis epitopes. It has 
previously been shown that genes within the Igh-1 locus are predominantly 
associated with the course of a herpes simplex virus type-1 (HSV-1) infection in 
mice by an unknown mechanism (11,23,32). Pro-inflammatory cytokines such 
as IL-1, IL-4, IL-6 and IL-7 participate in this infection (1). Interestingly, 
natural killer cell activity appears to be regulated by the Igh-1 locus but could 
not simply explain the differences in HSV-1 susceptibility (32). Igh-linked genes 
have further been implicated in T suppressor cell activity (15,22). 
 
Conclusions 
In this study we reduced the number of candidate susceptibility genes within the 
Bps1 locus by microarray analysis. Gene expression changes upon B. pertussis 
infection appear highly identical between C3H and HcB-28 mouse strains despite 
the different course of B. pertussis infection in these strains. Because the genes 
that were differentially regulated between the mouse strains only showed 
differences in expression before infection, it appears likely that such intrinsic 
differences in gene regulation are involved in determining differences in 
susceptibility to B. pertussis infection. Alternatively, such genetic differences in 
susceptibility may be explained by genes that are not differentially regulated 
between these two mouse strains or by processes other than differential gene 
expression. Genes in the Igh complex, among which Igh-1, may be likely 
candidates to explain differences in susceptibility to B. pertussis. Further work 
should establish the role of the Igh complex in B. pertussis infection and 
determine its mode of action. 
 
Supplementary data 
Raw data as well as the detailed description of the experiment was uploaded to 
the freely accessible online database ArrayExpress 
http://www.ebi.ac.uk/arrayexpress/. Expression levels of all 2,559 genes are 
presented in the supplementary data. 
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Abstract 
Susceptibility to and severity of Bordetella pertussis infections in infants and 
children varies widely, suggesting that genetic differences between individuals 
influence the course of infection. We have previously identified three novel loci 
that influence the severity of whooping cough using recombinant congenic 
strains of mice, Bordetella pertussis susceptibility locus 1, 2 and 3 (Bps1, 2 and 
3). Because these loci could not account for all genetic differences between 
mice, we extended our research for additional susceptibility loci. We therefore 
screened eleven inbred strains of mice for susceptibility towards a pertussis 
infection after intranasal infection. Susceptibility was defined by the number of 
bacteria in the lungs, being indicative for the effect between the clearance and 
replication of bacteria. The most resistant (A/J) and the most susceptible 
(C3H/HeJ) strains were selected for further genetic and phenotypic 
characterization.  
Linkage between bacterial clearance and chromosomal location was investigated 
using 300 F2 mice, generated by crossing A/J and C3H/HeJ mice. We found 
linkage between delayed clearance of bacteria from the lung and a large part of 
chromosome 4 in F2 mice with a maximum LOD-score of 33.6 at 65.4 Mb, which 
is the location of Tlr4. C3H/HeJ mice carry a functional mutation in the 
intracellular domain of Tlr4. This locus accounted for all detectable genetic 
differences between these strains.  
Compared to A/J mice, C3H/HeJ mice showed a delayed clearance of bacteria 
from the lung, a higher relative lung weight, and increased body weight loss. 
Splenocytes from infected C3H/HeJ mice produced almost no IL1- and TNF- 
upon ex vivo restimulation with B. pertussis, compared to A/J mice, and also 
showed a delayed IFN- production. TNF- expression in the lungs three days 
after infection was 5-fold increased compared to non-infected controls in A/J 
mice and unaffected in C3H/HeJ mice.  
In conclusion, Tlr4 is a major host factor explaining the differences in the course 
of infection between these inbred strains of mice. Functional Tlr4 is essential for 
an efficiënt IL1-, TNF- and IFN- response,  efficient clearance of bacteria from 
the lung, and reduced lung pathology. 
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Introduction 
The clinical course of Bordetella pertussis infection varies widely. Knowledge 
about host genetic and immunological factors that influence susceptibility and 
severity of infection, may lead to the identification of new approaches for 
prevention or treatment of this disease (13). Knowledge of human genetic 
factors that influence B. pertussis infection is still very limited. A number of 
studies have provided clues for the role of host genes in susceptibility of mice to 
B. pertussis infection (4,11,19,23). We have recently shown that host genes of 
mice affects the clearance of bacteria from the lung and that B. pertussis 
infection is under multigenic control. This study resulted in the identification of 
three novel loci (Bps1 – 3) that influence the clearance of B. pertussis from the 
lung These loci could explain up to 10% of the variation in the lung colonization 
observed in F2 mice Therefore additional loci are likely to influence the course of 
B. pertussis infection (2). In the present study, we used inbred strains of mice to 
identify additional genetic factors. 
In addition to Bps1-3, others identified the Toll Like Receptor 4 (Tlr4) as a major 
factor that influences the course of Bordetella bronchiseptica and B. pertussis 
infection in mice (11,20,21). In these studies C3H/HeJ mice were used. These 
mice carry a functional mutation in the gene coding for Tlr4 rendering them 
unresponsive to lipopolysaccharide (LPS) (6,26). 
The aims of the present study were, first, to examine whether inbred strains of 
mice show genetic differences in susceptibility to B. pertussis and second, 
whether we could identify genetic loci responsible for such differences, and third, 
to examine the pathobiological mechanisms of the identified susceptibility loci. 
To this aim, we compared the present approach using inbred strains of mice to 
our previous approach using recombinant congenic strains of mice. We 
examined lung colonization, lung pathology, and the immune responses of 
inbred strains after infection to correlate phenotypic characteristics of infection 
with the genetic background of the mice. 
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Materials and Methods 
Experimental design 
We examined the course of B. pertussis infection in 11 inbred strains of mice. 
Approximately 8 animals of each strain were initially used to determine the 
number of bacteria in the lung one week post infection.  A total of 300 F2 hybrid 
mice were obtained by crossing the strain with the highest number of bacteria in 
the lung (C3H/HeJ) with the strain with the lowest number of bacteria in the 
lung (A/J) and subsequently intercrossing their F1 progeny. The 300 F2 hybrid 
mice were examined as described below. Due to logistical limitations we infected 
50 mice per day and combined the results. To assure the reproducibility of the 
infection model, BALB/c mice were included on each day of infection and 
infected in the same way. The original inbred strains of mice were examined on 
three different days. The F2 hybrid mice were examined on six different days. 
To confirm that differences in lung pathology and clinical response were caused 
by Tlr4, Tlr4 defective (Tlr4Lps-d) C3H/HeJ mice, Tlr4 wild-type (Tlr4Lps-n) A/J and 
C3H/HeOuJ mice were infected with B. pertussis as described below. To control 
groups (mock) a similar volume of Verwey medium was given.  
The number of bacteria in the lungs of the BALB/c control mice, one week post-
infection, was similar regardless of the day the experiment was performed.  
Because there was no significant difference between any of the control groups 
(p>0.05), we combined the results of all experiments (data not shown). 
 
Animals 
Female mice were used for the infection experiments. A/J, C57BL/6J, SPRET/Ei, 
Cast/Ei, DBA/2J, B10.D2.H2/oSnJ, AKR/J, BALB/cJ, 129X1/SvJ, C3H/HeOuJ and 
C3H/HeJ strains of mice were supplied by the Jackson Laboratory (JAX, Bar 
Harbor, USA). BALB/cOlaHsd (referred to as BALB/c) mice were supplied by 
Harlan (Harlan Europe, Horst, The Netherlands). F2 hybrid mice were generated 
by crossing A/J mice with C3H/HeJ mice, and subsequently intercrossing their F1 
progeny. Mice were acclimatized for at least one week before the start of the 
experiments. Mice received standard laboratory chow (SRM-A, Hope Farms, 
Woerden, the Netherlands) and tap water ad libitum. All animal experiments 
were approved by the Institute’s Animal Ethics Committee.  
 
Bacteria 
B. pertussis strain B213, a Tohama derivative (ptxA1,prn1), and B. pertussis 
strain B2566, a clinical isolate from 1997 (ptxA2, prn2) (14,25) were cultured by 
plating on Bordet-Gengou agar supplemented with 15% sheep blood and 
30g/ml streptomycin. Plates were incubated for 4 days at 35°C.  The number of 
colony forming units (CFU) was determined using a ProtoCOL SR Colony counter 
(Synbiosis, Camebridge, UK). All dilutions of bacteria were made in Verwey 
medium (NVI, Bilthoven, the Netherlands). 
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Infection experiments 
The number of viable B. pertussis bacteria was determined in the lung one week 
after infection (14,35). Briefly, mice were intranasally infected with 2*107 colony 
forming units (CFU) of B. pertussis after being anaesthetized with isoflurane. 
Seven days after infection, mice were sacrificed and the lungs were collected. A 
ligature was made around the right bronchus, after which the right lobes were 
removed for counting of bacteria (34). The remaining left lung lobe were fixed 
intratracheally using 4% formalin for histological examination. The right lung 
lobes were homogenized in Verwey medium, and diluted 10 and 1,000 times. 
The number of CFU in these dilutions was determined by plating on Bordet 
Gengou agar supplemented with 15% sheep blood and 30g/ml streptomycin. 
Plates were incubated for 4 days at 35°C before counting the number of bacteria 
using a ProtoCOL Colony counter (Synbiosis). 
 
Macroscopic and histopathologic examination 
Mice were weighed one week before infection, and three, seven, fourteen and 
twenty-one days after infection to determine the relative gain or loss of weight. 
Lung weights were determined after sacrifice of mice as a parameter for lung 
inflammation. Lung weights are represented relative to the body weights.  
Formalin-fixed lungs were embedded in paraplast (Monoject). Transverse 
sections of 5 m were stained with hematoxylin-eosin. In a blinded fashion, an 
independent observer examined the slides for peribronchiolitis (i.e., infiltration of 
inflammatory cells in the peribronchiolar space), alveolitis (i.e., infiltration of 
inflammatory cells in the alveoli), perivasculitis (i.e., infiltration of inflammatory 
cells in the perivascular space), hypertrophy of mucus-producing glands, free 
protein and eosinophilia. Lung lesions were scored semi-quantitatively as absent 
(0), minimal (1), slight (2), moderate (3), marked (4), or severe (5),  as 
previously described (3). 
 
Genotyping 
Genomic DNA was isolated from mice tails using the DNeasy Tissue kit (Qiagen). 
The sequences of all primers were obtained from the mouse genome database of 
the Massachusetts Institute of Technology (MIT) (24). DNA was amplified in 10 
μl volume using 5 μl hotstar 2x Mastermix (Qiagen), 1.0 μM of each primer and 
approximately 10ng tail-DNA. 6-Carboxyfluorescein (FAM)-labeled microsatelite 
primer-sets were used (Isogen Life science, Maarssen, the Netherlands). 
Amplification was performed on a GeneAmp PCR System 9700 (Applied 
Biosystems), as follows: 15 min at 95°C to denature the DNA and activate the 
Hotstar Taq, 30 cycles of 45 sec at 94°, 45 sec at 57°C and 1 min at 70°C, and 
finally 10 min at 72°C. Fragment sizes were determined on a 3700 Capillary 
DNA Sequencer/Genotyper system (Applied Biosystems) using Genotyper 
software (Applied Biosystems).  The single nucleotide polymorphism (SNP) 
markers were analyzed by Restriction Fragment Length Polymorphism (RFLP)-
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assay on a 2.5% agarose gel (Table 1). PCR was performed as described above, 
restriction conditions were used according to the manufacturer’s instructions 
(New England Biolabs).  
 
Cytokine responses 
To examine cytokine production by spleen cells after infection, single-cell 
suspensions were prepared from the spleen by pressing the tissue through a cell 
strainer (Falcon). The cells were washed once in RPMI 1640 (Gibco BRL, Life 
Technologies). The splenocytes (1.5*105 cells per well) were cultured (37°C, 5% 
CO2) in 96-wells tissue culture plates (Nunc, Denmark) in the presence of 
concanavalin A (ConA) (5 g/ml, Sigma Chemical Co.) or B. pertussis (1.0*105 
heat-inactivated bacteria per well). Bacteria were heat-inactivated at 56°C 
during 30 min. The culture medium was composed of RPMI 1640 (Gibco BRL, 
Life Technologies), supplemented with 2 mM glutamine, penicillin, streptomycin, 
HEPES buffer, 	-mercaptoethanol (50 mM) and 10% FCS. After 72 h, culture 
supernatant was collected and stored at 
80°C until analysed for cytokine 
production (5,33). 
IL1-	, IFN- and TNF- concentrations were determined by ELISA (Biosource 
International) using the concentrations recommended by the manufacterer.  
Briefly, 96-well plates (Nunc-Immuno Plate) were coated with 1.25 g/ml anti-
mouse IL1-	, IFN- or TNF- in coating buffer (0.05 M carbonate buffer, pH 9.6, 
Sigma). After overnight incubation at 4°C, the plates were incubated in blocking 
buffer (1% BSA in Tris buffered saline, Sigma) for 2 h at room temperature 
(RT), and washed (0.05% Tween-20, Merck, the Netherlands). Recombinant 
mouse cytokines (Biosource) were used as a standard. Standards, as well as 
serial dilutions of splenocyte culture supernatants, were added to the plate. 
Plates were incubated at 37 °C for 2 h and washed. Biotinylated anti-mouse IL1-
	, IFN- or TNF- (0.125 g/ml) was added, and incubated for 1 h at RT. The 
plates were washed, and horseradish peroxidase-labeled streptavidin (10000-
fold dilution, Strepta-E+, Central Laboratory of the Blood transfusion service, 
Amsterdam, the Netherlands) was added and incubated for 1 h at RT. After 
washing, Tetramethylbenzidine solution (0.1 mg/ml TMB, Sigma-Aldrich) plus 
0.006% H2O2, in 0.1 M Sodium Acetate (pH 5.5) was added. The color reaction 
was stopped by adding Sulfuric acid (10%, Merck). The plates were measured  
at 450 nm on a fluostar platereader (Fluostar galaxy, BMG Labtech, 
Germany)(32). 
 
Table 1: SNP assays 
a Mismatch primer was used to create a restriction site for SspI. 
Chromosome Position (Mb) Forward primer Reverse Primer Restriction Enzyme
C3H A/J
Rs4224427 4 32 caaagaggctgaagcacttg gtctaggaccttcccacaa A G SspI
rs3023006(Tlr4) 4 65,4 gctttcacctctgccttcac ataaccttccggctcttgtg A C Hsp92 II
Rs3022979 4 75,5 ataatggggctaacgcaatg gaagagggcatcagtgttcc A C BsrI
SNP Allele
a
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TLR4 and TNF- mRNA expression 
To examine mRNA expression, lungs from infected animals were incubated 
overnight in RNA-later (Qiagen) at 4°C, and stored at -80°C. Lungs were 
homogenized in RLT-buffer (Qiagen) with a rotor homogenizator, and RNA was 
extracted with a RNeasy kit (Qiagen) as described by the manufacturer. cDNA 
was generated using the High Capacity cDNA archive kit containing random 
hexamer primers (Applied Biosystems). mRNA expression was measured using 
Taqman gene expression assays (Applied Biosystems) on a 7500 Fast Real-Time 
PCR System. We used assays on demand for Tlr4 (Mm00445274_m1) and TNF- 
(Mm00443258_m1). For the reference gene, RNA Polymerase IIa (Polr2a),  the 
assay was designed using the primer express program (Applied Biosystems) 
resulting in probe CATCCGCTTCAATTCAT, forward PCR primer 
GCAGTTCGGAGTCCTGAGT, and reverse PCR primer 
CCCTCTGTTGTTTCTGGGTATTTGA. Taqman probes carried a 5' FAM reporter 
label and a 3' Non Fluoro quencher(NFQ) group. Taq polymerase was activated 
by heating for 20 sec at 95°C. Amplification was for 3 sec at 95°C and 30 sec at 
60°C for 40 cycles in a Taqman Fast Universal PCR Master mix (Applied 
Biosystems) containing 5 μl of cDNA template, 1l TaqMan Gene Expression 
Assay mix (20X mix containing primers and probes) in a total volume of 20 μl. 
The fluorescence intensity of the reporter label was normalized to the rhodamine 
derivative ROX as a passive reference label present in the buffer solution (9,30). 
The relative concentration of  the Tlr4 and TNF- mRNA was determined by the 
comparative threshold cycle method (ddCt) (1,9,30). Each sample was run in 
triplicate. 
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Statistical analysis 
The differences in numbers of CFU in the lungs between the different inbred 
strains of mice were examined by Analysis of Variance (ANOVA, SPSS) and 
tested with the Student-Newman-Keuls test for multiple comparisons or 
Bonferoni post hoc test. The Bonferoni post hoc test is known to be the most 
conservative test for analysis of variance (ANOVA) analysis. The test is similar to 
for instance the Fisher’s least significant difference test (LSD), but the observed 
significance levels are adjusted for the number of comparisons made. If a 
difference is significant according to the Bonferoni, it is for all other tests. The 
Student-Newman-Keuls test was used to test the difference between multiple 
groups. To stabilize variances and to obtain approximately normal distributions, 
the CFU’s were square root (sqrt) or natural definition (ln) transformed. In F2 
mice, linkage between the CFU’s in the lung and the genetic markers, and the 
effect on the total phenotypic variation, were calculated by ANOVA with 
genotype as fixed factor, and CFU as dependent variable. To correct for the 
influence of experiment, experiment was included as random factor. All single 
markers and all pairs of non-linked markers were tested for linkage with another 
marker or interaction between markers. Interaction, or epistasis, is defined as 
the combined effect of two or more genes on a phenotype that could not have 
been predicted as the sum of their separate effects (8). Linkage is presented as 
p-value and Log of the odds (LOD) score. The latter was calculated as –log of 
the significance (p-value).  
All markers and interactions were tested at the level of 0.05 (p<0.05). p-values 
were corrected for multiple comparisons using the formula (15,16) : 
 
Pcorrected = [C+2GT
2]P 
 
Where Pcorrected is the desired corrected p-value, C is the number of 
chromosomes segregating in the cross (20 for mice),   is the crossover rate 
(1.5 for a F2 hybrid generation), G is the genome length of the segregating part 
of the donor genome in Morgans (the mouse genome is  16M), T2 is the 
threshold (the F-value from ANOVA for the observed p-value is used as T2) and 
P is the observed uncorrected p-value. 
The estimated effect of a linked locus on the total of the observed phenotypic 
variation is presented as R2 (ANOVA, SPSS). To test the reproducibility of the 
infection protocol, we performed a T-test between the CFU’s of the control mice 
infected in different experiments. 
Difference in survival of animals was calculated by Kaplan Meier analysis 
(Survival, SPSS). We used time after infection when death occurred as Time, 
Death as status, and Group as factor.   
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Results  
Colonization 
To examine whether inbred strains of mice differ in susceptibility to B. pertussis, 
we examined 11 different inbred strains of mice. The number of viable B. 
pertussis bacteria in the lung one week after infection was used as phenotype. 
The number of CFU varied from 2.4*105 to 1.2*107 CFU per lung (Figure 1), 
therewith confirming the genetic basis for modulation of the course of B. 
pertussis infection. Significant differences in lung colonization were observed 
between some of these strains of mice.  From these strains we selected A/J as 
most resistant strain and C3H/HeJ as most susceptible strain to generate an F2 
intercross generation.  
 
Figure 1: Colonization of  inbred strains of mice by B.pertussis. 
Inbred strains of mice were infected intranasally with B.pertussis strain B213, and seven days later 
lungs were removed, and the number of viable B.pertussis (B213) was determined. Each dot 
represents the number of bacteria in the lung of an individual mouse.  Horizontal lines indicate the 
group average. Upper horizontal lines connect groups of mice who are mutually not significantly 
different according to the Student Neuman Keuls test. From these strains, A/J and C3H/HeJ were 
selected for generating F2 hybrid generations. 
A/J C57Black6/J SPRET/Ei Cast/ei DBA/2J B10.D2.H2/oSNj AKR/J BALB/cJ 129X1/SvJ BALB/cOlaHsd C3H/HeJ
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Linkage analysis 
To search for genetic loci that could explain the differences between C3H/HeJ 
and A/J mice, 300 (A/J x C3H/HeJ) F2 hybrid mice were infected and examined 
as described above. As expected, the F2 mice showed a greater variation in the 
numbers of bacteria compared to the parental strains (Figure 2).  The number of 
CFU per lung ranged from 1 x 102 (detection limit) to almost 1 x 108. The 
average number of CFU was 4,5 x 106. All mice were individually genotyped, and 
we compared the genotypes with phenotypes to identify possible susceptibility 
loci by linkage analysis.  
We started testing markers in the Bps1 region (2) and a mutation in the Tlr4 
gene that was described in C3H/HeJ mice (11,21).  We found no linkage with 
markers from the Bps1 region (data not shown), but strong linkage was found 
with the Tlr4 locus with a LOD-score of 33.6 (P=2.324 x 10-34,  Pcorrected=1.188 x 
10-30). Additional markers surrounding this gene were tested and almost all 
markers located on chromosome 4 showed linkage with reduced clearance of 
bacteria from the lungs, with a maximum LOD-score of 33.6 at 50.3cM, which is 
the location of Tlr4 (Figure 3).  Forty-five percent (r2=0.451) of the variation in 
the number of bacteria in the experiments could be ascribed to Tlr4.  Due to 
logistical limitations the F2 hybrid mice were examined in six experiments. To 
assure the reproducibility of the infection model each experimental group 
contained BALB/c mice that were infected in the same way.  There was no 
significant difference in CFU’s in BALB/c mice between different experiments 
(P=0.365). However, the residual mean square error of the results in the BALB/c 
mice (2 = 1.35 x 106) is larger than the residual mean square error of the Tlr4 
genotype (2 = 1.07 x 106), which means that the residual variation is due to 
environmental variation. Thus, virtually all of the genetically detectable variation 
in lung clearance in these experiments could be ascribed to the Tlr4 gene. 
Though we set out to test approximately 5 markers per chromosome, we 
decided that further testing was no longer informative.   
 
Influence of bacterial genetic differences 
To examine whether genetic differences in B. pertussis also affect the course of 
infection in these mice, we infected A/J and C3H/HeJ mice with B. pertussis 
strain B213 and a recent clinical isolate (B2566). The two strains differ with 
respect to pertussis toxin and pertactin. The number of bacteria in the lungs of 
mice infected with B. pertussis strain B2566 was similar to the number of 
bacteria in the lungs of mice infected with B. pertussis strain B213. A/J mice 
showed an average of 2*105 bacteria per lung while C3H/HeJ mice showed an 
average of 2*107 CFU per lung (Figure 4). So, the observed difference between 
these inbred strains of mice does not appear to be B. pertussis strain-specific.  
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Figure 2: Colonization of 
B213 in A/J x C3H/HeJ F2 
mice. 
The F2 generation, obtained 
by crossing C3H/HeJ mice 
with A/J mice and 
subsequently intercrossing 
their F1 progeny, was 
infected intranasally with 
B.pertussis. Seven days after 
infection, lungs were 
removed, and the number of 
viable B.pertussis was 
determined. Each dot 
represents the number of 
bacteria in the lung per 
individual mouse.  Horizontal 
lines indicate the group 
average. Horizontal 
connecting lines represent the 
level of significance of 
difference between groups. 
The experiment was 
performed twice and a 
representative result was 
shown. 
Figure 3: Linkage between 
the degree of colonization 
and markers on 
chromosome 4. 
Linkage (LOD-score) between 
the degree of lung 
colonization by B.pertussis 
(phenotype) and 
chromosomal loci (genotype). 
The association was 
calculated by ANOVA with 
genotypes as fixed factor, 
and square root CFU as 
dependent variable. The LOD 
score is plotted as -log p 
against the physical distance 
of chromosome 4. The region, 
has a maximum LOD-score of 
33.6 (p=2.324*10-34, R2 = 
0,451) for the p712h mutant 
in Toll like receptor 4(Tlr4). 
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Time course of colonization 
Because Tlr4 appeared to be a dominant genetic factor, we subsequently 
characterized the role of Tlr4 in more detail. We first examined the number of 
bacteria at different time points after infection in different strains of mice.  
The number of bacteria in the lung was determined 3, 7, 14 and 21 days after 
infection of A/J(Tlr4Lps-n), C3H/HeOuJ(Tlr4Lps-n) and C3H/HeJ (Tlr4Lps-d) mice 
(Figure 5). C3H/HeOuJ mice are genetically identical to C3H/HeJ mice except for 
the mutation in the Tlr4 gene (31). A/J and C3H/HeOuJ showed the same course 
of clearance of bacteria from the lung, while C3H/HeJ mice showed a 
significantly slower clearance as evidenced by a higher number of CFU’s per lung 
up to 14 days post-infection. Twenty-one days after infection, almost all bacteria 
were cleared from the lung in all groups of mice.  
 
Clinical observations.  
To characterize differences in the clinical course of infection between C3H/HeJ 
(Tlr4Lps-d) and A/J (Tlr4Lps-n) mice, 24 mice of both strains were inoculated with 
B. pertussis (6.1x107CFU per mice). Unexpectedly several animals died after 
infection (Figure 6). Nine A/J mice died within the first four days after infection, 
while eleven C3H/HeJ mice died after four days.   
All mice were weighed one week before infection, and 3, 7, 14 and 21 days after 
infection. Differences in body weight are presented in Figure 7. Infected mice 
lost 5 to 15 percent of their body weight in the first seven days after infection. 
Fourteen days after infection, A/J mice had regained most of their initial weight, 
while C3H/HeJ mice were still losing weight. Twenty-one days after infection all 
mice had regained their weight. Thus, in these two strains of mice, mortality 
appears to be inversely related to weight loss after infection, i.e. A/J mice died 
earlier, but surviving mice recovered quicker compared to C3H/HeJ mice.   
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Figure 4: Colonization in two inbred strains of mice by distinct B.pertussis strains. 
Seven days after inoculation with B.pertussis B213 (Tohama) and B2566 (a recent clinical isolate), 
lungs were removed, and the number of viable B.pertussis was determined. Each dot represents 
the number of bacteria in the lung of an individual mouse.  Horizontal lines indicate the group 
average. Horizontal connecting lines represent the level of significance of difference between 
groups. Mice inoculated with B.pertussis B213 are displayed in the left panel, mice inoculated with 
B.pertussis B2566 are displayed in the right panel.  
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Figure 5: Time course of colonization of B.pertussis in different strains of mice.  
CFU’s in the lungs of A/J, C3H/HeOuJ (both Tlr4Lps-n) and C3H/HeJ (Tlr4Lps-d) mice. Three, seven, 
fourteen and twenty-one days after inoculation with B.pertussis, lungs were removed, and the 
number of viable B.pertussis was determined. The mean of the number of CFU’s was plotted with 
the standard deviation. Asterisks indicate a significant difference in the number of CFU’s between 
C3H/HeJ mice and A/J or C3H/HeOuJ mice. One asterisk indicate a p<0.05, 2 asterisks indicate 
p<0.01. The data are representative of two different experiments.  
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Figure 5: Time course of colonization of B.pertussis in different strains of mice.  
CFU’s in the lungs of A/J, C3H/HeOuJ (both Tlr4Lps-n) and C3H/HeJ (Tlr4Lps-d) mice. Three, seven, 
fourteen and twenty-one days after inoculation with B.pertussis, lungs were removed, and the 
number of viable B.pertussis was determined. The mean of the number of CFU’s was plotted with 
the standard deviation. Asterisks indicate a significant difference in the number of CFU’s between 
C3H/HeJ mice and A/J or C3H/HeOuJ mice. One asterisk indicate a p<0.05, 2 asterisks indicate 
p<0.01. The data are representative of two different experiments.  
Figure 6: Survival of mice after infection  
Survival of mice after infection with B.pertussis.  Solid line represents C3H/HeJ mice (Tlr4Lps-d), 
dashed line represents A/J mice (Tlr4Lps-n).   
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Lung pathology 
The role of Tlr4 in lung pathology was examined by comparing differences in 
lung lesions between C3H/HeJ (Tlr4Lps-d) and A/J (Tlr4Lps-n) mice. Lungs were 
weighed as a marker for inflammation. Relative lung weights are presented in 
Figure 8. Mock-infected mice had an average relative lung weight of 1%, while 
B. pertussis-infected mice had higher relative lung weights. C3H/HeJ mice had 
significantly higher relative lung weights after infection compared to A/J mice.  
Lung lesions are summarized in Table 2. Examples of typical lesions are 
presented in Figure  9. The inflammatory response to B. pertussis in the two 
strains of mice examined were similar during the first week after infection. After 
three and seven days, the peribronchiolar and perivascular inflammation 
remained slight to moderate. However, two and three weeks after infection, 
perivasculitis was stronger in the A/J strain than in the C3H/HeJ strain. Also a 
remarkable difference in the quantity of free protein in the alveoli, which is 
indicative for  inflammatory exudate, was observed. C3H/HeJ mice had a 
marked inflammatory exudate at three days post infection, which was even 
more pronounced  at days 14 and 21. This inflammatory exudate is very likely 
responsible for the increased lung weight. In contrast, the A/J mice had no or 
only a slight inflammatory exudate. No strain differences were seen in 
peribronchiolitis, alveolitis, the extent of the hypertrophy of the bronchiolar 
epithelium,  and  eosinophilia. 
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Figure 7: Gain of weight after infection  
Gain of weight after B.pertussis inoculation. Solid boxes represent the mean of C3H/HeJ mice (Tlr4Lps-d), grey 
boxes represent A/J mice (Tlr4Lps-n). Asterisks represent the significance between the two inbred strains at 
the specific point of time. One asterisk represents p<0.05 while two asterisks represent p<0.001. The data 
are representative of two different experiments. 
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Mouse strain 
Days after infection Mock 3 7 14 21 Mock 3 7 14 21 
Intercurrent deaths - - 2 2 3     - - 5 2 1 
Number examined 6 6 4 4 3     6 6 1 4 5 
Peribronchiolitis 
  minimal 
  slight 
  moderate 
  marked 
 
- 
- 
- 
- 
 
- 
6 
- 
- 
 
- 
3 
1 
- 
 
- 
1 
3 
- 
 
- 
- 
3 
- 
 
- 
- 
- 
- 
 
- 
2 
3 
- 
 
- 
1 
- 
- 
 
- 
- 
2 
2 
 
- 
- 
5 
- 
Perivascular infiltrate 
  minimal 
  slight 
  moderate 
  marked 
  strong 
 
3 
- 
- 
- 
- 
 
- 
5 
1 
- 
- 
 
- 
- 
4 
- 
- 
 
- 
- 
3 
1 
- 
 
- 
- 
3 
- 
- 
 
- 
- 
- 
- 
 
 
- 
1 
3 
1 
- 
 
- 
- 
1 
- 
- 
 
- 
- 
- 
2 
2 
 
- 
- 
1 
3 
1 
Hypertrophy br.epithelium 
  minimal 
  slight 
  moderate 
  marked 
  strong 
 
- 
- 
- 
- 
- 
 
- 
- 
- 
6 
- 
 
- 
- 
- 
1 
3 
 
- 
- 
- 
2 
2 
 
- 
- 
1 
2 
- 
 
- 
- 
- 
- 
- 
 
- 
- 
2 
3 
- 
 
- 
- 
- 
1 
- 
 
- 
- 
- 
1 
3 
 
- 
- 
1 
4 
- 
Alveolitis 
  minimal 
  slight 
  moderate 
  marked 
  strong 
 
- 
- 
- 
- 
- 
 
- 
- 
6 
- 
- 
 
- 
- 
2 
2 
- 
 
- 
- 
2 
1 
1 
 
1 
1 
1 
- 
- 
 
- 
- 
- 
- 
- 
 
- 
2 
2 
1 
- 
 
- 
- 
1 
- 
- 
 
- 
- 
- 
4 
- 
 
2 
2 
1 
- 
- 
Protein in alveoli 
 minimal 
 slight 
 moderate 
 marked 
 strong 
 
- 
- 
- 
- 
- 
 
- 
- 
2 
2 
2 
 
- 
- 
1 
- 
3 
 
- 
1 
1 
- 
2 
 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
 
5 
- 
- 
- 
- 
 
- 
- 
- 
1 
- 
 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
C3H/HeJ A/J
a
Table 2: Summary of histological lung changes in two strain of mice infected with B. 
pertussis.  
a H&E stained slides were examined for peribronchiolitis, alveolitis, perivasculitis, hypertrophy of 
mucus-producing glands, free protein and eosinophili. Lung lesions were scored semi-quantitatively 
as absent (0), minimal (1), slight (2), moderate (3), marked (4), or severe (5)  
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Figure 9: Examples of time dependency of Lung Pathology after infection. 
H&E-stained lung sections, bar = 100 m. a. Control A/J mouse bronchiole with thin epithelial layer 
surrounded by empty alveoli. b. Three days post infection of  a C3H/HeJ mouse a slight 
peribronchiolar (asterisk, score 2) and perivascular infiltrate (arrow) is obvious, together with a 
moderate hypertrophy of the bronchiolar epithelium (centre right, score 3). The alveoli show a 
moderate infiltrate and free protein in the alveolar space.  
c. Seven days post infection a C3H/HeJ mouse shows a slight peribronchiolitis (asterisk) and a 
moderate perivasculitis (arrow). The hypertrophy of the bronchiolar epithelium is very strong (score 
5). In all alveoli free cells as well as protein are present.  
d. Two weeks after infection an A/J mouse has a moderate peribronchiolitis (score 3) and a marked 
perivasculitis (centre, score 4). A strong hypertrophy of the bronchiolar epithelium is shown with 
inflammatory cells inside. Some alveolar macrophages are observed (top, right).  
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Figure 8: Lung weight 
after infection
Relative lung weight of 
mice after infection with 
B.pertussis. Solid boxes 
represent the mean of 
C3H/HeJ mice (Tlr4Lps-d), 
grey boxes represent A/J 
mice (Tlr4Lps-n). Asterisks 
represent the significance 
between the two inbred 
strains at the specific point 
of time. One asterisk 
represents p<0.05 while 
two asterisks represent 
p<0.001. The data are 
representative of two 
different experiments. 
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Figure 10: Cytokine production 
after ex vivo stimulation of 
splenocytes  
IL1- (a), TNF- (b) and IFN- (c) 
cytokine production of splenocytes 
isolated from B.pertussis-infected 
mice after 3 days of ex vivo re-
stimulation with heat-inactivated 
B.pertussis. Solid line represents the 
mean of C3H/HeJ mice (Tlr4Lps-d), 
dashed line represents A/J mice 
(Tlr4Lps-n).  The plotted p-value 
represents the overall difference in 
cytokine production between the 
mice. 
Cytokine response 
IL1-	, TNF- and IFN- production were determined in supernatants of 
splenocytes isolated at various days after infection from B. pertussis-infected A/J 
and C3H/HeJ mice after 3 days of ex vivo re-stimulation with heat-inactivated B. 
pertussis or ConA.  Because Tlr4 engagement also modulates the adaptive Th1 
immune response (7,12,18,22),   IFN- was taken as  parameter of the  aquired 
immune response.  
As expected, supernatants of cells that were cultured in the absence of antigens 
did not show cytokine production, while supernatants of cells that were cultured 
in the presence of ConA showed production of all three cytokines. There was no 
difference in ConA-induced cytokine production between mouse genotypes or 
the various days after infection.   
The cytokine production of splenocytes restimulated with heat-inactivated B. 
pertussis is shown in Figure 10. Culture supernatants from splenocytes isolated 
from A/J mice showed an increase of IL1-	, TNF- and IFN- from 3 days till 14 
after infection. At day 21 after infection, the cytokine concentrations decreased. 
In contrast, culture supernatants from splenocytes isolated from C3H/HeJ mice 
only showed a small cytokine response. No IL1-	 response and only a slight 
increase in TNF- and IFN- production was seen from 14 days after infection 
onwards.  
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TLR4 and TNF- gene expression 
The Tlr4-dependend induction of TNF- has been shown to be critical for the 
early host response to B.bronchiseptica (20,21). Therefore, we examined gene 
expression of Tlr4 and TNF- in lung tissue of mice three days after infection 
with B. pertussis. Data are presented in Figure 11 as fold expression relative to 
mock-treated A/J mice (shown in grey). All expression data are calculated 
relative to the housekeeping gene RNA polymerase IIa (Polr2a). C3H/HeJ mice, 
either MOCK-treated or B. pertussis infected, showed no upregulation of 
expression of Tlr4, while B. pertussis-infected A/J mice showed a 1.5-fold 
upregulation of this receptor.  In addition B. pertussis-infected A/J mice showed 
a 5-fold upregulation of TNF-, while infected C3H/HeJ mice only showed a 
slight, insignificant upregulation in expression of this gene.  
 
0,0
0,5
1,0
1,5
2,0
2,5
   MOCK    B.pertussis     MOCK     B.pertussis
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
8,0
   MOCK    B.pertussis     MOCK     B.pertussis
fo
ld
 e
x
p
re
s
s
io
n
 o
f 
T
L
R
-4
fo
ld
 e
x
p
re
s
s
io
n
 o
f 
T
N
F
-a
a
b
*
*
Figure 11: Gene expression of TLR-4 and TNF- in infected lung tissue. 
Gene expression of TLR-4 (a) and TNF- (b) in lung tissue of mice three days after inoculation with 
B.pertussis. Gene expression was compared relative to mock-treated A/J mice. Solid boxes 
represent the mean of 5 C3H/HeJ mice (Tlr4Lps-d), grey boxes represent the mean of 5 A/J mice 
(Tlr4Lps-n). Stars indicate a significant difference of p<0.05 according to the Bonferoni test between 
groups. 
Chapter 5 
 
 
 
127 
Discussion 
By previously identifying three susceptibility loci (Bps1 – 3) in recombinant 
congenic strains of mice we showed that the clearance and/or replication of 
pertussis in mice is under multigenic control. These loci could explain up to 10% 
of the variation in the lung colonization observed in F2 mice (2). Because the 
contribution of these loci to genetic variation was small, we started the present 
study using inbred strains of mice instead of recombinant congenic strains of 
mice. By using this approach, we expected to examine a broader range of 
genetic variation, possibly leading to the identification of additional susceptibility 
loci. 
Significant differences in clearance were observed between these strains of 
mice.  From these strains we selected A/J as the most resistant strain and 
C3H/HeJ as the most susceptible strain, to generate an F2 intercross generation 
and to subsequently identify susceptibility loci, and to examine phenotypic 
characteristics. 
We had originally planned to use a low-density genome-wide scan, with SNP 
markers, but mainly due to the Poltorak paper(26) we started by analyzing this 
particular mutation in Tlr4. It turned out that the association between CFU’s and 
this mutation was so prominent that we calculated that possible other genetic 
effects could not be detected in this F2 generation. We therefore have not 
performed a whole genome-wide scan, but concentrated on markers on 
chromosome 4 as displayed in Figure  2. 
We subsequently identified Tlr4 as a major factor that influences the course of B. 
pertussis infection in mice. We calculated by linkage analysis that a large part of 
chromosome 4 was linked with reduced clearance of bacteria from the lungs , 
with a maximum LOD-score of 33.6 at 65.4Mb, which is the location of Tlr4. 
As the number of mice was too large for analysis on a single day, the 
experiments were executed on multiple days. Because BALB/c control mice were 
included in each of these days we were able to estimate the contribution of Tlr4 
to the total variation. We calculated that the residual mean square error of the 
BALB/c mice is larger than the residual mean square error of the Tlr4 genotype. 
This means that the residual variation is smaller than the variation in inbred 
strains, strongly suggesting that no additional detectable genetic variation was 
left. We therefore concluded that the residual variation is due to environmental 
variation, and that all of the genetically described variation in these experiments 
could be ascribed to the Tlr4 gene. Although other (modifier) genes are 
expected to influence the course of pertussis, it is not possible to detect the 
effect of these genes in F2 hybrids generated from these two strains of mice due 
to the strong effect of Tlr4. We did, however, analyze markers located in Bps1, 
but did not find any linkage, probably due to the reason mentioned before. Thus, 
Tlr4 dominates the variation in clearance of bacteria from the lungs in the first 
week after infection in these strains of mice.  
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To confirm the importance of Tlr4 function in B. pertussis infection, we infected 
mice of A/J(Tlr4Lps-n), C3H/HeOuJ(Tlr4Lps-n) and C3H/HeJ (Tlr4Lps-d). C3H/HeOuJ 
mice are genetically identical to C3H/HeJ mice except for the pro712his 
mutation in the gene encoding for Tlr4 (31).  A/J and C3H/HeOuJ mice showed 
the same course of clearance of bacteria from the lung, while C3H/HeJ mice 
showed a delayed clearance of bacteria from the lung. Thus this experiment 
unequivocally confirmed the significance of Tlr4.  
Remarkably, although A/J mice cleared B. pertussis more efficiently, we 
observed no difference in overall mortality after B. pertussis infection between 
A/J and C3H/HeJ mice. However A/J mice died earlier than C3H/HeJ mice. Thus 
mortality appeared associated in time with the inflammatory response. As 
described below, additional inflammatatory and pathobiological parameters 
confirmed the association between bacterial clearance, inflammation and clinical 
effects. 
In A/J mice, cytokine production of splenocytes re-stimulated ex-vivo with heat-
inactivated B. pertussis showed an increase of IL1-	, TNF-, and IFN- 
production, three days after infection, with a maximum at day 14 after infection. 
In C3H/HeJ mice, however, there was very little production of IL1-	, and little 
production of TNF-, and no IFN- production. Although Higgins et.al. (11)  
suggested a role for Tlr4 in inhibiting Th1 responses by activating IL-10 
production, our results indicate that Tlr4 engagement is not only essential for 
the innate response, but also for stimulation of the ensuing Th1 response, which 
is in line with other reports (7,12,18,22).  Functional Tlr4 may be required for 
the production of IL-10, which is associated with limiting the inflammatory 
pathology (11). In the present study we observed enhanced lung pathology in 
Tlr4-defective mice, especially enhanced lung weight, which underlines the 
significance of Tlr4 limiting bacterial growth and probably also inflammation. 
However, it is likely that in C3H/HeJ mice pathology resulting from infection 
differs from that in TLR-4 competent mice as a result of different levels of 
expression or production of IL-1, TNF-, and IFN-. In response to LPS 
inhalation a TNF--dependent neutrophil influx in the BALF is seen in C3H/HeN 
but not in C3H/HeJ mice (10). In addition, gene profiling of lung tissue showed 
that 74% of the genes responsive to a Klebsiella  pneumoniae infection was TLR-
4 dependent(28). Interestingly, during lung inflammation C3H/HeJ mice did not 
show perivascular accumulation of inflammatory cells, whereas A/J mice did 
(29). In addition, Escherichia coli inhalation resulted in a similar clearance in 
C3H/HeJ and in C3H/HeSnJ mice, but resulted in lower proinflammatory cytokine 
levels and reduced neutrophils accumulation in C3H/HeJ mice(17). 
Three days after infection B. pertussis-infected C3H/HeJ mice showed no 
expression of Tlr4 while similarly treated A/J mice showed a 1.5-fold 
upregulation of this receptor. This upregulation may be suggestive of actual 
receptor engagement. B. pertussis-infected A/J mice showed a 5-fold 
upregulation of TNF-, while C3H/HeJ mice only showed a slight, not significant, 
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upregulation of this gene. This suggests that Tlr4-dependent TNF- expression 
in the lung is an innate response to B. pertussis infection, similar to the 
observations for B.  bronchiseptica (20,21). It has been shown that early elicited 
TNF- release is critical for host defence against B.  bronchiseptica, and that this 
process is Tlr4 dependent (20,21). Although the course of infection with B. 
bronchiseptica is different from infection with B. pertussis, our data underline 
the significance of early TNF- production in limiting bacterial growth. In 
C3H/HeJ mice other, possibly compensatory mechanisms might be operational. 
Functional Tlr4 seems to affect TNF- levels both in lung and spleen.   
Also in humans the role of Tlr4 in infectious diseases has been investigated in 
genetic association studies (27). Associations were usually investigated for two 
SNP’s, Asp299Gly and Thr399Ile, that result in amino acid changes in the 
extracellular domain of the receptor. Associations were found in some reports, 
but not in others, as recently reviewed by Schröder and Schumann (27). 
In conclusion, we have shown that C3H/HeJ mice have delayed clearance of 
bacteria from the lung, increased lung pathology, more weight loss, and a lower 
IL1-	, TNF-, and IFN- production after infection compared to A/J mice. We 
showed that Tlr4 is a major genetic factor that was sufficient to explain all 
detectable genetic differences in bacterial clearance between these mice. 
Functional Tlr4 is required for an early TNF-, IL1-	, and IFN- response that 
may enhance bacterial clearance and thus, despite the proinflammatory nature 
of theses cytokines may limit pathology. This early cytokine response was fatal 
for app. 50% of the mice, but the surviving mice had efficiently cleared the 
bacteria from the lungs, and little lung pathology and rather quickly regained 
their body weight. A lack of this response resulted in delayed mortality, but 
these mice were less efficient in clearing the bacteria from the lungs and 
became very ill from lung edema, slowly regained their body weights. 
 
 
Acknowledgements 
The authors thank Kees Heuvelman and Marjolein van Gent for helping with the 
animal experiments, and Marina van Doeselaar for her work on the genetic 
markers. Next we want to thank Eric Gremmer for his useful help in setting up 
ELISA’s. We are grateful for the expert histotechnical assistance of Mrs.F.M. de 
Vlugt- van den Koedijk. Furthermore we would like to thank all biotechnicians of 
our animal facility, for performing the animal experiments. 
 
Host genetics and genomics of Bordetella pertussis infection and vaccination 
 
 
 
130 
Reference list 
 
 1.  Ariani, F., F. Mari, C. Pescucci, I. Longo, M. Bruttini, I. Meloni, G. 
Hayek, R. Rocchi, M. Zappella, and A. Renieri. 2004. Real-time 
quantitative PCR as a routine method for screening large rearrangements 
in Rett syndrome: Report of one case of MECP2 deletion and one case of 
MECP2 duplication. Hum.Mutat. 24:172-177 
 2.  Banus, S., H. J. van Kranen, F. R. Mooi, B. Hoebee, N. J. 
Nagelkerke, P. Demant, and T. G. Kimman. 2005. Genetic Control of 
Bordetella pertussis Infection: Identification of Susceptibility Loci Using 
Recombinant Congenic Strains of Mice. Infect.Immun. 73:741-747 
 3.  Barends, M., M. van Oosten, C. G. De Rond, J. A. Dormans, A. D. 
Osterhaus, H. J. Neijens, and T. G. Kimman. 2004. Timing of infection 
and prior immunization with respiratory syncytial virus (RSV) in RSV-
enhanced allergic inflammation. J.Infect.Dis. 189:1866-1872 
 4.  Barnard, A., B. P. Mahon, J. Watkins, K. Redhead, and K. H. Mills. 
1996. Th1/Th2 cell dichotomy in acquired immunity to Bordetella 
pertussis: variables in the in vivo priming and in vitro cytokine detection 
techniques affect the classification of T-cell subsets as Th1, Th2 or Th0. 
Immunology 87:372-380 
 5.  Boelen, A., A. Andeweg, J. Kwakkel, W. Lokhorst, T. Bestebroer, J. 
Dormans, and T. Kimman. 2000. Both immunisation with a formalin-
inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen 
vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-
challenged mice. Vaccine 19:982-991 
 6.  Buer, J. and R. Balling. 2003. Mice, microbes and models of infection. 
Nat.Rev.Genet. 4:195-205 
 7.  Dillon, S., A. Agrawal, T. Van Dyke, G. Landreth, L. McCauley, A. 
Koh, C. Maliszewski, S. Akira, and B. Pulendran. 2004. A Toll-like 
receptor 2 ligand stimulates Th2 responses in vivo, via induction of 
extracellular signal-regulated kinase mitogen-activated protein kinase and 
c-Fos in dendritic cells. J.Immunol. 172:4733-4743 
 8.  Frankel, W. N. and N. J. Schork. 1996. Who's afraid of epistasis? 
Nat.Genet. 14:371-373 
Chapter 5 
 
 
 
131 
 9.  Giulietti, A., L. Overbergh, D. Valckx, B. Decallonne, R. Bouillon, 
and C. Mathieu. 2001. An overview of real-time quantitative PCR: 
applications to quantify cytokine gene expression. Methods 25:386-401 
 10.  Goncalves, d. M., V, V. B. Boris, J. Lefort, A. Meager, and M. 
Chignard. 1996. Effect of cyclo-oxygenase inhibitors and modulators of 
cyclic AMP formation on lipopolysaccharide-induced neutrophil infiltration 
in mouse lung. Br.J.Pharmacol. 117:1792-1796 
 11.  Higgins, S. C., E. C. Lavelle, C. McCann, B. Keogh, E. McNeela, P. 
Byrne, B. O'Gorman, A. Jarnicki, P. McGuirk, and K. H. Mills. 2003. 
Toll-like receptor 4-mediated innate IL-10 activates antigen-specific 
regulatory T cells and confers resistance to Bordetella pertussis by 
inhibiting inflammatory pathology. J.Immunol. 171:3119-3127 
 12.  Kapsenberg, M. L. 2003. Dendritic-cell control of pathogen-driven T-cell 
polarization. Nat.Rev.Immunol. 3:984-993 
 13.  Kimman, T.2001.Genetics of Infectious Disease Susceptibility. Kluwer 
Academic Publishers, 0-7923-7155-0 
 14.  King, A. J., G. Berbers, H. F. van Oirschot, P. Hoogerhout, K. 
Knipping, and F. R. Mooi. 2001. Role of the polymorphic region 1 of the 
Bordetella pertussis protein pertactin in immunity. Microbiology 147:2885-
2895 
 15.  Lander, E. and L. Kruglyak. 1995. Genetic dissection of complex traits: 
guidelines for interpreting and reporting linkage results. Nat.Genet. 
11:241-247 
 16.  Lander, E. S. and N. J. Schork. 1994. Genetic dissection of complex 
traits. Science 265:2037-2048 
 17.  Lee, J. S., C. W. Frevert, G. Matute-Bello, M. M. Wurfel, V. A. Wong, 
S. M. Lin, J. Ruzinski, S. Mongovin, R. B. Goodman, and T. R. 
Martin. 2005. TLR-4 pathway mediates the inflammatory response but 
not bacterial elimination in E. coli pneumonia. Am.J.Physiol Lung Cell 
Mol.Physiol  
 18.  Li, W., T. Yajima, K. Saito, H. Nishimura, T. Fushimi, Y. Ohshima, Y. 
Tsukamoto, and Y. Yoshikai. 2004. Immunostimulating properties of 
intragastrically administered Acetobacter-derived soluble branched (1,4)-
Host genetics and genomics of Bordetella pertussis infection and vaccination 
 
 
 
132 
beta-D-glucans decrease murine susceptibility to Listeria monocytogenes. 
Infect.Immun. 72:7005-7011 
 19.  Mahon, B. P., B. J. Sheahan, F. Griffin, G. Murphy, and K. H. Mills. 
1997. Atypical disease after Bordetella pertussis respiratory infection of 
mice with targeted disruptions of interferon-gamma receptor or 
immunoglobulin mu chain genes. J.Exp.Med. 186:1843-1851 
 20.  Mann, P. B., K. D. Elder, M. J. Kennett, and E. T. Harvill. 2004. Toll-
like receptor 4-dependent early elicited tumor necrosis factor alpha 
expression is critical for innate host defense against Bordetella 
bronchiseptica. Infect.Immun. 72:6650-6658 
 21.  Mann, P. B., M. J. Kennett, and E. T. Harvill. 2004. Toll-Like Receptor 4 
Is Critical to Innate Host Defense in a Murine Model of Bordetellosis. 
J.Infect.Dis. 189:833-836 
 22.  Medzhitov, R. 2001. Toll-like receptors and innate immunity. 
Nat.Rev.Immunol. 1:135-145 
 23.  Mills, K. H., M. Ryan, E. Ryan, and B. P. Mahon. 1998. A murine model 
in which protection correlates with pertussis vaccine efficacy in children 
reveals complementary roles for humoral and cell- mediated immunity in 
protection against Bordetella pertussis. Infect.Immun. 66:594-602 
 24.  MIT. 2004. Look Up STSs by Name. 
[Online].http://www.broad.mit.edu/cgi-
bin/mouse/sts_info?database=mouserelease Accessed 28 April 2004 
 25.  Mooi, F. R., H. van Oirschot, K. Heuvelman, H. G. van der Heide, W. 
Gaastra, and R. J. Willems. 1998. Polymorphism in the Bordetella 
pertussis virulence factors P.69/pertactin and pertussis toxin in The 
Netherlands: temporal trends and evidence for vaccine-driven evolution. 
Infect.Immun. 66:670-675 
 26.  Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. 
Birdwell, E. Alejos, M. Silva, C. Galanos, M. Freudenberg, P. 
Ricciardi-Castagnoli, B. Layton, and B. Beutler. 1998. Defective LPS 
signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. 
Science 282:2085-2088 
Chapter 5 
 
 
 
133 
 27.  Schroder, N. W. and R. R. Schumann. 2005. Single nucleotide 
polymorphisms of Toll-like receptors and susceptibility to infectious 
disease. Lancet Infect.Dis. 5:156-164 
 28.  Schurr, J. R., E. Young, P. Byrne, C. Steele, J. E. Shellito, and J. K. 
Kolls. 2005. Central role of toll-like receptor 4 signaling and host defense 
in experimental pneumonia caused by Gram-negative bacteria. 
Infect.Immun. 73:532-545 
 29.  Singh, B., K. Shinagawa, C. Taube, E. W. Gelfand, and R. Pabst. 
2005. Strain-specific differences in perivascular inflammation in lungs in 
two murine models of allergic airway inflammation. Clin.Exp.Immunol. 
141:223-229 
 30.  Swillens, S., J. C. Goffard, Y. Marechal, d. A. de Kerchove, and H. El 
Housni. 2004. Instant evaluation of the absolute initial number of cDNA 
copies from a single real-time PCR curve. Nucleic Acids Res. 32:e56 
 31.  The Jackson Laboratory. 2005. Mouse Phenome Database; View mouse 
SNPs. [Online].http://aretha.jax.org/pub-
cgi/phenome/mpdcgi?rtn=snps/door Accessed 10 August 2005 
 32.  Vandebriel, R. J., W. H. De Jong, J. J. Hendriks, and H. Van 
Loveren. 2003. Impact of exposure duration by low molecular weight 
compounds on interferon-gamma and interleukin-4 mRNA expression and 
production in the draining lymph nodes of mice. Toxicology 188:1-13 
 33.  Vandebriel, R. J., S. M. Hellwig, J. P. Vermeulen, J. H. Hoekman, J. 
A. Dormans, P. J. Roholl, and F. R. Mooi. 2003. Association of 
Bordetella pertussis with host immune cells in the mouse lung. 
Microb.Pathog. 35:19-29 
 34.  Verwey, W. F., E. H. Thiele, D. N. Sage, and L. T. Suchardt. 1949. A 
simplified liquid culture medium for the growth of Haemophilus pertussis. 
J.Bacteriol. 58:127-134 
 35.  Willems, R. J., J. Kamerbeek, C. A. Geuijen, J. Top, H. Gielen, W. 
Gaastra, and F. R. Mooi. 1998. The efficacy of a whole cell pertussis 
vaccine and fimbriae against Bordetella pertussis and Bordetella 
parapertussis infections in a respiratory mouse model. Vaccine 16:410-
416 
 
 
Host genetics and genomics of Bordetella pertussis infection and vaccination 
 
 
 
134 
Host genetics and genomics of Bordetella pertussis infection and vaccination 
 
Chapter 6 
The role of Toll-like receptor-4 in pertussis 
vaccine-induced immunity. 
Submitted for publication 
Sander Banus1,2, Rachel Stenger3, Eric Gremmer2, Jan Dormans2, Frits 
Mooi1, Tjeerd Kimman1, and Rob Vandebriel2 
 
1Laboratories for Infectious Diseases and Screening, 2Health Protection Research, National Institute 
of Public Health and the Environment (RIVM) 3The Netherlands Vaccine Institute (NVI) 
 
 
Chapter 6 
 
 
 
137 
Abstract 
Pertussis is an infectious disease of the respiratory tract. The gram-negative 
bacterium Bordetella pertussis is an important causative agent of this disease. In 
most developed countries whole-cell pertussis vaccines (wP) have been replaced 
by acellular vaccines (aP), because wP were found to be reactogenic. In contrast 
to wP, aP do not contain LPS, raising concerns on the efficacy of aP, and also on 
the efficacy of vaccines administered simultaneously with aP. Adjuvants like LPS 
that activate toll-like receptor-4 (Tlr4) may improve the efficacy of bacterial 
subunit vaccines. To establish the role of Tlr4 in pertussis vaccine-induced 
immune responses we compare Tlr4-deficient C3H/HeJ and wild-type C3H/HeOuJ 
mice in our model of B. pertussis challenge after wP or aP vaccination. aP 
consisted of pertussis toxin (Ptx), filamentous hemagglutinin (FHA), and 
pertactin (Prn). 
In Tlr4-deficient mice, compared to wild-type controls (i) after vaccination only, 
Ptx-IgG, FHA-IgG, and Prn-IgG levels were similar, (ii) after infection (only), the 
number of bacteria was higher, while IL-1 and IL-1 expression and IFN- and 
IL-17 production were lower, (iii) after wP vaccination and challenge, the 
number of bacteria, Prn-IgG levels, and IL-5 expression were higher, while IL-
1, TNF-, IFN-, IL-17, and IL-23 expression and IL-17 production were lower, 
and lung pathology was absent, and (iv) after aP vaccination and challenge, the 
number of bacteria, Prn-IgG levels, and IL-5 expression were higher, while Ptx-
IgG levels were lower. 
Tlr4 plays an important role in natural immunity, wP and aP efficacy, and the 
induction of Th1 and Th17 responses after wP vaccination and challenge. Tlr4 
affects a more limited set of parameters in case of aP vaccination than in case of 
wP vaccination. The presence of functional Tlr4 is critical for lung pathology after 
wP vaccination and challenge, enhances pro-inflammatory cytokine production 
after wP vaccination and challenge, and diminishes Th2 responses after wP and 
aP vaccination and challenge. The humoral response to vaccination (without 
challenge) is not influenced by Tlr4. The importance of Tlr4 in efficacy underlines 
a role for Tlr4 agonists (such as LPS analogs) in improving efficacy of bacterial 
subunit vaccines.  
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Background 
Pertussis is among the ten infectious diseases with the highest morbidity and 
mortality worldwide. An important causative agent of pertussis is the gram-
negative bacterium Bordetella pertussis. After introduction of whole-cell vaccines 
(wP) in the 1950’s, pertussis incidence has decreased significantly. Although 
being efficacious, wP vaccines were found to be reactogenic. Therefore, acellular 
vaccines (aP) comprising purified B. pertussis proteins have been developed. 
Concerns have been raised, however, with respect to the relative efficacy of aP 
as compared with wP, and also of vaccines administered simultaneously with aP, 
such as diphtheria, tetanus, polio, and Haemophilus influenzae b (Hib) vaccines 
(1). 
 
It has been suggested that the limited efficacy of aP may be caused, in part, by 
the fact that, in contrast to wP, aP do not contain lipopolysaccharide (LPS). In 
mice Th17 cells (2) as well as Th1 cells are induced by wP vaccination, but not 
(or to a much lesser extent) by aP vaccination (3). Furthermore, the induction of 
these Th17 and Th1 cells is Tlr4-dependent (3). Importantly, Th17 and Th1 cells 
are critical for clearing a B. pertussis challenge (3). Together, these results 
underline the importance of Tlr4 (and hence, also its agonists such as LPS) in 
generating immune responses induced by pertussis vaccines, at least in mice. 
Besides, Tlr4 is also critical for pertussis clearance and ensuing adaptive 
immunity in non-vaccinated mice (4,5,6). The efficacy of vaccines that do not 
contain LPS, such as viral vaccines, can be improved by supplementation with 
Tlr4 agonists that show no or little endotoxin activity. We have shown that 
supplementing the bacterial subunit vaccine aP with the Tlr4 agonist 
monophosphoryl lipid A improved its efficacy (7). 
 
We have previously shown that Tlr4 influenced lung pathology and production of 
proinflammatory cytokines, such as IL-1 and TNF-, after B. pertussis infection 
of mice (9). In another study, we have shown that (particularly) wP vaccination 
and B. pertussis challenge induced lung pathology and lung TNF- expression 
(8). In addition, wP and especially aP vaccination and B. pertussis challenge 
induced type I hypersensitivity, a Th2 driven response (8). A role for Tlr4 was, 
however, not addressed. To improve our understanding of supplementing aP 
with Tlr4 agonists, and following data from our group (6,8) and others (3,4,5) 
we studied the role of Tlr4 in bacterial clearance, humoral immune response, 
and lung pathology. To detect inflammatory as well as Th1, Th17, and Th2 
responses, lung and systemic cytokine expression was measured. 
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In this study, we confirm that Tlr4 plays an important role in natural immunity, 
and show its important role in wP and aP efficacy, as well as induction of Th1 
and Th17 responses. The set of parameters affected by Tlr4 is more limited in 
case of aP vaccination than in case of wP vaccination. The presence of functional 
Tlr4 is critical for lung pathology after wP vaccination and challenge, enhances 
pro-inflammatory cytokine production after wP vaccination and challenge, and 
diminishes Th2 responses after both wP and aP vaccination and challenge. The 
humoral response to vaccination (without challenge) is not influenced by Tlr4.  
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Figure 1: Colonization of the lungs by B. pertussis.  
Tlr4-deficient C3H/HeJ and control C3H/HeOuJ mice were subcutaneously (sc) injected with 1/5 
human dose (HD) wP, aP, or adjuvant (C), twice before intranasal B. pertussis infection. Three and 
seven days after challenge lungs were excised, and the number of viable B. pertussis was 
determined in right lung lobes. Each symbol represents the number of bacteria in the lung of an 
individual mouse; horizontal lines represent the group average. (**) P<0.01; (***) P<0.001. Non-
boxed asterisks show the P-value against the indicated group. Boxed asterisks show the P-value against 
the wild-type mouse strain. ANOVA followed by Bonferroni post-hoc test. A single representative 
experiment of 2 is shown. 
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Materials and Methods 
Animals 
Female mice were used at 6-8 weeks of age. Tlr4Lps-d C3H/HeJ (31) and wild-type 
control C3H/HeOuJ mice were obtained from Jackson (Bar Harbor, ME). The diet 
consisted of ground standard laboratory chow (RMH-B, Hope Farms, Woerden, the 
Netherlands). Food and water were given ad libitum. All animal experiments were 
performed according to national and international guidelines. 
 
Vaccines 
The wP vaccine is a whole-cell pertussis vaccine, combined with vaccines against 
diphtheria, tetanus, and poliomyelitis, and produced by the Netherlands Vaccine 
Institute, Bilthoven, the Netherlands. One human dose (HD) contains 1.6x1010 
CFU of two B. pertussis strains (strains 509 and 134; 8 opacity units /strain) in 1 
ml saline, and is adjuvated with 1.5 mg aluminum phosphate. 
 
The aP vaccine is 3-component acellular pertussis vaccine, combined with 
vaccines against diphtheria and tetanus, and produced by GlaxoSmithKline, 
Rixensart, Belgium. One HD contains 25 g formaldehyde- and glutaraldehyde-
detoxified pertussis toxin, 25 g filamentous hemagglutinin, and 8 g pertactin 
in 0.5 ml saline, and is adjuvated with aluminum hydroxide (< 0.625 mg Al per 
HD). 
 
Vaccination 
One HD wP or aP was diluted with 0.5% Al(OH)3 gel (Serva, Heidelberg, 
Germany) to a final volume of 2.5 ml. Mice (6 per group) received a 
subcutaneous injection with 0.5 ml of 1/5 HD wP, 1/5 HD aP, or adjuvant alone, 
28 and 14 days before infection (8,11). Note that the ratio between adjuvant 
and bacteria (in case of wP) or between adjuvant and proteins (in case of aP) 
was considerably higher in the murine vaccine doses than in the original human 
vaccine doses. 
 
Infection of mice and autopsy 
The mice were anaesthetized with isoflurane. Two h before infection, 3 drops of 
blood were collected from the orbital plexus. A single drop of 40-l inoculum 
containing 2x107 B. pertussis cells (Tohama strain B213) was carefully placed on 
the top of the nose and allowed to be inhaled ((32)). 
 
Mice were sacrificed 3 or 7 days after challenge, except in case of lung 
pathology in which case the mice were sacrificed 3 days after infection only. 
They were anaesthetized with ketamine, rompun, and atropine, and blood was 
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collected from the orbital plexus. Perfusion of the right ventricle was performed 
with 2 ml PBS supplemented with 3.5% heat-inactivated Fetal Calf Serum (FCS; 
PAA, Linz, Austria). The lungs were excised and used to obtain bronchial lymph 
nodes (LN) and lung lobes. The left lung lobes were formalin-fixed for histological 
examination or collected in RNA-later (Qiagen, Venlo, the Netherlands) for RNA 
extraction, while the right lung lobes were used for enumeration of bacteria. 
 
Lung lobes, CFU determination, and histological examination 
A ligature was made around the right bronchus after which the right lobes were 
removed for enumeration of bacteria. The lobes were homogenized in 900 l of 
Verwey medium using a tissue homogenizer (Pro-200, ProScientific, Monroe, CT) 
at maximum speed for 10 s. The homogenates were diluted in Verwey medium 
10- and 100-fold for the immunized mice, and 1000-fold for the control mice. 
Hundred-l aliquots of the dilutions were plated on BG plates supplemented with 
streptomycin and incubated at 35oC for 5 days. The remaining left lung lobes 
were fixed intratracheally using 4% formalin for 24 h. After overnight dehydration, 
they were embedded in paraffin. Five-m sections were cut and stained with 
haematoxylin/eosin. Histological lesions were semi-quantitatively scored as absent 
(0), minimal (1), slight (2), moderate (3), strong (4), or severe (5), respectively. 
This score incorporates the frequency as well as the severity of the lesions. 
 
 
Ptx-, FHA-, and Prn-specific IgG 
Pertussis toxin (Ptx) and filamentous hemagglutinin (FHA) were obtained from 
Kaketsuken, Kumamoto, Japan. Pertactin (Prn1) was prepared as described 
previously (33). Immulon 2HB plates (Thermo Scientific, Waltham, MA) were 
coated with 2 g/ml Ptx, 2 g/ml FHA, or 5 g/ml Prn1, in PBS, incubated 
overnight, and washed. After addition of a dilution series of control and test 
sera, the plates were incubated for 1 h and washed. After addition of detection 
antibody (1:5,000 anti-mouse IgG-horseradish peroxidase (HRP); Southern 
Biotechnology Associates, Birmingham, AL) in PBS, 0.1% Tween-80, 0.5% 
Protifar (Nutricia, Zoetermeer, the Netherlands), the plates were incubated for 1 
h and washed. To detect HRP, the plates were washed and incubated for 10 min in 
10% sodium acetate, 1% tetramethylbenzidine (Sigma, Axel, the Netherlands), 
and 0.01% H2O2. 2M H2SO4 was added to stop color development and the plates 
were read at 450 nm. Washing steps were 5 times with PBS-0.03% Tween-80. 
Incubations were at room temperature. 
 
Cell culture 
The culture medium used was RPMI-1640 (Gibco, Grand Island, NY) supplemented 
with 10% FCS, 100 g/ml streptomycin, and 100 IU/ml penicillin. Cell suspensions 
were made by pressing the LN or spleens through a cell strainer (Falcon, Franklin 
Lakes, NJ). Cells were counted using a Coulter Counter (Coulter Electronics, Luton, 
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UK). LN cell suspensions were cultured at 106 cells per ml culture medium with 5 
g/ml Concanavalin A (Con A; MP Biomedicals, Irvine, CA) in flat-bottom 12-well 
culture plates (Costar, Cambridge, MA) at 37C in a humidified atmosphere 
containing 5% CO2 for 24 h. Spleen cell suspensions were cultured at 10
6 cells per 
ml culture medium with 5 g/ml Con A or B. pertussis (105 heat-inactivated 
bacteria per well) in 96-well tissue culture plates (Nunc) at 37C in a humidified 
atmosphere containing 5% CO2 for 72 h. Bacteria were heat-inactivated at 56°C 
during 30 min. 
 
Cytokine measurements 
An 8-plex panel containing beads for mouse IL-1, IL-4, IL-5, IL-10, IL-13, IL-
17, IFN-, and TNF- (Bio-Rad, Hercules, CA) was used. After incubation and 
washing steps (see (8) for details) the beads were measured on a Bio-Plex (Bio-
Rad). 
 
Cytokine expression 
Cytokine mRNA expression was measured using Taqman gene expression assays 
(Applied Biosystems, Foster City, CA) as described previously (6,8). Briefly, RNA 
was extracted with an RNeasy kit (Qiagen). Copy DNA was generated using the 
High Capacity cDNA archive kit containing random hexamer primers (Applied 
Biosystems). Messenger RNA expression was measured on a 7500 Fast Real-
Time PCR System (Applied Biosystems). We used the assay on demand (Applied 
Biosystems) for IL-1 (Mm99999060), IL-1 (Mm01336189), IL-4 
(Mm00445259), IL-5 (Mm00439646), IL-17 (Mm00439618), IL-23 
(Mm00518984), IFN- (Mm00801778), and TNF- (Mm00443258). For the 
reference gene, hypoxanthine phosphoribosyl transferase (HPRT), the assay was 
designed using the primer express program (Applied Biosystems) resulting in 
probe CAGTCCTGTCCATAATCA, forward primer 
GCCGAGGATTTGGAAAAAGTGTTTA, and reverse primer 
TTCATGACATCTCGAGCAAGTCTTT. The relative concentration of the various 
mRNA’s was determined by the comparative threshold cycle method (ddCt) (34-
36). 
The fold change in mRNA expression is relative to lung tissue of untreated 
C57BL/6J mice. This third-party control strain does not favor either of the two 
strains of mice tested (the C3H/HeJ or the C3H/HeOuJ strain). 
 
Statistics 
One-way analysis of variance (ANOVA), followed by the Bonferroni post-hoc test 
was performed (SPSS, Chicago, IL). Histological data were analyzed using the non-
parametric Mann-Whitney U test (SPSS). 
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Results 
B. pertussis colonization of the lungs 
Tlr4-deficient C3H/HeJ and wild-type control C3H/HeOuJ mice (6 per group) were 
vaccinated twice with 1/5 human dose (HD) wP, 1/5 HD aP, or adjuvant, and 
challenged intranasally with B. pertussis. Three and seven days after infection, 
mice were sacrificed and CFU in the lungs were enumerated. Vaccinated mice 
generally showed a lower number of bacteria than adjuvant-treated animals, while 
Tlr4-deficient mice generally showed a higher number of bacteria than wild-type 
animals (Figure 1). Adjuvant-treated Tlr4-deficient mice showed an increasing 
number of bacteria from day 3 till day 7 ( log CFU = 0.28, P = 0.029), while 
similarly treated wild-type animals showed a decreasing number in this time period 
( log CFU = -1.09, P < 0.001). Tlr4-deficient mice that were wP-vaccinated before 
challenge failed to show a decreasing number of bacteria from day 3 till day 7, 
while similarly treated wild-type animals did show a decreasing number in this time 
period ( log CFU = -3.33, P < 0.001). In aP-vaccinated mice of either strain the 
number of bacteria was similar between day 3 and day 7. 
These data show (i) the important role of Tlr4 in the natural defense to B. pertussis 
infection and confirms our earlier findings (6), (ii) the important role of Tlr4 in wP-
induced clearance, and (iii) vaccine-induced clearance is faster after aP vaccination 
than after wP vaccination, regardless of the presence of Tlr4. This latter notion is 
supported by the higher clearance in aP-vaccinated than wP-vaccinated mice at day 
3 but not day 7 in either mouse strain. 
 
Vaccination-induced protection, i.e. the difference in the number of bacteria 
between vaccinated and control mice, was lower in Tlr4-deficient mice than in wild-
type animals (P < 0.01), except for aP vaccination at day 7 where this effect was 
not statistically significant ( log CFU = -1.23 and -2.19 (day 3, wP), -2.22 and -
4.37 (day 3, aP), -1.15 and -4.43 (day 7, wP), and -1.99 and -3.48 (day 7, aP) for 
Tlr4-deficient and wild-type mice, respectively). 
Collectively, these data show that Tlr4 is not only involved in the natural defense to 
B. pertussis infection but also in vaccination-induced protection to this pathogen, 
both after wP and after aP vaccination. 
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Figure 2: Ptx- (A), FHA- 
(B), and Prn- (C) specific 
IgG in serum.  
Tlr4-deficient and control 
mice were sc injected with 
1/5 HD wP, aP, or adjuvant 
(C), twice before intranasal 
B. pertussis infection. Two 
hours before challenge, and 
three and seven days after 
challenge blood was taken. 
Test and positive control 
sera were tested for Ptx-, 
FHA-, and Prn-specific IgG. 
Each symbol represents the 
serum level of an individual 
mouse; horizontal lines 
represent the group 
average. (#) increased 
compared to its adjuvant-
treated control (P < 0.001), 
(+) increased compared to 
corresponding wP-
vaccinated mice (P < 
0.001). (*) P<0.05, (**) 
P<0.01, and (***) P<0.001. 
Non-boxed asterisks show 
the P-value against the 
indicated group, boxed 
asterisks show the P-value 
against the wild-type mouse 
strain, and stippled-boxed 
asterisks show the P-value 
against the pre-challenge 
levels. ANOVA followed by 
Bonferroni post-hoc test. A 
single representative 
experiment of 2 is shown. 
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Ptx-, FHA-, and Prn-specific IgG 
Serum was taken 2 hours before challenge and 3 and 7 days after challenge, and 
analyzed for IgG specific for Pertussis toxin (Ptx), filamentous hemagglutinin 
(FHA), and Pertactin 1 (Prn). Only aP-vaccinated mice showed significant Ptx-IgG 
levels. Before challenge these levels were not affected by Tlr4 (Figure 2A). At days 
3 and 7 after challenge Tlr4-deficient aP-vaccinated mice showed significantly lower 
Ptx-IgG levels than similarly treated wild-type animals. In each mouse strain Ptx-
IgG levels were similar before and after challenge. 
 
Both wP- and aP-vaccinated mice showed significant FHA-IgG levels. aP-vaccinated 
mice showed higher levels than wP-vaccinated animals (irrespective of challenge; 
Figure 2B). Both before and after challenge FHA-IgG levels were not affected by 
Tlr4. Generally, both wP- and aP-vaccinated wild-type mice but not Tlr4-deficient 
animals showed lower FHA-IgG levels after challenge than before. 
 
Both wP- and aP-vaccinated mice showed significant Prn-IgG levels (Figure 2C). 
Generally, aP-vaccinated mice showed higher Prn-IgG levels than wP-vaccinated 
animals. Before challenge Prn-IgG levels were not affected by Tlr4. Rather 
unexpectedly after challenge Prn-IgG levels were higher in wP- and aP-vaccinated 
Tlr4-deficient mice than in similarly treated wild-type animals.  
 
Collectively, these data show that before challenge Tlr4 does not affect vaccination-
induced Ptx-, FHA-, and Prn-IgG levels. After challenge, Ptx-IgG levels are lower in 
Tlr4-deficient mice than in wild-type animals, while the reverse is true for Prn-IgG 
levels. FHA-IgG levels are unaffected by the Tlr4 mutation. 
 
Weight gain 
Mice were weighed immediately before challenge, and 3 and 7 days after 
challenge (Figure 3). Irrespective of the animal strain, in this time period the 
adjuvant-treated and challenged mice lost weight, while both wP- and aP-
vaccinated and challenged animals gained weight. Only aP-vaccinated mice at 
day 7 after challenge showed a weight gain that was significantly higher in wild-
type mice than in Tlr4-deficient animals. 
Taken together, these data show that vaccination but not (or to a much lesser 
extent) Tlr4 affects weight gain during the first 7 days after B. pertussis 
challenge. 
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Histological changes 
We have previously shown that after challenge wP- and aP-vaccinated mice 
revealed increased lung pathology compared to animals that had only received 
adjuvant, with wP-vaccinated mice showing more severe pathology than aP-
vaccinated animals (8). Here we addressed whether Tlr4 influenced this 
pathology. 
Lung lesions were scored 3 days after challenge (Figure 4). No effect of Tlr4 on 
lung pathology was seen after challenge of adjuvant-treated mice. In wild-type 
mice, wP but not aP vaccination resulted in a more severe challenge-induced 
peribronchiolitis, perivasculitis, and alveolitis compared to adjuvant treatment 
and challenge, rather similar to our previous findings (8). Lung pathology was 
less severe in similarly treated Tlr4-deficient mice. Vaccination resulted in less 
severe challenge-induced alveolitis compared to adjuvant treatment, in wild-
type mice for aP vaccination and in Tlr4-deficient animals for both wP and aP 
vaccination. No treatment effects on hypertrophy of the bronchiolar mucous cells 
were seen in either strain, while eosinophilia was absent in all groups. 
These data show that challenge-induced pathology in wP-vaccinated animals is 
Tlr4-dependent. 
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Figure 3: Gain of weight. 
Tlr4-deficient and control mice were sc injected with 1/5 HD wP, aP, or adjuvant (C), twice before 
intranasal B. pertussis infection. Two hours before challenge, and three and seven days after 
challenge mice were weighed. Data are indicated as mean  SEM (N=6). Non-boxed numbers show 
the P-value against the adjuvant-treated and challenged group. The boxed number shows the P-value 
against the wild-type strain. ANOVA followed by Bonferroni post-hoc test. A single representative 
experiment of 2 is shown. 
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Figure 4: Lung pathology.  
Tlr4-deficient and control mice 
were sc injected with 1/5 HD 
wP, aP, or adjuvant (C), twice 
before intranasal B. pertussis 
infection. Three days after 
infection the left lung lobes 
were excised. H&E staining. 
Histological lesions were semi-
quantitatively scored as absent 
(0), minimal (1), slight (2), 
moderate (3), strong (4), or 
severe (5), respectively. Each 
symbol represents an 
individual mouse; horizontal 
lines represent the group 
average. Non-boxed numbers 
show the P-value against the 
indicated group. Boxed 
numbers show the P-value 
against the wild-type strain. 
Mann-Whitney U test. A single 
representative experiment of 2 
is shown. 
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Cytokine gene expression in lung tissue 
In this analysis we focused on (i) proinflammatory cytokines, as B. pertussis 
infection induced the production of TNF-, IL-6, and IL-1 in a Tlr4-dependent 
way (4,5,6), (ii) Th1 and Th17 cytokines, as Th1 and Th17 cells were induced by 
wP vaccination in a Tlr4-dependent way and they were shown to be critical for 
clearance after wP-vaccination (3), and (iii) Th2 cytokines, as pertussis 
vaccination (especially aP) before challenge induced a Th2-dependent response 
(8), and this response could be skewed towards a Th1 response by adding LPS 
analogs (7). Post-challenge lung lobes were subjected to real-time PCR. The fold 
change is relative to lung tissue of untreated C57BL/6J mice. Irrespective of 
prior vaccination, IL-1 mRNA expression is lower in challenged C3H mice than 
in untreated C57BL/6 mice, while the reverse is true for the other cytokines 
analyzed.  
 
Proinflammatory cytokines. Tlr4-deficient adjuvant-treated mice showed higher 
IL-1 and IL-1 expression than similarly treated wild-type animals at day 7 
after challenge (Figure 5A). Tlr4-deficient wP-vaccinated mice revealed lower IL-
1 and TNF- expression than similarly treated wild-type animals at day 3 after 
challenge. In general, in both strains of mice both wP and aP vaccination 
resulted in lower challenge-induced IL-1, IL-1, and TNF- expression than 
adjuvant treatment. 
 
Th1/Th17 cytokines. In adjuvant-treated mice no Tlr4-dependent effects on 
post-challenge Th1/Th17 cytokines were seen (Figure 5B). In contrast, Tlr4-
deficient wP-vaccinated mice showed lower IFN-, IL-17, and IL-23 expression 
than similarly treated wild-type animals at day 3 after challenge. In both strains 
of mice wP vaccination resulted in lower challenge-induced IFN- and IL-23 
expression than adjuvant treatment, while aP vaccination resulted in lower 
challenge-induced expression of IFN-, IL-17, and IL-23 expression than 
adjuvant treatment. 
 
Th2 cytokines. In adjuvant-treated mice no Tlr4-dependent effects on post-
challenge Th2 cytokines were observed (Figure 5C). Tlr4-deficient aP-vaccinated 
mice showed higher challenge-induced IL-5 expression than similarly treated 
wild-type animals. This was also seen for wP-vaccinated animals at day 3 after 
challenge. In both strains of mice wP and aP vaccination resulted in higher 
challenge-induced IL-4 and IL-5 expression than adjuvant-treatment. 
 
In summary, in both strains of mice wP and aP vaccination resulted in lower 
challenge-induced IL-1, IL-1, TNF-, IFN-, IL-17, and IL-23 expression, and 
higher challenge-induced IL-4 and IL-5 expression. The exceptions to this latter 
picture were higher TNF- and IL-17 expression in wP-vaccinated wild-type 
mice. 
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For Tlr4-deficient mice compared to wild-type controls, after challenge (i) 
adjuvant-treated mice showed higher expression of the pro-inflammatory 
cytokines IL-1 and IL-1 at day 7 after infection, (ii) wP-vaccinated mice 
showed lower expression of the pro-inflammatory cytokines IL-1 and TNF-, 
and of Th1 and Th17 cytokines at day 3 after challenge, and (iii) wP- and aP-
vaccinated mice showed higher IL-5 expression. 
 
In short, these data show that in the lung the presence of functional Tlr4 results 
in a lower inflammatory response after infection, a higher inflammatory 
response and Th1/Th17 response after wP vaccination and challenge, and a 
lower Th2 response after wP and aP vaccination and challenge. 
 
Cytokine production by bronchial lymph node cells 
To investigate the role of Tlr4 in cytokine production, cell suspensions from post-
challenge bronchial LN were Con A-stimulated ex vivo. From the panel of 
cytokines tested (IL-1, IL-4, IL-5, IL-10, IL-13, IL-17, IFN-, and TNF-), IL-1 
and IL-13 were excluded from further analysis because for these cytokines one 
or more of the treatment groups showed concentrations below the detection 
limit for 4 or more of the 6 samples tested. 
 
Tlr4-deficient adjuvant-treated mice showed lower IFN- and IL-17 production 
than similarly treated wild-type animals at day 7 after challenge (Figure 6). Tlr4-
deficient wP-vaccinated mice showed lower IL-17 production than similarly 
treated wild-type mice at day 3 after challenge. Vaccinated wild-type mice 
showed lower IFN-  and IL-17 production than adjuvant-treated animals at day 
7 after challenge. 
 
IL-4, IL-5, and IL-10 production was 13-, 11-, and 9-fold higher, respectively, in 
wP-vaccinated than in adjuvant-treated Tlr4-deficient mice at day 3 after 
challenge (P = 0.004, P = 0.028, and P = 0.015, respectively). No other mouse 
strain- or treatment-related effects on the production of these cytokines were 
seen. No mouse strain- or treatment-related effects on TNF-  production were 
seen (data not shown). 
 
Together, these data show that in the bronchial LN the presence of functional 
Tlr4 results in a higher Th1/Th17 response after infection, and a higher Th17 
response and a lower Th2 response after wP vaccination and challenge. 
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Figure 5: Cytokine expression in lung.  
Tlr4-deficient and control mice were sc injected with 1/5 HD wP (), aP (), or adjuvant ( ), 
twice before intranasal B. pertussis infection. Three and seven days after challenge the left lung 
lobes were excised. RNA was extracted and analyzed by real-time PCR. The fold change in mRNA 
expression is relative to lung tissue of untreated C57BL/6J mice. Data are indicated as mean  SEM 
(N=6). Non-boxed values show the P-value against the adjuvant control, or against the wP-vaccinated 
group (vs. wP). Boxed values show the P-value against similarly treated wild-type mice. ANOVA 
followed by Bonferroni. A single representative experiment of 2 is shown. 
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Cytokine production by splenocytes 
Cell suspensions from post-challenge spleens were stimulated ex vivo with heat-
killed B. pertussis. From the panel of cytokines tested (IL-1, IL-4, IL-5, IL-10, 
IL-13, IL-17, IFN-, and TNF-), IL-1, IL-4, IL-5, IL-13, IL-17, and IFN- were 
excluded from further analysis because for these cytokines one or more of the 
treatment groups showed concentrations below the detection limit for 4 or more 
of the 6 samples tested. 
 
Tlr4-deficient adjuvant-treated mice showed lower IL-10 and TNF- production 
than similarly treated wild-type animals at both time points after challenge 
(Figure 6). Tlr4-deficient wP-vaccinated mice showed lower TNF- production 
than similarly treated wild-type animals at day 7 after challenge. Vaccination 
failed to show effects on IL-10 production. 
 
Together, these data show that in the spleen the presence of functional Tlr4 
results in a higher inflammatory and IL-10 response after infection and a higher 
inflammatory response after wP vaccination and challenge. 
 
 Pre-challenge Post-challenge Post-challenge Post-challenge 
  Non-vaccinated wP-vaccinated aP-vaccinated 
Number of bacteria     
Ptx-IgG =1 ND3 ND  
FHA-IgG =2 ND = = 
Prn-IgG =2 ND   
Weight gain  = =  
Lung pathology  =  = 
Pro-inflammatory cytokines4      = = 
Th1/Th17 cytokines4  =    = = 
Th2 cytokines4  = ND  ND  ND 
Table 1: summary of Tlr4 mutation effects (Tlr4Lps-d vs. wild-type) 
1Only aP-vaccinated mice showed detectable Ptx-IgG levels. 2Only wP- and aP-vaccinated mice showed 
detectable FHA-IgG and Prn-IgG levels. 3ND, not detected. 4First symbol indicates mRNA expression; second 
symbol indicates production. 
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Figure 6: Ex vivo 
cytokine 
production by 
bronchial lymph 
node and spleen 
cells.  
Tlr4-deficient and 
control mice were 
sc injected with 
1/5 HD wP (), 
aP (), or 
adjuvant ( ), 
twice before 
intranasal B. 
pertussis infection. 
Three and seven 
days after 
challenge the 
bronchial lymph 
nodes (LN) and 
spleens were 
excised and cell 
suspensions were 
made. Bronchial 
LN cells were 
cultured with Con 
A for 24 hr; spleen 
cells were cultured 
with heat-killed B. 
pertussis for 72 hr. 
Culture 
supernatants were 
analyzed for 
cytokine content 
by Luminex. Data 
are indicated as 
mean  SEM 
(N=6). Non-boxed 
values show the P-
value against the 
adjuvant control, or 
against the wP-
vaccinated group 
(vs. wP). Boxed 
values show the P-
value against 
similarly treated 
wild-type mice. 
ANOVA followed by 
Bonferroni. A single 
representative 
experiment of 2 is 
shown. 
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Discussion 
Here we show that in non-vaccinated Tlr4-deficient mice the number of bacteria 
is higher, expression in the lung of IL-1 and IL-1 is higher, and the production 
of IFN- and IL-17 by bronchial LN cells and TNF- and IL-10 by splenocytes is 
lower than in similarly treated Tlr4-sufficient animals. Table 1 summarizes the 
findings of the present study. No effect of Tlr4 on the humoral response to 
vaccination (before challenge) is seen. Next, in wP-vaccinated and challenged 
Tlr4-deficient mice the number of bacteria is higher, Prn-IgG levels are higher, 
lung pathology is diminished, and expression in the lung of IL-1, TNF-, IFN-, 
IL-17, and IL-23 is lower, as is TNF- and IL-17 production by bronchial LN cells, 
while IL-5 expression in the lung is higher compared to Tlr4-sufficient animals. 
In aP-vaccinated and challenged Tlr4-deficient mice the number of bacteria is 
higher, Ptx-IgG levels are lower and Prn-IgG levels are higher, weight gain is 
lower, and IL-5 expression in the lung is higher compared to Tlr4-sufficient 
animals. Collectively, these data show an important role for Tlr4 in events 
following wP vaccination, being bacterial clearance but also concomitant 
pathology, the induction of pro-inflammatory cytokines, and the induction of 
Th1, Th17, and Th2 responses. Tlr4 plays an important role also in aP 
vaccination, with a somewhat limited number of parameters affected, being 
bacterial clearance and the Th2 response. Our data confirm previous data by 
Higgins et al. (6), who showed an important role of Tlr4 in bacterial clearance 
after wP- and aP-vaccination, induction of Th1 and Th17 cells by wP but not aP 
vaccination, and induction of Th17 cells by infection. 
 
On day 3 after infection vaccination resulted in a lower number of bacteria 
compared to adjuvant controls and this may have affected cytokine levels. 
Therefore, we plan to study cytokine responses earlier in infection to determine 
their effects on bacterial clearance. 
 
Our data show that Tlr4 does not affect the humoral response to vaccination, 
and that Tlr4-dependent differences are seen only after challenge. This suggests 
a Tlr4-dependent effect of bacterial challenge on the humoral response, and that 
for this type of response Tlr4 plays a more important role in the challenge phase 
than in the vaccination phase. Transfer studies from vaccinated Tlr4-deficient 
mice to naive Tlr4-sufficient animals and challenge, or studies using conditional 
Tlr4-knockout mice should settle this issue. Our failure to detect Ptx-IgG in wP-
vaccinated animals is in line with observations in both humans (9) and mice 
(10,11), which showed that aP vaccines induce much higher Ptx-IgG levels than 
wP vaccines. In contrast to a previous report where it was shown that Prn-IgG 
could be detected in convalescent serum from B. parapertussis but not B. 
pertussis infected mice (12), we did observe Prn-IgG in vaccinated mice. The 
lower FHA- and Prn-IgG levels after challenge may be explained by Ptx-
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mediated suppression of serum antibody levels after infection (13) or by binding 
of the antibodies by the bacterial challenge. 
 
Here we have shown that Tlr4 is important for the lung pathology observed after 
wP vaccination and challenge. Until recently, it has been assumed that tissue 
damage is mediated by Th1 cells (14). We have previously shown, however, that 
Th1 cells are not involved in lung pathology induced by wP vaccination and 
challenge, as T-bet KO mice that lack Th1 cells showed similar pathology 
compared to wild-type controls (8), suggesting that a different subset is 
involved. Possibly, Th17 cells may be the subset that is responsible for this 
pathology, as they are important in mediating tissue damage (14,15) and they 
are induced by wP vaccination in a Tlr4-dependent way (3). Th17 cells are 
induced in the presence of IL-6, while regulatory T-cells are induced in the 
absence of this cytokine (in an otherwise similar cytokine milieu) (15). Possibly, 
the induction of IL-6 by wP vaccination (7) may play a role in the generation of 
Th17 cells. Whether indeed Th17 cells are responsible for the observed 
pathology awaits further study. 
 
We performed bronchoalveolar lavage at day 3 after infection and observed a 
12-fold lower percentage of neutrophils in wP- and aP-vaccinated Tlr4-deficient 
mice than in adjuvant-treated controls (P < 0.004), while the percentage of 
lymphocytes was 17-fold higher (P < 0.008). In similarly treated wild-type 
animals we did not observe differences in the percentages of neutrophils and 
lymphocytes. These data suggest an impaired neutrophil response to B. 
pertussis infection in vaccinated Tlr4-deficient mice. Neutrophils are important in 
the clearance of B. pertussis infection in mice (16). A defective neutrophil 
response in vaccinated Tlr4-deficient mice may be an explanation for the 
impaired clearance in these mice. 
 
Our finding of infection-induced IL-17 production is in line with the observation 
of IL-23 production by human monocyte-derived DC after B. pertussis infection 
(17). Since IL-23 is required for amplifying and/or stabilizing Th17 cells (2), 
both findings suggest Th17 induction by B. pertussis infection. 
 
It is intriguing but also complicating that not only LPS but also Ptx may play a 
role in the Tlr4-dependent induction of Th17 cells. Ptx has Tlr4-dependent 
adjuvant activity (18,19) and is able to induce Th17 cells (20). It is likely, but 
not formally proven, that this latter effect is Tlr4-dependent (X. Chen, personal 
communication). Vaccination with wP that is derived from Ptx-deleted B. 
pertussis may clarify this issue. 
 
In non-vaccinated controls, IFN- and IL-17 production by bronchial LN cells is 
lower when these cells are taken from infected Tlr4-deficient mice compared to 
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similarly treated wild-type animals, in line with previous observations by others 
for IFN- (4) (IL-17 was not measured in that study). These findings suggest 
that not only wP vaccination but also B. pertussis infection induces Th1 and 
Th17 cells in a Tlr4-dependent way. 
 
IL-10 production by B. pertussis-stimulated splenocytes is lower when these 
cells are taken from infected Tlr4-deficient mice than when they are taken from 
similarly treated wild-type animals, in line with observations by others (4). It 
has been suggested that IL-10 induced by B. pertussis infection limits lung 
pathology (4). In the present study, however, we do not observe differences in 
challenge-induced pathology between adjuvant-treated Tlr4-deficient and wild-
type mice. Next, while challenged-induced pathology is observed in wP 
vaccinated wild-type mice, and not seen in similarly treated Tlr4-deficient 
animals, IL-10 production by B. pertussis-stimulated splenocytes is higher in 
wild-type mice than Tlr4-deficient animals, again suggesting that in our model 
IL-10 is not involved in limiting pathology. It should be mentioned, however, 
that our observations were made earlier after challenge (day 3 compared to day 
14-21). 
 
A recent paper has shown that the number of bacteria in the lungs of B. 
pertussis infected TNF- deficient mice was higher than in similarly treated wild-
type controls (21). In the present study, B. pertussis-stimulated splenocytes 
from infected Tlr4-deficient mice produce less TNF- than the same cells from 
similarly treated wild-type animals. The lower systemic TNF- response 
observed in our study may contribute to the higher number of bacteria in the 
lungs of Tlr4-deficient mice. It has to be noted, however, that the differences in 
bacterial numbers between TNF- deficient mice and their controls were not 
seen until day 10 after infection (21). 
 
Two signal transduction pathways downstream of Tlr4 have been identified, the 
MyD88-dependent pathway and the MyD88-independent (TRIF) pathway. The 
former pathway involves the adaptor proteins TIRAP and MyD88, the latter one 
TRIF and TRAM (22). The bacterial species from which LPS originates, 
determines the pathway(s) activated (23). Since wP is derived from B. pertussis, 
they harbor the same LPS suggesting similar pathway activation. The wP, 
however, consists of glutaraldehyde-fixed bacteria, and its LPS may thus 
activate a different pathway than LPS from live B. pertussis (24). To study 
possible differences in pathway activation, TRIF-deficient (C57BL/6J-Ticam1Lps2/J 
(25)) and wild-type controls (C57BL/6J) were compared in our model. TRIF-
deficient mice are readily available and are not deficient in other pathways 
besides TRIF/TRAM, while MyD88 KO mice are not only deficient in 
MyD88/TIRAP but also in the IL-1R and IL-18R pathways (26). Three days after 
infection, wP- and aP-vaccinated mice showed a ~500-fold lower colonization than 
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non-vaccinated controls, and no differences in colonization were seen between 
TRIF-deficient and wild-type mice (data not shown). This shows that the TRIF 
pathway is not involved in clearance of a B. pertussis infection, nor is it involved in 
wP or aP vaccine-induced clearance. 
 
TRIF-deficient mice are strongly impaired in LPS-induced CD40, CD80, CD86, 
and MHC class II upregulation, as well as type I IFN production in macrophages 
in vitro, and CD40, CD80, and CD86 upregulation in CD11+ DC in vivo. Also, the 
CD4+ and CD8+ T-cell response is abolished when LPS is used as adjuvant (27). 
Importantly, type I interferons promote memory T-cell proliferation (28). Thus, 
the lack of an effect of TRIF-deficiency suggests that clearance of a B. pertussis 
infection, as well as wP- and aP-induced immunity are also functional under 
conditions of severely reduced costimulation and (memory) T-cell responses. 
This lack of an effect of TRIF-deficiency also suggests involvement of the 
MyD88-dependent pathway. We set out to study this pathway, but breeding 
problems with MyD88 KO mice prohibited these experiments. Still, a role for 
MyD88 is likely from a study by Togbe et al. (29) who showed a TIRAP- and 
MyD88-dependent TRIF-independent response to LPS in the lungs, including Th1 
cytokine production and neutrophil influx. Both parameters are characteristic of 
B. pertussis challenge, as well as of wP but not aP vaccination and similar 
challenge (10,30). 
 
Conclusion 
We have shown that Tlr4 does not affect the humoral response to vaccination. 
Tlr4 is important in (i) the natural defense to B. pertussis infection, and also in 
the wP and aP vaccine-induced clearance, (ii) the challenge-induced lung 
pathology after wP vaccination, (iii) the induction of Th1 and Th17 responses, 
both by B. pertussis infection and after wP vaccination and challenge, and (iv) 
the reduced Th2 response after wP and aP vaccination and challenge. A 
summary of our findings is presented in Figure 7. 
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Figure 7: Effects of Tlr4 mutation in vaccine-induced immunity.  
Parameters that show a lower response in Tlr4-deficient mice compared to wild-type animals are 
represented in red, while parameters that show a higher response are represented in green. 
Parameters that are not affected or have not been determined are represented in black. Triangles 
represent wP vaccine, circles aP vaccine, and squares B. pertussis. IL-23 is put between brackets as 
this cytokine is able to maintain Th17 cells, rather than generate these cells. 
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Abstract 
 
We examined the association between haplotype-tagging SNPs in TLR4 and the 
pertussis toxin-specific IgG response after whole-cell pertussis(wP) vaccination 
in 515 one-year-old children from the KOALA study. A lower titer was associated 
with the minor allele of rs2770150 supporting a role for TLR4 in the antibody 
response to wP vaccination. 
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promotor exon1 exon2 exon3 3’UTRintron1 intron2
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c.-2570 A>G
rs6478317
c.-1607 T>C
rs10759932
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Single Nucleotide Polymorphism
Figure 1: Position, Linkage Disequilibrium and Haplotypes of the nine SNPs within TLR4.  
a) TLR4 is located on chromosome 9 (9q32) 119,506,431. Nine Haplotype-tagging SNPs were 
selected from the Innate Immunity web site http://www.innateimmunity.net/data/homology. All 
SNPs are in Hardy Weinberg equilibrium (p>0.05).  
b)Pairwise Linkage Disequilibrium (LD) plot according to Haploview3.32 (7). |D’| is presented as 
number if it deviates from 100. |D’| is 100 when no recombination has occurred between two SNPs. 
The measure of r2 is represented by color, varying from dark grey when r2=1 (the minor alleles at 
two SNP positions are always present on the same haplotype), to white when r2=0 (the minor 
alleles are always on separate haplotypes). 
c) The frequency of the major haplotypes of TLR4 present in the KOALA cohort as identified by the 
nine tagging SNPs genotyped in our study. Black boxes represent minor alleles. 
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Body 
Pertussis is a vaccine-preventable respiratory disease caused by Bordetella 
pertussis. Despite high vaccination coverage, pertussis is still endemic in most 
countries, including the Netherlands, with epidemic peaks that occur every 2 to 
3 years (13,14,28,29). Susceptibility to B. pertussis and the course of infection 
varies between individuals. Studies in mice have provided evidence that murine 
host genes regulate susceptibility to B. pertussis infection (5,20). Animal studies 
furthermore indicated involvement of the toll-like receptor 4 (Tlr4) gene in the 
infection process (6,18,24). In humans, two coding variants of TLR4 have been 
associated with enhanced susceptibility to infectious diseases, especially gram-
negative infections, and with endotoxin hyporesponsiveness (1,2,30,33). Since 
Tlr4 also plays a critical role in the response to whole-cell pertussis (wP) 
vaccination in mice (17) (and unpublished work (4)), we hypothesized that 
variation in the gene coding for TLR4 may account for some of the observed 
variability in the antibody response to this vaccine in humans. Furthermore, 
variation in response to vaccination may reflect differences in the course of 
infection (21). Here we studied the role of genetic variation in TLR4 in the 
response to wP vaccination in the Dutch KOALA Birth Cohort Study (8,22). We 
therefore examined the association of SNPs in TLR4 and pertussis toxin (PT)-
specific IgG following wP vaccination. The IgG antibody titer against PT, one of 
the dominant virulence factors of B. pertussis, correlates with protection against 
disease (12,31,32). We used vaccine-induced PT-IgG as a quantitative 
phenotype and compared the genotypes of high and low responders to PT. We 
hypothesized that minor TLR4 alleles that may affect promoter activity or 
receptor affinity of TLR4 are associated with an altered IgG titer to PT.  
The level of PT-IgG was determined by ELISA (15) in capillary blood collected at 
one year of age from 855 children. 151 children were excluded for further 
analysis because their parents stated in the questionnaires that the child had not 
received the standard pertussis vaccination (16,22). For 184 children DNA was 
not available, and a further five children were excluded because their PT-IgG 
level was above 200U/ml indicating natural infection (15). The remaining 515 
children were genotyped by K-Biosciences (Cambridge, UK; 
http://www.kbiosciences.co.uk/) for nine SNP’s located on TLR4 (Figure 1a). 
After Ln-transformation the PT-IgG-levels were normally distributed according to 
Levene’s test (P>0.05). To examine possible confounding factors we tested for 
associations between PT-IgG titer and the number of days between vaccination 
and blood sampling and infant gender using Pearson correlation. None of the 
tested factors influenced the PT-IgG-level (P > 0.05). All SNPs were in Hardy 
Weinberg equilibrium (chi-square, p>0.05). Associations between nine SNPs in 
TLR4 and PT-IgG titers were assessed by ANOVA and the distribution of the 
genotypes among individuals with extreme 10th percentiles in PT-IgG titer was 
tested using Pearson’s chi-square (Table 1). The rs2770150 (c.-3612 T>C SNP) 
was significantly associated with the lowest 10th percentile (low responders) 
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compared to the highest 10th percentile (high responders) titer of PT-IgG 
(P=0.027). Subjects homozygous for the minor C allele of this SNP had a 
significantly lower PT-IgG titer upon pertussis vaccination (P=0.040) compared 
with persons heterozygous for this allele (Figure 2).  
Homozygote major 
          n=277                        n=204                          n=34  
Heterozygote Homozygote minor
rs2770150 (c.-3612 T>C)
20
25
30
35
P
T
-I
g
G
 (
U
/m
l)
P=0.040
0
Figure 2: Pertussis toxin-specific IgG titer per genotype. 
Circles represent the mean of the PT-IgG titer and the standard deviation is represented by the 
vertical error-bars. Horizontal lines represent a statistical difference (P<0.05) between groups 
according to the Least Significant Difference Post Hoc test (ANOVA, SPSS). 
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y g
SNP 
Minor 
allele    P-value allele N1 Ln(PT-IgG) PT-IgG 
 frequency   Continuous2 Percentile3    (U/ml) 
rs2770150 0.26   0.083 0.027 TT 277 3.24 30.38 
c.-3612 T>C 4     CT 204 3.31 32.84 
     CC 34 3.09 24.97 
rs10759931 0.42  0.906 0.656 GG 187 3.26 31.03 
c.-2604 G>A     GA 210 3.24 29.87 
     AA 108 3.25 31.85 
rs6478317 0.35  0.957 0.676 AA 203 3.26 31.40 
c.-2570 A>G     GA 255 3.25 30.61 
     GG 52 3.28 31.48 
rs10759932 0.13  0.720 0.269 TT 365 3.25 30.71 
c.-1607 T>C     CT 115 3.30 32.15 
     CC 5 3.19 27.80 
rs1927911 0.25  0.630 0.491 CC 276 3.25 31.25 
c.93+3211 C>T     CT 207 3.23 29.49 
     TT 23 3.34 33.74 
rs11536878 0.12  0.620 0.649 CC 378 3.25 30.76 
c.260+546 C>A     CA 103 3.24 29.80 
     AA 7 3.04 21.57 
rs4986790 0.07  0.836 0.548 AA 441 3.25 30.86 
Asp299Gly     GA 68 3.26 30.60 
     GG 3 3.45 35.33 
rs4986791 0.07  0.659 0.518 CC 431 3.24 30.59 
Thr399Ile     CT 66 3.30 33.29 
     TT 3 3.45 35.33 
rs11536889 0.14  0.308 0.502 GG 373 3.27 31.66 
c.3648+78 G>C     CG 128 3.19 28.44 
          CC 8 3.36 32.63 
 
TABLE 1: Summary of TLR4 SNPs tested for association with PT-IgG titers. 
1Number of children per genotype. 
2The statistical differences in phenotypes (Ln transformed PT-IgG titers) were assessed by Analysis 
of Variance (ANOVA). 
3Distribution of the Pt-IgG titers among the extreme percentiles was tested by Pearson Chi-square 
test.  
4SNPs were named according to the Human Genome Variation Society guidelines 
http://www.hgvs.org/mutnomen/recs.html. 
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To examine whether the effect of rs2770150 could be due to a more distant 
variant, we performed haplotype analysis. We constructed haplotypes for the 
genotyped SNPs and tested them for association with PT-IgG titers using WHAP 
(http://pngu.mgh.harvard.edu/purcell//whap/). There is strong linkage 
disequilibrium (LD) between most genotyped SNPs within TLR4 (Figure 1b) (7). 
Therefore, the selected SNPs represent nine different haplotypes encompassing 
99% of the haplotypes in our cohort (Figure 1c). No significant associations were 
found between haplotypes and the PT-IgG titer (data not shown). This could be 
due to the small size of our cohort, or the need for two alleles (recessive model) 
to obtain an effect on titer which would be missed when analyzing haplotypes.  
Although all participants had PT-IgG titers that can be considered as protective 
at the time of blood-sampling (12) (approximately one month after receiving the 
fourth vaccination), TLR4 polymorphisms may be important in the duration of 
protective immunity. Future work should indicate whether this and other 
polymorphisms in TLR4 have clinical relevance either by affecting the antibody 
response following vaccination, during the waning of the antibody response, or 
by affecting the outcome of infection itself irrespective of vaccination. 
The children in this study were vaccinated 4 times (2, 3, 4 and 11 months old) 
with wP vaccine that contains the TLR4 ligands LPS and PT (19,26,27). In mice 
Tlr4 affected the vaccination response both after vaccination with the LPS-
containing wP vaccine and the (LPS-free) acellular vaccine. Both vaccines 
induced less bacterial clearance in Tlr4 defective C3H/HeJ mice (Tlr4Lps-d) 
compared to wild-type mice (Tlr4Lps-n) (4,17), suggesting that not only the 
interaction between TLR4 and LPS but also the interaction between TLR4 and PT 
is important in the generation of vaccine-induced immunity. 
The SNP that was associated with the PT-IgG titer, rs2770150, is characterized 
by a T to C substitution in the promoter region of TLR4 (position -3612). This 
SNP may therefore be involved in transcriptional regulation, suggesting that 
subjects with a minor allele of this SNP have a lower expression of the gene. In 
mice we have shown that Tlr4-mRNA expression is upregulated 1.5 times post 
B. pertussis infection, suggesting that transcriptional activation of Tlr4 is 
involved in the response to B. pertussis infection (6). The results of the present 
study may be explained by altered transcriptional activation of TLR4 upon wP 
vaccination in humans.  
PT-IgG levels have been shown to correlate with protection after vaccination, 
both in humans (12,31,32) and mice (9). Cell-mediated immunity, however, 
does also critically contribute to protection, both in humans (3,10,23) and mice 
(25). The association between PT-IgG levels and protective immunity is most 
apparent early after vaccination (11). We speculate that genetic diversity in 
TLR4 indeed affects antibody titers after wP vaccination, but that the variation in 
response of one-year-old children is limited due to the many booster 
vaccinations. Therefore the Dutch Vaccination Program comprising four 
vaccinations during the first year of life may adequately answer to the genetic 
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variation in the most vulnerable age group, at least regarding pertussis. It 
remains to be established, however, whether the same holds true for the 
persistence of the PT-specific antibody response and the response to other 
vaccines.  
In conclusion, we demonstrate that genetic variation in TLR4 is associated with 
the wP vaccination response in one-year-old children. To our knowledge, this is 
the first study to report the involvement of TLR4 in the induction of the antibody 
response after vaccination against B. pertussis in humans.  
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Abstract 
Pertussis is an infectious disease of the respiratory tract that is caused by the 
gram-negative bacterium Bordetella pertussis. Although acellular pertussis (aP) 
vaccines are safe, they are not fully effective and thus require improvement. In 
contrast to whole-cell (wP) vaccines, aP vaccines do not contain 
lipopolysaccharide (LPS). Monophosphoryl lipid A (MPL) and Neisseria 
meningitidis LpxL2 LPS have been shown to display immune-stimulating activity 
while exerting little endotoxin activity. Therefore, we evaluated whether these 
LPS analogs could increase the efficacy of the aP vaccine. Mice were vaccinated 
with Diphtheria-Tetanus-aP vaccine adjuvated with aluminum, MPL, or LpxL2 
LPS before intranasal challenge with B. pertussis. Compared to aluminum, 
vaccination with either LPS analog resulted in lower colonization and a higher 
pertussis toxin-specific serum IgG level, indicating increased efficacy. 
Vaccination with either LPS analog resulted in reduced lung eosinophilia, 
eosinophil numbers in the bronchoalveolar lavage, and ex vivo production of IL-4 
by bronchial lymph node cells and IL-5 by spleen cells, suggesting reduced type 
I hypersensitivity. Vaccination with either LPS analog increased IL-6 serum 
levels, although these levels remained well below the level induced by wP, 
suggesting that supplementation with LPS analogs may induce some 
reactogenicity but considerably less than wP. In conclusion, these results 
indicate that supplementation with LPS analogs forms a promising strategy to 
improve aP vaccines. 
 
Host genetics and genomics of Bordetella pertussis infection and vaccination 
 
 
 
182 
Introduction 
Pertussis is caused by Bordetella pertussis infection of the respiratory tract and 
among the ten infectious diseases with the highest morbidity and mortality 
worldwide. After introduction of whole-cell (wP) vaccines in the 1950’s, pertussis 
incidence has decreased significantly. Although being efficacious, wP vaccines 
were found to be reactogenic, leading to concerns about their safety in the 
1970’s. Therefore, acellular (aP) vaccines have been developed comprising 
purified B. pertussis proteins. In many countries, pertussis has re-emerged 
recently despite high vaccine coverage (13). Several approaches to reduce 
disease incidence and severity have been suggested, one of them being the 
improvement of existing aP. 
In contrast to wP vaccines, aP vaccines are devoid of lipopolysaccharide 
(LPS). By engaging toll-like receptor 4 (TLR4), this molecule induces Th1 
adaptive immunity (12,15,22,30,39). Consequently, concerns have been raised 
with respect to the relative efficacy of aP vaccines as compared with wP vaccines 
as well as of simultaneously administered vaccines, such as diphtheria, tetanus, 
polio, and Haemophilus influenzae b (Hib) vaccines. In fact, this concern has 
been substantiated by an increase in invasive Hib disease incidence in the UK 
that coincided with the distribution of combination vaccines that contain aP 
vaccine instead of wP vaccine (28). Thus, while the reactogenicity of LPS 
precludes its use, its adjuvanticity is regrettably missed. 
We and others have shown that LPS is an essential component of wP 
vaccines in mice, as wP-vaccinated C3H/HeJ mice that have a point mutation in 
the Tlr4 gene resulting in defective signal transduction, failed to clear a B. 
pertussis challenge (21; Banus et al., manuscript in preparation). This result 
underlines the important role of LPS in generating a productive immune 
response, at least in mice. Additionally, we have shown that a functional 
polymorphism in TLR4 was associated with reduced pertussis toxin (Ptx)-specific 
IgG titers in wP-vaccinated children one year of age (Banus et al., submitted). 
Together, these findings strongly suggest an important role of LPS in wP 
vaccines. 
To make use of this role of LPS, the development and use of LPS derivatives 
and novel LPS species have been investigated. The non-toxic LPS derivative 
monophosphoryl lipid A (MPL) engages TLR4 (17,33), inducing Th1 adaptive 
immunity and changing Th2-directed to Th1-directed responses (3,34,38,48). 
MPL combined with aluminum (denoted AS04) is registered for clinical use as 
adjuvant in viral vaccines, such as hepatitis B virus vaccine (6) and human 
papillomavirus vaccine (18), while MPL combined with L-tyrosine is registered 
for clinical use as adjuvant in allergy therapy (2,27). Furthermore, a Neisseria 
meningitidis strain deficient for the late acyltransferase LpxL2 displayed a 
strongly decreased endotoxic activity when tested for its capability to stimulate 
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human macrophages (46). This mutant LPS still exhibited immune-stimulating 
activity (46). 
In mice, Tlr4 is critical for pertussis clearance and ensuing adaptive 
immunity (4,20,25). The engagement of this receptor by MPL suggests that 
addition of this molecule to aP vaccines may induce a vaccination response that 
mimics natural infection better than the aP vaccine alone, with favorable 
outcome. Furthermore, vaccination and particularly aP vaccination induced type 
I hypersensitivity, a Th2-driven response (44). Since MPL can redirect responses 
from Th2 to Th1, it is conceivable that this hypersensitivity may be reduced by 
including this molecule in the vaccine. 
Here, we first investigated whether replacing aluminum by MPL in a 
Diphtheria-Tetanus-acellular Pertussis vaccine would beneficially affect the 
vaccine in a mouse model system. In a second series of experiments, also LpxL2 
LPS was included as an alternative adjuvant. The clearance of a B. pertussis 
challenge, Ptx-specific serum IgG levels, parameters of type I hypersensitivity, 
and serum IL-6 which at elevated levels suggest reactogenicity, were 
determined. 
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Materials and Methods 
Vaccines and adjuvants. 
Series 1. The acellular vaccine (DTaP) was a combined vaccine consisting of 
diphtheria toxoid, tetanus toxoid, and a 3-component acellular pertussis vaccine 
(25 g formaldehyde- and glutaraldehyde-detoxified pertussis toxin, 25 g 
filamentous hemagglutinin, and 8 g pertactin; GlaxoSmithKline, Rixensart, 
Belgium) in 0.5 ml saline (one human dose (HD)). The vaccine contained 
aluminum hydroxide as an adjuvant (< 0.625 mg aluminum/HD). 
The DTaP vaccine was supplemented with two adjuvants, aluminum 
adjuvant (2% Al(OH)3 gel (Serva, Heidelberg, Germany)) or monophosphoryl 
lipid A (MPL). To one HD DTaP, 2 ml aluminum/PBS (1/3 vol/vol) was added. 
MPL (from Salmonella enterica serotype minnesota Re 595) was from Sigma-
Aldrich, Zwijndrecht, the Netherlands. To one HD DTaP, 2 ml of 100 g/ml 
MPL/PBS was added. The amount of MPL administered is below the amount that 
showed no toxicological effects in a single-dose toxicity study (2). 
Series 2. The same DTaP was used as for series 1. 
The wP vaccine was prepared from B. pertussis strain B213, a 
streptomycin-resistant derivative of Tohama I (23). The bacteria were grown in 
synthetic THIJS medium (43) for 68 h at 35oC while shaking (175 rpm). The 
bacterial cell suspensions were heat-inactivated for 10 min at 56oC in the 
presence of 8 mM formaldehyde, after which the cells were collected by 
centrifugation for 10 min at 16,100 x g and resuspended in PBS to an A590 of 
2.5, i.e., 50 international opacity units per ml (~1.6 HD/ml). The suspensions 
were stored at 4oC. 
Before immunization, the DTaP and wP were diluted in PBS to 1/10 HD, 
after which 3 mg/ml aluminum phosphate (Brenntag, Dordrecht, the 
Netherlands), 40 g/ml MPL (Sigma-Aldrich), or 40 g/ml N. meningitidis LpxL2 
LPS (46) was added as an adjuvant. 
 
Animals. Female BALB/c mice were used at 6-8 weeks of age. They were 
obtained from our own breeding colony or from Harlan (Horst, the Netherlands). 
The diet consisted of ground standard laboratory chow (RMH-B, Hope Farms, 
Woerden, the Netherlands). Food and water were given ad libitum. All animal 
experiments were performed according to national and international guidelines. 
 
Vaccination.  
Series 1. Mice received a subcutaneous (sc) injection with 1/5 HD DTaP in 0.5 
ml aluminum, 1/5 HD DTaP in 0.5 ml MPL, 0.5 ml aluminum alone, or 0.5 ml 
MPL alone, 28 and 14 days before infection. In one experiment, mice received a 
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sc injection with 1/5, 1/25, or 1/125 HD DTaP in 0.5 ml aluminum, 1/5, 1/25, or 
1/125 HD DTaP in 0.5 ml MPL, 0.5 ml aluminum alone, or 0.5 ml MPL alone. 
Series 2. Mice received a sc injection with 1/10 HD wP in 0.5 ml aluminum, 
1/10 HD DTaP in 0.5 ml aluminum, 1/10 HD in 0.5 ml LpxL2 LPS, 1/10 HD in 0.5 
ml MPL, or 0.5 ml PBS, 28 and 14 days before infection. 
 
Bacterial strain and growth conditions. B. pertussis Tohama strain B213 
was used. The Tohama strain has been shown to multiply in the lungs of mice 
(8,16,19). The bacteria were grown on Bordet Gengou (BG) agar plates 
supplemented with 30 g/ml streptomycin (Tritium, Veldhoven, the Netherlands) 
at 35C for 3 days. Subsequently, the bacteria were plated on BG plates without 
antibiotics, cultured for 3 days, resuspended in Verwey medium (NVI, Bilthoven, 
the Netherlands), and used for infection. 
 
Infection of mice and autopsy. Intranasal infection was performed as 
described (47). Briefly, mice were lightly anaesthetized and a single drop of 40-
l inoculum containing 2x107 B. pertussis cells was carefully placed on the top of 
the nose and allowed to be inhaled. 
Mice were sacrificed 3, 5, or 7 days after infection. Animals were 
anaesthetized with ketamine, rompun, and atropine, and blood was collected 
from the orbital plexus. Perfusion of the right ventricle was performed with 2 ml 
PBS supplemented with 3.5% heat-inactivated Fetal Calf Serum (FCS; PAA, Linz, 
Austria). The lungs were excised and used either to obtain bronchial lymph nodes 
(LN) and lung lobes for enumeration of bacteria and for histological examinations, 
or to obtain bronchoalveolar lavage fluid (BALF) cells. 
 
Lung lobes, CFU determination, and histological examination. A ligature was 
made around the right bronchus after which the right lobes were removed for 
enumeration of bacteria. The lobes were homogenized in 900 l of Verwey 
medium using a tissue homogenizer (Pro-200, ProScientific, Monroe, CT) at 
maximum speed for 10 s. The homogenates were diluted in Verwey medium 10- 
and 100-fold for the immunized mice and 1000-fold for the control mice, and 
100-l aliquots of the dilutions were plated on BG plates supplemented with 
streptomycin and incubated at 35oC for 5 days. The remaining left lung lobes 
were fixed intratracheally using 4% formalin for 24 h. After overnight dehydration, 
they were embedded in paraffin. Five-m sections were cut and stained with 
haematoxylin/eosin. Histological lesions were semi-quantitatively scored as absent 
(0), minimal (1), slight (2), moderate (3), strong (4), or severe (5), respectively. 
This score incorporates the frequency as well as the severity of the lesions. 
  
Ptx-specific IgG. Ptx-specific IgG was measured essentially as described for 
the analysis of human sera (14). Briefly, 96-well plates (Nunc-Immuno Plate, 
Roskilde, Denmark) were pre-coated with Ptx (NVI). Positive control serum was a 
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pool of sera, obtained from a previous experiment in which mice were 
vaccinated with DTaP plus either aluminum or MPL and challenged with B. 
pertussis. The concentration of the positive control serum was arbitrarily set at 
1000 U. Dilution series of test sera and positive control sera were prepared in 
blocking buffer (0.5% BSA (Sigma-Aldrich, Axel, the Netherlands), 0.01% 
Tween-20 (Merck, Amsterdam, The Netherlands), in PBS). The plates were 
incubated for 2 h at 37°C and washed 3 times with 0.1% Tween-20 in PBS. The 
plates were then incubated with 2000-fold diluted peroxidase-labeled rabbit 
anti-mouse IgG (Dako, Glostrup, Denmark) in blocking buffer for 1 h at 37°C 
and washed. Finally, the plates were incubated with substrate solution (10% 
sodium acetate, 1.66% tetramethylbenzidine (Sigma-Aldrich), and 0.02% H2O2) 
for 5 min and read at 450 nm. 
 
Total serum IgE. Blood was allowed to clot at 4C overnight and centrifuged for 2 
min at 13,000 g. Total serum IgE was measured as previously described (44). 
 
Bronchoalveolar lavage fluid cells. A cannula was placed intratracheally and 
fixed using a suture. The lungs were placed in a 50-ml tube filled with PBS. One ml 
PBS was brought into the lung and sucked up. This was repeated twice. BALF cells 
were pelleted by centrifugation, resuspended in PBS, counted using a Coulter 
Counter (Coulter Electronics, Luton, UK), and visually differentiated after Giemsa 
staining. 
 
Cell culture. The culture medium used was RPMI-1640 (Gibco, Grand Island, NY) 
supplemented with 10% FCS, 100 g/ml streptomycin, and 100 IU/ml penicillin. 
Cell suspensions were made by pressing the LN or spleens through a cell strainer 
(Falcon, Franklin Lakes, NJ). Cells were counted using a Coulter Counter. LN cell 
suspensions were cultured at 106 cells per ml culture medium with 5 g/ml 
Concanavalin A (Con A; MP Biomedicals, Irvine, CA) in flat-bottom 12-well culture 
plates (Costar, Cambridge, MA) at 37C in a humidified atmosphere containing 
5% CO2 for 24 h. Spleen cell suspensions were cultured at 10
6 cells per ml culture 
medium with 5 g/ml Con A or B. pertussis (105 heat-inactivated bacteria per well) 
in 96-well tissue culture plates (Nunc) at 37C in a humidified atmosphere 
containing 5% CO2 for 72 h. Bacteria were heat-inactivated at 56°C during 30 min. 
 
Cytokine measurements. Cytokine concentrations in the culture supernatants 
were measured using a 5-plex panel containing beads for mouse IL-4, IL-5, IL-
10, IL-13, and IFN-, or an 8-plex panel containing beads for mouse IL-2, IL-4, 
IL-5, IL-10, IL-12p70, GM-CSF, IFN-, and TNF- (Bio-Rad, Hercules, CA) as 
described (44). IL-6 concentrations in the sera were quantified with an ELISA 
according to the manufacturer’s instructions (eBioscience, San Diego, CA). 
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Statistics. One-way analysis of variance (ANOVA) followed by the Bonferroni post-
hoc test was performed when multiple groups were compared (SPSS, Chicago, IL). 
The independent-samples T Test was used when two groups were compared 
(SPSS). Histological data were analyzed using the non-parametric Mann-Whitney U 
test (SPSS). 
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Results 
B. pertussis colonization of the lungs. To analyze whether supplementation of 
DTaP with MPL improved vaccine efficacy compared to supplementation with 
aluminum, mice were vaccinated twice with 1/5, 1/25, or 1/125 HD DTaP 
supplemented with either MPL or aluminum as adjuvant and then challenged 
intranasally with B. pertussis. Three and seven days after infection, mice were 
sacrificed and CFU in the lungs were enumerated. Animals treated with the 
adjuvants only showed a decreased number of CFU at day 7 compared to day 3 
after infection (Figure 1). Vaccination with 1/5, 1/25, or 1/125 HD DTaP resulted in 
a reduced number of CFU at day 3 after infection, independent of the adjuvant 
used. Also at day 7 post infection, the vaccinated animals showed a reduced 
number of CFU compared to the animals treated with adjuvant only, although the 
difference was not significant in the case of mice vaccinated with 1/125 HD DTaP 
plus aluminum. Importantly, vaccination with 1/5 HD DTaP adjuvated with MPL 
resulted in a lower number of CFU than when the same dose DTaP adjuvated with 
aluminum was used, both at day 3 and day 7 after infection.  At day 3 after 
infection this was also observed when 1/125 HD DTaP was used. In conclusion, the 
MPL-supplemented vaccine provided better protection than the aluminum-
supplemented vaccine. 
 
Ptx-specific IgG. Since Ptx-specific IgG titers have previously been shown to 
correlate with protective immunity (11,41), Ptx-specific IgG was measured in 
serum. When MPL was used as the adjuvant, the vaccinated animals showed a 5.4- 
and 2.6-fold higher Ptx-specific IgG level at days 3 and 7, respectively, compared 
to the mice vaccinated with DTaP plus aluminum (Figure 2). Treatment with 
aluminum or MPL only did not result in detectable Ptx-specific IgG levels. In 
conclusion, the better protection observed in the case of MPL-supplemented 
vaccine correlated with higher Ptx-specific IgG levels. 
 
Evaluation of histological changes. We have previously shown that mice 
vaccinated with aluminum-adjuvated DTaP and subsequently challenged with B. 
pertussis revealed increased lung pathology compared to mice that were only 
treated with adjuvant before challenge (44). To address whether the adjuvant in 
the vaccine influenced lung pathology, lung histology was scored three days 
after infection. For both types of adjuvant, the vaccinated animals showed 
increased perivasculitis (P = 0.009 compared to aluminum only and P = 0.015 
compared to MPL only). Eosinophilia was lower in mice vaccinated with DTaP 
adjuvated with MPL, compared to MPL only and compared to DTaP adjuvated with 
aluminum (Figure 3). Vaccination resulted in minor increases in peribronchiolitis, 
hypertrophy of the bronchiolar mucus cells, and alveolitis (data not shown). In 
conclusion, the MPL-supplemented vaccine induced lower eosinophilia than the 
aluminum-supplemented one, which is suggestive of a lower type I 
hypersensitivity. 
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Total serum IgE levels. Another parameter of type I hypersensitivity is an 
increased serum IgE level. We have previously shown that mice vaccinated with 
aluminum-adjuvated DTaP and subsequently challenged with B. pertussis 
displayed a large increase in serum IgE compared to mice that were only treated 
with adjuvant before challenge (44). To investigate whether supplementation of 
DTaP with MPL instead of aluminum resulted in lower total serum IgE, serum 
was taken three days after infection and analyzed. Total IgE was higher in both 
vaccinated groups, and no significant differences that depended on the type of 
adjuvant in the vaccine were seen (Figure 4). Thus, the type of adjuvant used in 
the vaccine did not influence total serum IgE levels. 
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Figure 1: Colonization of the lungs by B. pertussis.  
Mice were subcutaneously injected with (H) 1/5, (M) 1/25, or (L) 1/125 HD DTaP plus aluminum or 
MPL, or (C) the adjuvants only, twice before intranasal B. pertussis infection. Three and seven days 
after infection lungs were excised, and the number of viable B. pertussis was determined in the 
right lung lobes. Each symbol represents the number of bacteria in the lung of an individual mouse; 
horizontal lines represent the group average. Non-boxed numbers show p-values when the different 
vaccine doses are compared, with the same adjuvant and day of sacrifice. Boxed numbers show p-
values when the different adjuvants are compared, with the same vaccine dose and day of sacrifice. 
ANOVA followed by t-test. A single representative experiment of 3 is shown. 
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Figure 2: Ptx-specific IgG in 
serum.  
Mice were sc injected with 1/5 
HD DTaP plus aluminum or 
MPL, or the adjuvants only, 
twice before intranasal B. 
pertussis infection. Three and 
seven days after infection, 
mice were euthanized. Serum 
was taken, and serial dilutions 
of test and positive control sera 
were tested for Ptx-specific 
IgG. Mean ± SEM (N=5). 
ANOVA followed by t-test. A 
single representative experiment 
of 2 is shown. 
Figure 3: Lung eosinophilia.  
Mice were sc injected with 1/5 
HD DTaP plus aluminum or 
MPL, or the adjuvants only, 
twice before intranasal B. 
pertussis infection. Three days 
after infection, the left lung 
lobes were excised. Each 
symbol represents an 
individual mouse; horizontal 
lines represent the group 
average. Mann-Whitney U test. 
A single representative 
experiment of 2 is shown.  
Figure 4: Total serum IgE.  
Mice were sc injected with 1/5 
HD DTaP plus aluminum or 
MPL, or the adjuvants only, 
twice before intranasal B. 
pertussis infection. Three days 
after infection serum was taken 
and assayed for total IgE. Data 
are indicated as mean  SEM 
(N=6). ANOVA followed by 
Bonferroni. A single 
representative experiment of 2 
is shown. 
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Figure 5A: IL-4 production by ex 
vivo Con A-stimulated bronchial LN 
cells. Mice were sc injected with 1/5 
HD DTaP plus aluminum or MPL, or the 
adjuvants only, twice before intranasal 
B. pertussis infection. Three days after 
infection, the bronchial LN were 
excised, the cells cultured with Con A 
for 24 h, and the supernatants 
analyzed for cytokine content. 5B: IL-
5 production by splenocytes 
stimulated ex vivo with heat-killed 
B. pertussis. The splenocytes were 
cultured with heat-killed B. pertussis 
for 72 h and the supernatants analyzed 
for cytokine content. Mean ± SEM 
(N=6). ANOVA followed by Bonferroni. A 
single representative experiment of 2 is 
shown. 
Cytokine production by bronchial lymph node cells. Next to lung 
eosinophilia, increased production of the Th2 cytokines IL-4, IL-5, IL-10, and IL-
13 was, in previous vaccination experiments with aluminum-adjuvated DTaP, 
suggestive of a type I hypersensitivity response (44). As MPL can redirect Th2 to 
Th1 responses, we reasoned that the hypersensitivity response might be lower 
after vaccination with the MPL-supplemented vaccine. To examine this possibility 
further, bronchial LN cells were cultured in the presence of Con A for 24 h and the 
supernatants were analyzed for cytokine content using an 8-plex assay that 
measured three Th2 cytokines (IL-4, IL-5, and IL-10), one Th1 cytokine (IFN-), 
and four additional cytokines involved in immune regulation (IL-2, IL-12p70, GM-
CSF, and TNF-). Bronchial LN cells from mice that were vaccinated with DTaP in 
aluminum showed a higher IL-4 production than those of mice that received 
aluminum only or of mice that were vaccinated with DTaP in MPL (Figure 5A). No 
treatment-related differences were seen for IL-2 and IFN-. The production of IL-5, 
IL-10, IL-12p70, GM-CSF, and TNF- by the bronchial LN cells from mice that 
received aluminum only was below the detection limit. Bronchial LN cells from mice 
that were vaccinated with DTaP in MPL showed a higher TNF-  production than 
those of mice that received MPL only (P = 0.011). No further differences were seen 
when the production of these cytokines by bronchial LN of mice vaccinated with 
DTaP in MPL was compared with those of mice vaccinated with DTaP in aluminum 
or of mice that received MPL only (data not shown). In conclusion, vaccination 
with the MPL-adjuvated vaccine resulted in lower ex vivo Con A-induced IL-4 
production by bronchial LN compared to the aluminum-supplemented vaccine, 
indicating that the immune response was skewed more toward a Th1-type 
response. 
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Cytokine production by splenocytes. To evaluate whether the adjuvant used 
in the vaccine affected ex vivo cytokine production by splenocytes these cells 
from vaccinated and control mice were isolated and cultured in the presence of 
heat-killed B. pertussis for 72 h and the supernatants were analyzed for cytokine 
content using a 5-plex assay that measured four Th2 cytokines (IL-4, IL-5, IL-10, 
and IL-13), and one Th1 cytokine (IFN-). Splenocytes from mice that were 
vaccinated with DTaP in aluminum showed a higher IL-5 production than those of 
mice that received aluminum only or of mice that were vaccinated with DTaP in 
MPL (Figure 5B). No IL-4 production was detected in splenocytes from animals that 
received either of the adjuvants only, whereas those of the vaccinated animals 
showed a mutually similar IL-4 production of ~ 7 pg/ml (data not shown). 
Splenocytes from all treatment groups showed a similar IFN- production of ~ 8 
pg/ml, while IL-10 and IL-13 production could not be detected (data not shown). 
In conclusion, the lower ex vivo B. pertussis-induced IL-5 production by 
splenocytes from the MPL-DTaP vaccinated mice compared to the aluminum-
DTaP vaccinated ones is again suggestive of a more Th1-type response. 
 
B. pertussis colonization of the lungs. The results presented so far indicate 
that MPL compares favorably to aluminum as an adjuvant for the DTaP vaccine. 
To determine whether also LpxL2 LPS would be a suitable adjuvant, a second 
series of experiments was performed in which mice were vaccinated twice with 
1/10 HD DTaP plus either aluminum, LpxL2 LPS, or MPL before intranasal B. 
pertussis infection. Five days after infection, the mice were sacrificed and the CFU 
in their lungs were enumerated. When compared to the control group that 
received PBS, all three vaccines conferred significant protection against 
colonization (Figure 6). Importantly, the vaccines with LpxL2 LPS and MPL as 
adjuvant provided a significantly better protection than the vaccine with 
aluminum. Thus, with respect to efficacy, LpxL2, like MPL, compared favorably 
to aluminum as the adjuvant in the vaccine. 
 
Bronchoalveolar lavage fluid cells. In order to determine whether the 
various adjuvants in the vaccine affected the cell-type distribution differently, 
lung lavage was performed five days after infection, and the BALF cells were 
counted and visually differentiated. The percentages and numbers of 
macrophages, neutrophils, and lymphocytes were similar in all groups, and also the 
total number of BALF cells was not differentially affected. However, the group 
immunized with DTaP plus aluminum showed a significantly higher number of 
eosinophils than all other groups (Figure 7). In conclusion, the use of LpxL2 LPS, 
like that of MPL, instead of aluminum as adjuvant in the DTaP vaccine resulted in 
a lower percentage and number of eosinophils in the BALF, which is indicative of a 
lower type I hypersensitivity. 
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Figure 6: Colonization of 
the lungs by B. pertussis.  
Mice were sc injected with 
PBS or 1/10 HD DTaP plus 
aluminum, LpxL2 LPS, or 
MPL, twice before intranasal 
B. pertussis infection. Five 
days after infection the lungs 
were excised, and the 
number of viable B. pertussis 
was determined. Each symbol 
represents the number of 
bacteria in the lung of an 
individual mouse; horizontal 
lines represent the group 
average. ANOVA followed by t-
test. A single representative 
experiment of 2 is shown. 
Figure 7: BALF eosinophil 
numbers.  
Mice were sc injected with 
1/10 HD DTaP plus 
aluminum, LpxL2 LPS, or 
MPL, or with PBS, twice before 
intranasal B. pertussis 
infection. Five days after 
infection, lung lavage was 
performed and the BALF cells 
were counted and visually 
differentiated. Data are 
indicated as mean  SEM 
(N=6). ANOVA followed by 
Bonferroni. A single 
representative experiment of 2 
is shown. 
 
 
Figure 8: Serum IL-6.  
Mice were sc injected with 
1/10 HD wP, 1/10 HD DTaP 
plus aluminum, LpxL2 LPS, or 
MPL, or with PBS. Serum IL-6 
concentrations were 
determined 4 h post 
immunization. Mean ± SEM 
(N=7). ANOVA followed by 
Bonferroni. A single 
representative experiment of 2 
is shown. 
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Vaccine reactogenicity. While both LPS analogs, as compared to aluminum, 
improve the efficacy of the DTaP vaccine and reduce type I hypersensitivity, 
they should not increase its reactogenicity. To address this issue, the 
concentration of the pro-inflammatory cytokine IL-6 was analyzed in serum 
samples taken 4 h after primary or booster immunization. A group of mice, 
immunized with a wP vaccine, which is known to display considerable 
reactogenicity, was included as an additional control in these experiments. 
Consistent with the relatively high reactogenicity of the wP vaccine, significantly 
higher serum IL-6 levels were elicited in the group of mice that received this 
vaccine as compared to all other groups (Figure 8). The IL-6 levels elicited by 
aluminum-adjuvated vaccine were similar to the PBS controls. Importantly, 
supplementation of the vaccine with either LPS analog elicited higher IL-6 levels 
than with aluminum, although these IL-6 levels were considerably lower than 
elicited by wP. Aluminum-adjuvated vaccine elicited higher IL-6 levels during 
booster immunization than during primary immunization (P = 0.004); a similar 
effect was observed for vaccination with LpxL2 LPS-adjuvated DTaP (P = 0.007), 
but not the MPL-adjuvated vaccine. In conclusion, the higher IL-6 levels when 
using LpxL2 LPS or MPL, as adjuvant in the DTaP vaccine may suggest some 
reactogenicity. The considerably lower IL-6 level than the level induced by wP 
suggests lower reactogenicity of DTaP supplemented with LPS analogs compared 
to wP. 
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Discussion 
Here, we have shown that substitution of aluminum by either one of two LPS 
analogs, MPL or LpxL2 LPS, as adjuvant in DTaP improves the vaccine in two 
ways; firstly, it enhances its efficacy, as shown by reduced colonization of the 
lungs after challenge and (in the case of MPL) increased Ptx-specific IgG titer; 
secondly, it skews the response more towards a Th1-type response as indicated 
by the lower Th2 cytokine production resulting in a decrease in parameters 
indicative of type I hypersensitivity, being lung eosinophilia and eosinophil 
numbers.  The higher IL-6 levels induced by these supplemented DTaP vaccines 
compared to aluminum adjuvated DTaP may suggest some reactogenicity, 
although being well below the reactogenicity of wP. 
We have investigated whether MPL is able to enhance vaccine efficacy by 
performing a dose-response analysis. While vaccination with 1/5 HD MPL-
adjuvated DTaP resulted in a significantly decreased colonization compared to 
aluminum-adjuvated DTaP, this was not observed for 1/25 and 1/125 HD, 
suggesting that  MPL is more effective than aluminum only at relatively high 
DTaP dosage. When LpxL2 LPS and MPL were compared, both LPS analogs seem 
to improve DTaP efficacy to a similar extent at 1/10 HD DTaP. 
There is controversy regarding the correlation between Ptx-specific IgG 
levels and protective immunity. Ptx-specific IgG levels have been shown to 
correlate with protection, both in humans (11,41,42) and mice (7). Cell-
mediated immunity, however, does also critically contribute to protection, both 
in humans (1,9,24) and mice (29). This latter notion may be an explanation of 
the varying association between serum levels against B. pertussis antigens and 
protective immunity. The association between Ptx-specific IgG levels and 
protective immunity is most apparent early after vaccination (10). We measured 
Ptx-specific IgG titers 17 and 21 days after the second vaccination, that is 
relatively early after vaccination, making it plausible that in our study indeed 
Ptx-specific IgG levels correlate with protection. 
Using MPL as adjuvant resulted in higher Ptx-specific IgG than when 
aluminum was used, suggesting an improved protection. Thus, both the 
improved clearance of B. pertussis and the higher Ptx-specific IgG suggest a 
more efficacious vaccine when MPL is used as adjuvant in DTaP. Both in humans 
(5) and mice (37,45) aP vaccines induce much higher Ptx-specific IgG levels 
than wP vaccines. However, in the present study we compared Ptx-specific IgG 
levels between aP vaccinated mice only. It may be suggested that the Ptx-
specific IgG levels that are induced by vaccination are affected by bacterial 
challenge. Pre-challenge levels are, however, similar to levels 3 and 7 days post-
challenge (Stenger and Vandebriel, unpublished observations). 
We have previously shown that pertussis vaccination, especially with DTaP, 
resulted in type I hypersensitivity. IL-4 KO mice that showed a reduced 
hypersensitivity response showed an unaffected clearance suggesting that the 
hypersensitivity is not beneficial and possibly detrimental to the host (44). As 
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MPL can redirect Th2 to Th1 responses (3,34,38,48), we reasoned that the 
hypersensitivity response might be decreased by adding MPL to DTaP. Indeed, 
lung eosinophilia, lung eosinophil numbers, and Th2 cytokine production were all 
decreased when MPL was added to DTaP. The increase in total IgE in serum was, 
however, unaffected by the addition of MPL. Possibly, the immune modulating 
capacity of MPL is too small to affect this response, or the underlying 
mechanism(s) of this response are (partly) different from Th2 to Th1 redirection. 
LpxL2 LPS harbors strongly reduced endotoxic activity while still exhibiting 
some adjuvant activity compared to wild-type N. meningitidis LPS (46). We 
speculated that it might also be effective in redirecting Th2 to Th1 responses. 
Consistently, lung eosinophil numbers were reduced when DTaP was 
supplemented with LpxL2 LPS. 
Levels of the pro-inflammatory cytokine IL-6 in serum samples taken 4 h 
after primary and booster immunization were higher when either of the LPS 
analogs was used as adjuvant, compared to aluminum. As expected, the IL-6 
levels induced by wP were significantly higher than those induced by DTaP with 
any of the three adjuvants. Thus, the higher IL-6 levels induced by DTaP 
supplemented with either LPS may suggest some reactogenicity, albeit 
considerably lower than wP. Unexpectedly, aluminum-adjuvated vaccine evoked 
significantly higher IL-6 levels during booster immunization than during primary 
immunization (P = 0.004). This suggests that booster immunization, also in the 
absence of strong immune stimulatory molecules such as LPS, may elicit a 
stronger IL-6 response than primary immunization. A similar effect was observed 
for vaccination with LpxL2 LPS-adjuvated DTaP (P = 0.007), but not the MPL-
adjuvated vaccine. This latter finding may suggest that LpxL2 LPS and MPL differ 
in their mechanism(s) of action. 
We have chosen to measure IL-6 as parameter for reactogenicity as this 
cytokine was most sensitive in the response to several pyrogens in an in vitro 
system based on a human monocytic cell line and the ex vivo human whole 
blood culture test system. This latter test represents the rabbit pyrogen test 
(31). While low or moderate IL-6 levels form an essential part of the immune 
response, excessive levels may be detrimental. A level that can be taken as 
threshold for reactogenicity has not been established, however, and we 
therefore interpret increased serum IL-6 levels as being suggestive of 
reactogenicity. 
Although MPL is believed to mimic the effects of LPS, albeit with 
considerably lower toxicity, differences in cytokine induction between these two 
molecules have been reported with MPL inducing IL-10 and IL-12, and LPS 
inducing only IL-12 (40). This finding may be explained by later studies, showing 
that MPL engages both TLR2 and TLR4, whereas LPS only acts on TLR4 (26), 
with TLR2 agonists inducing IL-10 and TLR4 agonists inducing IL-12 (35,36). 
The lack of induction of IL-1 and caspase-1 may also be an expression of the 
reduced toxicity of MPL compared to LPS (32). Knowledge on the mechanisms of 
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action of LpxL2 regarding receptor specificity and downstream effects are 
currently lacking. 
The present study has shown that supplementation of DTaP with LPS 
analogs improves efficacy and reduces type I hypersensitivity. Follow-up studies 
are, however, required. In these studies aP adjuvated with aluminum should be 
compared to aP adjuvated with LPS analogs in the total absence of aluminum, a 
reference B. pertussis strain should be used for challenge, and pre- and post-
challenge T-cell responses against the individual vaccine components should be 
measured. 
In conclusion, our results demonstrate that adjuvating the DTaP vaccine 
with the LPS analogs MPL or LpxL2 LPS improves vaccine efficacy and redirects 
the immune response from a Th2- to a Th1-type response, thereby reducing 
type I hypersensitivity. 
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General discussion: 
Host factors in Bordetella pertussis infection 
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9.1 Introduction 
 “Why do individuals respond differently to infection with the same pathogen?” 
“Why is the response to vaccination with the same vaccine so different per 
person?” “Why do patients react differently to the same treatment?” Possible 
explanations for these differences are variable environmental factors, differences 
in immune status, or pathogen variation. Another likely answer to these 
questions is the topic of this thesis: “individuals are different” and in particular: 
“they carry different genetic factors”. In this thesis we examine these genetic 
differences to learn more about pertussis. 
In spite of world wide vaccination against pertussis, whooping cough is still 
endemic in most countries, causing 297,000 deaths annually. Whooping cough, 
or pertussis, is caused by an acute infection of the respiratory tract with the 
gram-negative bacterium Bordetella pertussis. Especially young non-vaccinated 
infants are at risk for developing severe infections with complications or even 
resulting in a fatal infection (89). In the Netherlands, pertussis has shown 
epidemic peaks every 2 to 3 years during the last decade. Since 1996 a large 
increase in the number of notifications, positive cultures, positive serologic 
results, and hospital admissions was observed (20,21). The incidence of 
pertussis rose suddenly from 1996 to reach 58,3 reported cases per 100 000 
population in 2004, compared with 2.3/100 000 on average from 1989 to 1995 
(70,71). Also in several other European countries, as well as Canada, The United 
States and Australia, a re-emergence of pertussis has been observed (18,19).  
Waning immunity, increased reporting, improved diagnosis, and adaptation of 
the bacterium have been proposed to explain this re-emergence. While pertussis 
is commonly known as a childhood disease, nowadays there has been a shift in 
the incidence of pertussis to adolescents and adults (5,86). 
The objective of this chapter is to summarize our knowledge of genetic and 
genomic host factors that influence the pathogenesis of B. pertussis as well as 
the response to vaccination against pertussis. We consider that application of 
novel genetic and genomic techniques may identify novel insights in the 
pathogenesis of pertussis. There are several detailed studies which intensively 
describe the pathogenesis, genetic variation, virulence factors and epidemiology 
of pertussis (52,57,58), this chapter focuses primary on the host factors of 
pertussis.  By increasing our insight in host factors, new methods may be 
developed for treatment or prevention of whooping cough. Eventually, such 
insights may provide novel concepts for infectious disease control by 
extrapolation of the knowledge acquired for B. pertussis to other infectious 
diseases.  
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9.2 Pathogenesis of pertussis 
Biological processes of health and disease are nowadays often characterized by 
the involvement of biological pathways. A ‘pathway’ is defined as the mutual 
coherence of factors (such as proteins, DNA) and the sequence of 
communication between these factors. These biological processes are explored 
as complex systems of functionally interacting macromolecules. For pertussis, a 
substantial number of biological pathways have been identified in the past using 
‘classic’ immunological and pathological techniques. Pathogenesis of B. pertussis 
infection is characterized by the attachment of the bacteria to ciliated epithelial 
cells (involving the fimbrial-like structure on the bacterial surface and cell-bound 
pertussis toxin), colonization of and proliferation on the ciliated mucosal cells, 
resulting in damage of the respiratory epithelium (by the release of toxins such 
as pertussis toxin which facilitates the attachment and entry of pertussis toxin 
into host cells (27,88)), and an acute increase in the levels of inflammatory 
cytokines resulting in cellular infiltrate in the alveolar spaces, bronchi and 
bronchioli (52,57,64). B. pertussis expresses various virulence factors with 
different functions to facilitate the infection of the host. Circulating 
polymorphonuclear leukocytes (PMN’s) are rapidly recruited to the lungs by 
chemotaxis. PMN’s migrate to the infection site by the detection of gradients of 
molecules such as interleukin-8 (IL-8), interferon gamma (IFN-gamma), and 
C5a. PMN’s bind and ingest B. pertussis subsequently killing the bacteria by a 
combination of reactive oxygen and granule components. Finally, the PMN’s 
undergo apoptosis, a process that appears important for the resolution of 
infection and inflammation (44). Toll-like receptor (TLR, a pathogen-accociated 
molecular pattern receptor on antigen presenting cells such as macrophages or 
dendritic cells) ligands such as lipopolysaccharide (LPS) are critical components 
for the recruitment and priming of PMN’s. Serum antibody–mediated clearance 
of B. pertussis also requires a TLR-induced early recruitment of PMN’s. However, 
pertussis toxin limits this rapid serum antibody–mediated clearance by inhibiting 
PMN recruitment (43).  
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9.3 Combining host genetics with genomics 
9.3.1 Genetics 
Knowledge of genetic factors that determine susceptibility or resistance to 
infectious diseases can be exploited to gain knowledge of infectious diseases and 
improve their treatment and prevention (16,40,42).  Generally, there are two 
approaches for the identification of host genetic factors that influence the course 
of an infectious disease: with or without a priori. With a priori knowledge, the 
researcher makes a selection of the genes to be studied, based on his 
hypothesis that these genes could have a role in disease. Without a priori 
knowledge, no genes are excluded from analysis in advance. This is called a 
whole-genome-wide approach. In humans the identification of host genetic 
factors in genetic complex (or multigenic) diseases is difficult because of the 
small effects of individual genes and the genetic heterogeneity of the population. 
Most studies in humans focus on a specific pathway and study the association 
between single nucleotide polymorphisms (SNPs) in specific genes within such 
pathways and a phenotypic parameter (42). In contrast, the mouse offers 
significant advantages as a model to study the effects of host genetics on 
infectious diseases, but the path from susceptibility locus to susceptibility genes 
requires intensive study and many animals and the obtained results should also 
be extrapolated to humans (13,72).  
To define numerous susceptibility genes that have small but cumulative effects 
on a specific phenotype, it seems that at this moment, a suitable approach is to 
first identify them in a mouse model, and subsequently to study the role of their 
human homologues in humans (24,72). To map susceptibility genes in mice, 
several different strategies are available encompassing different mouse models 
as ´genetic tool´ to facilitate linkage studies (22).  
An example of such a strategy is the identification of a locus on mouse 
chromosome 6 that controls Bordetella pertussis-induced histamine sensitization 
(Bphs). This locus was identified by performing linkage analysis of congenic mice 
that have been administered with Ptx followed by histamine sensitization. This 
disease-susceptibility gene Bphs maps distal to the T-cell receptor beta-chain 
gene (81). This candidate region was subsequently reduced by testing additional 
markers resulting in the mapping to a cluster of genes from the TNF receptor 
superfamily on mouse chromosome 6 (55). Three years later it was 
demonstrated that this region links to the histamine H1 receptor (Hrh1) gene 
and that natural alleles of Hrh1 control autoimmune T cell and vascular 
responses regulated by histamine after Ptx sensitization (48).  
When our studies were initiated, the murine genome was only partially 
sequenced and whole genome based genetic or genomic approaches were not 
available at that time. We have therefore used different genetic tools and 
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combined this knowledge with genomic and classical immunological and 
pathological techniques to unravel the pathogenesis of B. pertussis. We started 
by using recombinant congenic strains (RCS) of mice (23) to study if genetic 
factors influence the course of pertussis and to identify possible susceptibility 
loci for B. pertussis. We described the identification of three novel susceptibility 
loci (9), and designated these loci Bordetella pertussis susceptibility loci-1, -2 
and -3. For this, we screened two sets of RCS of mice for susceptibility to B. 
pertussis infection and found a wide range in bacterial numbers in the lung at 1 
week post inoculation. This indicated multigenic control of the B. pertussis 
infection. We identified one locus located on chromosome 12, which we 
designated as Bps-1, and two interacting loci on chromosomes 5 and 11, 
designated Bps-2 and -3, which influence the number of bacteria in the lung 1 
week after inoculation. The presence of C57BL/10 DNA in Bps-1 instead of C3H 
DNA has a dominant-positive effect on the clearance of bacteria from the lung 
(9). We found maximum linkage between the number of CFU and the Bps-1 
locus with a LOD score of 4.6 (P = 0.000025) compared to a LOD score of 2.92 
(P=0.010) found between the interacting loci Bps-2 and Bps-3 and the number 
of CFU’s.  
We have subsequently primarily focused on genes within the Bps-1 locus 
because the significance of the linkage was stronger for Bps-1 and the region 
was better demarcated. 
 
9.3.2 Genomics 
Omics is a general term for a broad discipline of science and engineering that 
analyzes the interactions of biological information objects in various omes. 
These include genomics, proteomics, metabolomics, transcriptomics (26).  
With the introduction of whole genome expression assays (genomics or 
transcriptomics), ‘classic’ pathways have been confirmed and supplemented with 
mRNA expression data. It has been shown that genes that function in these 
pathways are upregulated during pertussis infection (7,10).  
We have chosen to study the genomics of pertussis for three reasons; 1. to get 
more insight in the pathogenesis of pertussis on a molecular level, 2. to identify 
more candidate genes which play a role in the course of infection, and 3. to 
identify the candidate susceptibility genes within Bps-1.  
These experiments have greatly contributed to a detailed understanding of the 
role of a large number of individual genes and proteins in pertussis infection. 
Combining these data to pathways requires advanced analysis in which 
bioinformatics plays a crucial role.  To assign functions to differentially 
expressed genes and to reveal inter-gene relationships, we performed 
MetaCoreTM analysis. MetaCore is based on a manually curated database of 
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human protein-protein, protein-DNA and protein-compound interactions, 
metabolic and signaling pathways, and the effects of bioactive molecules in gene 
expression. It allows the identification of affected pathways during pathologic 
process from microarray analysis by calculating enrichment for Gene Ontology 
(29) and GeneGo (56) annotated processes. We determined enrichment for 
these categories to identify the pathophysiological processes involved in 
response to B. pertussis. The array data are scored for pathway relevance 
(pathways with the highest percentage differentially expressed genes) and give 
specific insights in the biological processes involved (56,59).  
Overall we observed that eight percent of the 22,000 genes investigated in our 
study was significantly differentially expressed after B. pertussis  infection. From 
these genes, most upregulated genes were involved in immune-related 
processes, such as the acute-phase response, antigen presentation, cytokine 
production, inflammation, and apoptosis, while downregulated genes were 
mainly involved in nonimmune processes, such as development and muscle 
contraction. Additional pathway analysis revealed the involvement of 
granulocyte function, toll-like receptor signaling pathway, and apoptosis (7). 
 
9.3.3 Combination of genetics and genomics 
We have used recombinant congenic mouse strains as tool to further study the 
genetic basis of susceptibility to B. pertussis infection. The traditional approach 
for mapping genes in susceptibility loci is a combination of positional cloning and 
linkage analysis (67,75). Although this strategy has proven to be effective 
(22,73), the approach is quite costly and animal-consuming. Therefore, we 
compared the gene expression profiles in the lungs of two mouse strains, i.e. 
HcB-28/Dem and C3H, which showed a different course of B. pertussis infection, 
in order to further identify candidate susceptibility genes without the need for 
positional cloning. We hypothesized that candidate genes are differentially 
regulated between the two strains of mice mentioned above. By this strategy we 
have identified 17 genes within Bps-1 that are differentially expressed between 
the two mouse strains. These genes were not regulated by B. pertussis. 
Remarkably, 17 of these genes were located in the Bps1 region, 8 of which 
mapped to the Igh complex. Among these 8 genes were the Igh-1 gene and 
genes that encode for Ig heavy chain variable regions. We observed a 
significantly higher expression of the gene variant of Igh-1 isotype b in HcB mice 
compared to C3H mice. Because the genes that were differentially regulated 
between the mouse strains already showed differences in expression before 
infection, it appears likely that such intrinsic differences in gene regulation are 
involved in determining differences in susceptibility to B. pertussis infection. 
Host genetics and genomics of Bordetella pertussis infection and vaccination 
 
 
 
212 
Figure 1. Approach used for identifying susceptibility genes to B. pertussis.  
HcB28 mice are derived from the inbred mouse strains C3H/DISnA and C57Black/10ScSnA, 
resulting in 12.5% Black genome across the C3H genome. The genome of the HcB28/Dem strain, 
thus, differs maximally 12.5% as compared to C3H mice (Approximately 3,000 genes). Bps-1 was 
identified by using a F2-intercross between HcB28 and C3H mice, resulting in the description of the 
susceptibility locus, containing 185 genes. 17 genes in Bps-1 were differentially expressed between 
the two strains of mice, 8 of which mapped to the Igh complex. We propose that eight genes are 
potential susceptibility genes that could explain the susceptibility conferred by the Bps-1 locus. 
 
Genesdifferent between
C3H and HcB28
Geneslocatedin Bps-1
Differentially
expressedin
Bps-1
17 genes
185 genes
Approximately3,000 genes
8 genes
Potential
candidate
genes
Alternatively, such genetic differences in susceptibility may be explained by 
genes that are not differentially regulated between these two mouse strains or  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
by processes other than differential gene expression. Genes in the Igh complex, 
among which Igh-1, may be likely candidates to explain differences in 
susceptibility to B. pertussis as will be discussed below. By testing these RCS, 
we did not find Tlr4 as major susceptibility locus while Tlr4 is repeatedly 
described as influencing factor in gram-negative infections (15,63). Because the 
RCS used were genetically identical at 33cM, chromosome 4, Tlr4 cannot be 
detected as susceptibility locus.  
Summarizing, we have used recombinant congenic strains of mice as a tool to 
study the susceptibility to a Bordetella pertussis infection (Figure 1). We 
observed a difference in the susceptibility to B. pertussis between two strains of 
mice that are genetically different for maximally 12.5% (approximately 3000 
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genes). By using a F2-intercross between HcB28 and C3H mice we identified the 
B. pertussis susceptibility locus-1 (Bps-1), containing 185 genes. In the 
following step, we identified 17 genes within Bps-1 that are differentially 
expressed between these two strains of mice, 8 of which mapped to the Igh 
complex. Among these 8 genes were the Igh-1 gene and genes that encode for 
Ig heavy chain variable regions. We can therefore state that eight genes are 
potential susceptibility genes that could explain the susceptibility conferring by 
the Bps-1 locus. Of these eight genes Igh-1 shows the strongest difference in 
gene-expression between the two strains of mice.  
 
9.3.4 Result of the combination: Igh 
As described above, we used microarray analysis of differential gene-expression 
between the C3H/DISnA and HcB28/Dem strains, the two strains of mice in 
which we identified the Bps-1 locus, to reduce the  number  of  candidate  
susceptibility  genes within  the  Bps1 locus (10). Genes  in  the  Igh  complex,  
among  which  Igh-1,  are  likely  candidates  to  explain differences in 
susceptibility to B. pertussis (10). We observed a significantly higher expression 
(up to 2.8-fold) of Igh-1 isotype b in HcB mice compared to C3H mice. The Igh 
locus is genetically polymorphic and very complex (78). The Igh-1 gene exists in 
2 major genetic variants (Igh-1a and Igh-1b) with 83.8% similarity (51). The 
Igh-1a allele codes for the heavy chain of IgG2a while the Igh-1b allele codes for 
the heavy chain of IgG2c (50). Mouse strains such as C57BL/6 and C57BL/10 
(the donor strain of the HcB mice) only contain the Igh-1b variant and are 
therefore incapable of producing IgG2a, while mouse strains such as BALB/c 
only contain the Igh-1a variant and are therefore incapable of producing IgG2c 
(50,51). The oligo for Igh-1 spotted on the microarray, was designed based on 
accession number XM_484178 annotated as Igh-1a. Because this annotation is 
based on the reference C57BL/6 mice, this oligo can be considered as Igh-1b 
annotated. In the sera of HcB mice we detected no IgG2a while C3H mice had 
significant titers of IgG2a, thereby confirming the expression results. It is 
tempting to speculate if and how genes within the Igh complex may affect 
differences early in the course of B. pertussis infection. Possible mechanisms 
may include differences in transcriptional gene regulation affecting immune 
responsiveness, different function of the IgG2a or c isotypes, or different usage 
of V chains. This latter possibility might imply the existence of “natural 
antibodies” reacting with B. pertussis epitopes.  
It has previously been shown that genes within the Igh-1 locus are 
predominantly associated with the course of a herpes simplex virus type-1 
(HSV-1) infection in mice by an unknown mechanism (25,61,82). Pro-
inflammatory cytokines such as IL-1, IL-4, IL-6 and IL-7 participate in this 
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infection (3). Interestingly, natural killer cell activity appears to be regulated by 
the Igh-1 locus but could not simply explain the differences in HSV-1 
susceptibility (82). Igh-linked genes have further been implicated in T 
suppressor cell activity (47,60).  
Future studies should demonstrate if Igh-1 (and thus IgG2a / IgG2c) indeed 
explains the observed genetic differences between C3H and HcB mice. The 
functional role of Igh in the pathogenesis of B. pertussis can be studied in future 
studies such as knock-out mice or RNA interference studies.  
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9.4 Additional pathway information 
9.4.1 Neutrophils 
One of the major defense mechanisms against B. pertussis is the rapid 
recruitment of circulating polymorphonuclear leukocytes (PMN’s) to the lungs to 
bind and ingest B. pertussis, subsequently killing the bacteria by a combination 
of reactive oxygen and granule components (52,57). As determined by 
molecular pathway analysis in our study, one of the most significant pathways 
involved in the response to B. pertussis infection is regulation of PMN function 
confirming ‘classic’ knowledge (7). Of the 1,841 genes that were differentially 
regulated upon B. pertussis infection, twenty genes can be ascribed to the PMN 
pathway, such as GM-CSF and lactoferrin The PMN pathway contains 45 genes, 
so, almost half of these genes are regulated upon B. pertussis infection (Figure 
2).  Other pathways that are upregulated by B. pertussis are the TLR signaling 
pathway (of the 47 genes involved in this pathway, 16 are B. pertussis-
regulated), extracellular matrix remodeling (18 out of 60), and apoptosis (13 out 
of 36). It has been described that apoptosis of PMNs, in which TLR2 plays an 
important role (35), is accelerated following phagocytosis of bacteria (44,45). In 
conclusion,  our data support a central role of PMN’s in the course of B. 
pertussis. 
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Figure 2. Regulation of polymorphonuclear granulocytes. 
mRNA Expression profiles were determined from mRNA isolated from B. pertussis inoculated Mice 
(C3H/DISnA). Genes that were significantly different between mock- or inoculated mice (P<0.01) were 
included in the pathway analysis. Fold expression was defined as the difference between the expression of 
B. pertussis infected mice and the expression of Mock inoculated mice.  Genes in the pathway that are 
differently expressed are represented by the fold-expression histogram. The pathway contains 45 genes, 
twenty of which were regulated by B. pertussis infection. The Image was generated by MetaCoreTM 
(GeneGo). 
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9.4.2 Toll-like receptor signaling 
Toll-like receptor 4 (TLR4) was the first TLR to be described and was originally 
designated human Toll (53,54). It was shown that TLR4, the receptor for 
lipopolysaccharide, directly influences innate immunity to gram-negative 
bacteria by studies in Tlr4 defective mice (15,63). Studies in mice also indicated 
the involvement of the toll-like receptor 4 (TLR4) gene in the B. pertussis 
infection process (11,33,49). It was shown that TLR4 is not only the receptor for 
lipopolysaccharide (LPS), but also one of the receptors for pertussis toxin (PT) 
(39,63,66). LPS recognition by TLR4 on dendritic cells induces IL-12 production, 
which supports the development of Th1 cells (38).  In mice, Tlr4 is important for 
an effective immune response to B. pertussis, clearance of bacteria from the 
lung, and thereby reduction of lung pathology upon infection (11,33,49). 
Signaling through Tlr4 is also essential for induction of adaptive immunity to B. 
pertussis in response to vaccination in mice (32) (and unpublished work (8)). 
Whole-cell pertussis vaccination can  induce the development of Th1- and Th17-
cells through TLR4, which mediates protective cellular immunity to B. pertussis 
(32). In humans, two coding variants of TLR4 have been associated with 
enhanced susceptibility to infectious diseases, especially gram-negative 
infections and endotoxin hyporesponsiveness (1,2,76,83).  
In mice we demonstrated the significance of Tlr4 in genetic susceptibility and 
pathobiology of pertussis (11). Although the study was designed to perform a 
whole-genome analysis of genetic differences between different strains of mice, 
we came to the conclusion that all observed phenotypic differences were 
dominated by Tlr4.  We showed that C3H/HeJ mice that carry a functional 
mutation in the intracellular domain of Tlr4 showed a delayed clearance of 
bacteria from the lung, a higher relative lung weight, and increased body weight 
loss upon infection. Nine A/J mice died within the first four days after infection, 
while eleven C3H/HeJ mice died after four days. Remarkably, although A/J mice 
cleared B. pertussis more efficiently, we observed no significant difference in 
overall mortality after B. pertussis infection between A/J and C3H/HeJ mice. 
However A/J mice died earlier than C3H/HeJ mice. Thus mortality appeared 
associated in time with the inflammatory response. 
Splenocytes from infected C3H/HeJ mice produced almost no interleukin-1beta 
(IL-1beta) and tumor necrosis factor alpha (TNF-alpha) upon ex vivo 
restimulation with B. pertussis and also showed a delayed gamma interferon 
(IFN-gamma) production. TNF-alpha expression in the lungs 3 days after 
infection was not affected in C3H/HeJ mice. Thus functional Tlr4 is essential for 
an efficient (pro) inflammatory response and efficient clearance of bacteria from 
the lung. However, there may be a severe price for such an efficient 
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proinflammatory response, as discussed above, mortality appeared associated in 
time with the inflammatory response. 
Concluding, we showed that Tlr4 is a major genetic factor that is sufficient to 
explain all detectable genetic differences in bacterial clearance between these 
mice. Functional Tlr4 is required for an early IL-1	, TNF-, and IFN- response 
that may enhance bacterial clearance, and thus, despite the proinflammatory 
nature of these cytokines, may limit pathology. This early cytokine response was 
fatal for ca. 50% of the mice, but the surviving mice had efficiently cleared the 
bacteria from the lungs, little lung pathology and rather quickly regained their 
body weight. A lack of this response resulted in delayed mortality, but these 
mice were less efficient in clearing the bacteria from the lungs, became very ill 
from lung edema, and only slowly regained their body weights (11).  
As described above, B. pertussis induces pro-inflammatory cytokines by the 
activation of the Toll-like receptor signaling pathway. In addition to this ‘classic’ 
immunological cytokine measurement, we performed microarray analysis, which 
gives the ability to perform pathway analysis, i.e. to examine upregulation of the 
Toll-like receptor signaling pathway. Pathway analysis of B. pertussis-infected 
lungs of mice revealed that 16 of the 47 genes within the Toll-like receptor 
signaling pathway were regulated upon B. pertussis inoculation (Figure 3). 
In humans, two functional polymorphisms Asp299Gly and Thr399Ile have been 
associated with infectious diseases in humans, including myocardial infection, 
respiratory syncytial virus infection and septic shock (76,83). These two SNPs 
cause a differently amino acid change (Aspartic acid to Glycine at codon 299 and 
Threonine to Isoleucine at codon 399) in the extracellular domain of the 
receptor, and they may be responsible for altered ligand binding. The role of 
TLR4 in susceptibility to B. pertussis infection in humans is yet unknown. We 
therefore studied the role of TLR4 in the response to vaccination, which is 
described below.  
Chapter 9 
 
 
 
219 
 
Figure 3. Toll-like receptor signaling pathway.  
mRNA Expression profiles were determined from RNA isolated from the lungs of mock- and B. pertussis-
inoculated mice. Genes that were significantly different between mock- and infected mice (FDR<0.05) are 
included in the pathway analysis. Fold expression was defined as the difference between the expression of 
B. pertussis infected mice and the expression of Mock inoculated mice. Genes in the pathway that are 
differently expressed are represented by the fold-expression histogram.The pathway contains 47 genes 
sixteen of which are regulated by B. pertussis. The Image was generated by MetaCoreTM (GeneGo). The 
complete legend is presented at http://www.genego.com/files/MC_legend.pdf  
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9.5 Application of acquired knowledge: vaccination 
9.5.1 Vaccination against pertussis in humans 
Since the introduction of whole-cell pertussis vaccination in the Netherlands, 
mortality reduced drastically. However, the vaccine used was pyrogenic, and 
several side-effects were reported. Also, the effectiveness of the vaccine was not 
optimal and the vaccine-induced memory waned quickly. During the last 
decades, the incidence of pertussis increased, and the public opinion changed, 
and the Dutch government decided to switch from whole-cell pertussis vaccine 
(wP) to acellular pertussis vaccine (31,89). 
It has been shown that signaling through Tlr4 is essential for induction of 
adaptive immunity to B. pertussis in response to wP vaccination in mice. 
Activation of innate immune cells through Tlr4 helps to induce Th1 and Th-17 
cells and mediates protective cellular immunity to B. pertussis (8,32). Since Tlr4 
plays a critical role in the wP vaccination response in mice, we considered that 
variation in the gene coding for TLR4 may account for some of the observed 
variation in the vaccine-induced antibody response in humans. We examined the 
influence of TLR4 on the wP vaccination response also because variation in 
response to vaccination may reflect differences in the course of infection (41). 
For this purpose a large birth cohort study (the KOALA Birth Cohort Study (46)) 
was studied to provide the opportunity to assess single nucleotide 
polymorphisms (SNPs) in TLR4 as well as pertussis toxin (PT)-specific IgG 
antibodies. We showed that the c.-3612 T>C promoter SNP (rs2770150) was 
significantly associated with response to pertussis vaccination and that a lower 
antibody response was associated with the minor allele. This supports the notion 
that TLR4 is involved in the antibody response to wP vaccination. Future work 
should indicate whether this and other polymorphisms in TLR4 have clinical 
relevance either by affecting the antibody response following vaccination, during 
the waning of the antibody response, or by affecting the outcome of infection 
itself irrespective of vaccination. It should also be studied if TLR4 polymorphisms 
are also involved in the, in most countries used, acellular pertussis vaccination 
(aP). 
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9.5.2 Vaccination against pertussis in mice 
To establish the mechanisms by which Tlr4 affects pertussis vaccine-induced 
immunity we compared Tlr4-deficient mice (Tlr4LPS-d, C3H/HeJ) and wildtype 
mice (Tlr4WT, C3H/HeOuJ) in our model of B. pertussis challenge after wP or aP 
vaccination (84).  
We observed no difference in Ptx-IgG, FHA-IgG, and Prn-IgG responses after 
vaccination with either wP or aP. Bacterial clearance and IFN- and IL-17 
production were lower after infection of Tlr4LPS-d mice compared to Tlr4WTmice. 
After wP vaccination and challenge, bacterial clearance and IL-1, TNF-, IFN-, 
IL-17, and IL-23 expression were lower in Tlr4LPS-d mice compared to Tlr4WTmice, 
while Prn-IgG and IL-5 expression were higher, and lung pathology was absent. 
After aP vaccination and challenge, IL-5 expression was higher in Tlr4LPS-d mice 
compared to Tlr4WT mice, while bacterial clearance and Ptx-IgG titers were 
lower. Thus, Tlr4 plays an important role in natural immunity, wP and aP 
efficacy, and the induction of Th1 and Th17 responses after wP vaccination and 
challenge. Tlr4 affects a more limited set of parameters in case of aP vaccination 
than in case of wP vaccination. The presence of functional Tlr4 is critical for lung 
pathology after wP vaccination and challenge, enhances pro-inflammatory 
cytokine production after wP vaccination and challenge, and diminishes Th2 
responses after wP and aP vaccination and challenge. The humoral response to 
vaccination (without challenge) is not influenced by Tlr4 (Summarized in figure 
4) (8). Th17 cells have recently emerged as a third independent T cell subset 
that may play an essential role in protection against certain extracellular 
pathogens (12). Th17 cells have become notorious for their involvement in a 
range of autoimmune diseases, but an exclusive role as mediators of pathology 
is unlikely to be their primary function (80). The Th17 pathway is credited for 
causing and sustaining tissue damage (79). The Th17-induced cytokine IL-17 
stimulates the mobilization and generation of neutrophils by granulocyte-colony 
stimulating factor (G-CSF), thereby bridging innate and adaptive immunity. It 
has been suggested that this might constitute an early defense mechanism 
against severe trauma that would result in tissue necrosis or sepsis (80). IL-23 
is important in maintaining Th17 responses but a combination of IL-6 and TGF-	 
acts to induce the Th17 differentiation (69). 
In mice, Tlr4 affected the antibody response both after vaccination with the LPS-
containing whole-cell pertussis vaccine and the (LPS-free) acellular vaccine. Both 
vaccines induced less protective immunity in Tlr4 defective C3H/HeJ mice 
(Tlr4Lps-d) compared with the wild-type mice (Tlr4Lps-n) (8,32), suggesting that 
not only the interaction between TLR4 and LPS  but also the interaction between 
TLR4 and PT is important in the generation of vaccine-induced immunity and 
bacterial clearance. Our data show that Tlr4 does not affect the humoral 
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response to vaccination, and that Tlr4-dependent differences are seen only after 
challenge. This suggests a Tlr4-dependent effect of bacterial challenge on the 
humoral response, and that for this type of response Tlr4 plays a more 
important role in the challenge phase than in the vaccination phase. 
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Figure 4: Schematic representation of the induction of long-term memory 
Chapter 9 
 
 
 
223 
9.5.3 Adjuvants 
To enhance the effectiveness of vaccination, vaccines are substituted with 
adjuvant for the induction of long-term memory. The Dutch pertussis vaccine is 
adjuvated with aluminiumphosphate. The use of aluminum as adjuvant is 
associated with local reactions in young children (36).  In the wP vaccine, a 
substantial amount of LPS is present, which was shown to have an adjuvant-
effect on the vaccine-compontents administered simultaneously. aP vaccines 
lack the presence of LPS, resulting in a lower antibody response against the 
vaccine-components. It has been shown that LPS is an essential component of 
wP vaccines in mice, as wP-vaccinated C3H/HeJ mice that have a point mutation 
in the Tlr4 gene resulting in defective signal transduction, responded more 
slowly in clearing a B. pertussis challenge (8,32). This result underlines the 
important role of LPS in generating a productive immune response, at least in 
mice. Additionally, we have shown that a functional polymorphism in TLR4 was 
associated with reduced pertussis toxin (Ptx)-specific IgG titers in wP-vaccinated 
children one year of age (6,32).  Together, these findings strongly suggest an 
important role of LPS in wP vaccines. LPS would therefore be an interesting 
adjuvant to aP vaccines, but is too toxic, and will induce unwanted side-effects 
such as local reactions and reactogenicity. 
We have shown an application of the acquired knowledge of Tlr4 by showing that 
LPS analogs as adjuvant can improve acellular pertussis vaccine (28). To make 
use of this role of LPS, the development and use of LPS derivatives and novel 
LPS species have been investigated. The non-toxic LPS derivative 
monophosphoryl lipid A (MPL), a purified, detoxified glycolipid, engages TLR4 
(62), inducing Th1 adaptive immunity and changing Th2-directed to Th1-
directed responses (4,65,68). Furthermore, a Neisseria meningitidis strain 
deficient for the late acyltransferase LpxL2 displayed a strongly decreased 
endotoxic activity when tested for its capability to stimulate human 
macrophages (85). This mutant LPS still exhibited considerable immune-
stimulating activity (85). Compared to aluminum only, vaccination with either 
LPS analog resulted in a better clearance of pertussis from the lungs, a higher 
pertussis toxin-specific serum IgG level, reduced lung eosinophilia, a decrease in 
eosinophil numbers in the bronchoalveolar lavage, and reduced ex vivo 
production of IL-4 by bronchial lymph node cells and IL-5 by spleen cells. Our 
results demonstrate that use of the acellular pertussis vaccine with the LPS 
analogs MPL or LpxL2 LPS as adjuvant improves vaccine efficacy and redirects 
the immune response from a Th2- to a Th1-type response, thereby reducing 
type I hypersensitivity (28). 
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9.6 Future prospects 
Studying genetic control of susceptibility to infectious diseases may provide new 
tools for prevention and control of these diseases. Whole genome based genetic 
approaches have the major advantage that no a priori assumptions about 
mechanisms of pathogenesis need to be made in these studies, and thus 
previously unrecognized pathways of disease susceptibility can be detected (77). 
Disadvantages are that whole genome based genetic techniques are expensive, 
and powerful statistical models should be applied to avoid false positive 
associations (multiple testing errors). 
At this moment, array-based whole-genome genotyping assays are developed 
covering over one million SNPs to interrogate human genetic variation 
(30,34,37).  Such assays make whole-genome association studies more feasible 
and have good prospects for dissecting the genetics of common diseases, but 
they currently face a number of challenges, including problems with multiple 
testing and study design, definition of intermediate phenotypes and interaction 
between polymorphisms (17).  
 In our study, we have exploited an approach with no a priori assumptions to 
acquire knowledge of genetic host factors which influence the pathogenesis of B. 
pertussis and factors that influence the vaccination against pertussis.  
To define the numerous susceptibility genes that have small but cumulative 
effects on the described phenotypes, it seems that at this moment, a suitable 
approach is to first identify them in a mouse model, and subsequently to study 
the role of their human homologues in humans (24,72).  For instance, we have 
first identified the role of Tlr4 in B. pertussis infection and vaccination in mice, 
and subsequently the role of TLR4 in vaccination in children. The next step is 
investigation of the role of TLR4 in human pertussis infection.  
In humans (6) the identification of host genetic factors with no a priori 
assumptions is difficult because of the small individual effects and the genetic 
heterogeneity of the population. Most studies in humans focus on a specific 
pathway and study the association between single nucleotide polymorphisms 
(SNPs) of specific genes within such a pathway and a phenotypic parameter 
(42). In contrast, the mouse offers significant advantages as a model to study 
the effects of host genetics on infectious diseases with no a priori assumptions, 
but the path from susceptibility locus to susceptibility genes requires intensive 
study and many animals (13,72). One of the largest advantages of using mice 
as genetic tool is the possibility to reduce genetic complexity (without losing 
power). One of the approaches that proves the power of this principle has been 
described by Dr. Demant and coworkers in a series of publications. This is best 
illustrated for colon cancer indicating that susceptibility loci in mice may indeed 
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Short term Middle term    Long term 
Basic researc    Better understanding of 
gene function at the 
molecular level by the 
study of genetic 
polymorphisms
Detection of novel disease-specifi c genes by genome-
wide scans; targeted drug discovery; gene therapy 
(chronic infections, inherited immune defi ciencies)
Vaccine development Better understanding of 
individual responses to 
vaccines
Elaboration of vaccines 
with improved 
immunogenicity (use of 
innate immune adjuvants)
Genetic screening at birth, 
allowing customised 
vaccination programme
Preventive and 
predictive medicine
List of crucial 
polymorphisms 
associated with increased 
susceptibility to infection
Screening of individuals at 
high risk for infectious 
diseases and development 
of individualised 
prophylactic measures 
including antimicrobial 
prophylaxis; identifi cation 
of new therapeutic targets
Genetic screening at birth, 
allowing customised 
prophylaxis in case of 
high-risk condition 
(immunosuppressive 
therapy, major surgery); 
development of new 
treatment modalities
Table 1:  Examples of potential short, middle, and long-term applications and effects of innate  
immunogenetic studies for basic and translational research, adapted from Bochud et.al.,2007
be connected to functional gene polymorphisms in humans  (73-75). The study 
mentioned is, however, a very time- and animal-consuming method.  
In our studies we have combined genetics and genomics as an approach to 
reduce the number of possible candidate genes to accelerate the pace and to 
reduce the number of animals required. This approach yielded the identification 
of the candidate susceptibility gene Igh-1, and provided more insight into the 
pathogenesis of pertussis.  
Immunogenetic studies have provided researchers and clinical investigators 
crucial information that has improved our understanding of host defence against 
microbial pathogens. Table 1 shows examples of the effect of recent discoveries 
in the field of immunogenetics with foreseeable applications for the short, 
middle, and long term in areas such as vaccine development (14). For instance, 
our studies have yielded a better understanding of individual responses to 
vaccines by describing the role of Tlr4 in vaccine-induced immunity after 
pertussis vaccination (Short term) and used this knowledge to improve the 
vaccine by using the innate immune adjuvants MPL and LpxL2 (Middle term). 
With the development of new techniques host genetics can be studied in a broad 
way and with no a priori assumptions. Whole genome analysis of the human 
genome is no longer out of reach due to the introduction of array-based SNP 
assays that are able to test up to one million SNP’s simultaneously. The only 
bottlenecks at this moment are the excessive costs, multiple testing problems 
and the recruitment of large cohorts. But these techniques will be more easily 
available in the near future (87). 
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The question remains what to do with an established association with a 
‘candidate gene’, how to get hard evidence of the function of this gene in the 
pathogenesis of the disease and how to finally get rid of the prefix ‘candidate’?  
The most common path that can lead from ‘gene’ to ‘function’ is by knocking out 
the candidate gene, and test whether the phenotype changes. There are several 
ways to knock out a gene; the traditional approach is by introducing a STOP 
codon in the promoter region of the gene, or by introducing an extra base pair 
resulting in out-of-phase transcription. The problem is that about 15 percent of 
these gene knockouts are developmentally lethal, meaning that the genetically 
altered embryos cannot grow into adult mice. This problem is often overcome 
through the use of conditional mutations. Conditional mutants are engineered by 
the introduction of a LoxP site to both flanking regions of the target gene. These 
LoxP sites are silent, meaning that when no action is taken, the mouse has an 
normal phenotype. When the mouse is, however, treated with cre recombinase, 
the DNA flanked by the two mutant loxP sites is deleted, causing an instant 
‘knock-out’ of the gene.   
Another method of knocking out a gene is by interference RNA (RNAi, or, post 
transcriptional gene silencing). RNA interference or silencing RNA is a 
mechanism for RNA-guided regulation of gene expression in which double-
stranded RNA inhibits the expression of genes with complementary nucleotide 
sequences. There are several companies which provide complete assays of RNAi 
with targets that cover almost the complete murine genome (RNAi profiling).  
When the function of a gene has been established in mice, the next logical step 
is to extrapolate these data to humans. Although the genomes of both, mice and 
men, are nowadays fully unraveled and on-line available and most murine genes 
can be linked to its human homologue, the evidence of the functionality of a 
certain gene in humans is still a difficult and time-consuming job. In addition, 
the roles of several genes differ between mice and humans.   
For pertussis, great efforts have been made in the unraveling of the host 
response to infection and vaccination, especially in mice. With the introduction of 
the whole human genome SNP analysis, it would seem the most favorable step 
to study multiple vaccine-induced parameters in a large cohort of children and 
correlate these parameters to their whole genome SNP-profile. This strategy will 
presumably identify a large number of genes that are directly associated with 
the response to pertussis vaccination. Combining this acquired knowledge to the 
functional knowledge of host response of pertussis that is known so far, will 
open up the way to vaccine-improvement of pertussis vaccines (and perhaps of 
other vaccines).  
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Nederlandse samenvatting 
 
“Waarom reageren mensen zo verschillend op een infectie met dezelfde 
ziekteverwekker?” “Waarom reageren mensen zo verschillend op vaccinatie?” 
“Waarom reageren patiënten zo verschillend op een behandeling?”  Mogelijke 
verklaringen voor deze vragen zijn natuurlijk verschillende omgevingsfactoren, 
verschil in weerstand of verschillen in het type ziekteverwekkers. Maar ook: 
“Mensen zijn verschillend” en meer toegespitst: Ze hebben verschillende genen”. 
 
Ondanks dat er wereldwijd wordt gevaccineerd tegen kinkhoest,  sterven er 
jaarlijks bijna 300.000 kinderen aan deze ziekte, en is kinkhoest nog steeds 
endemisch in de meeste landen. Kinkhoest wordt veroorzaakt door de bacterie 
Bordetella pertussis, en is een acute infectie van de luchtwegen. Vooral jonge, 
(nog) niet gevaccineerde kinderen lopen het risico om een ernstige infectie door 
te maken als ze in aanraking komen met deze bacterie. In Nederland vertoont 
kinkhoest elke 2 à 3 jaar een verhoging in incidentie in de laatste decennia. 
Sinds 1996 is er in Nederland een grote toename waargenomen in het aantal 
kinkhoest-gevallen, met de epidemie van 2004 als hoogtepunt. Ook in andere 
landen als Canada en de Verenigde Staten is een toename van het aantal 
kinkhoest-gevallen waargenomen. Wegebbende immuniteit, verbeterde 
rapportage, verbeterde diagnose en aanpassingen van de bacterie zijn genoemd 
als mogelijke verklaringen van deze waargenomen toename. Dit proefschrift 
onderzoekt of genetische factoren van de gastheer een rol spelen in het verloop 
van de ziekte kinkhoest, in de afweer tegen kinkhoest en in de reactie op 
vaccinatie tegen kinkhoest.  
 
Alle lichaamscellen van de mens bevatten hetzelfde erfelijke materiaal (DNA). 
Toch vervullen ze elk een andere functie, of krijgen ze een andere functie als 
reactie op bepaalde prikkels of stress. Door bepaalde genen op het DNA 
geprogrammeerd ‘aan’ of ‘uit’ te zetten krijgt een cel een specifieke functie zoals 
het opruimen van bacteriën. Het proces om te kijken welke genen ‘aan’ of ‘uit’ 
staan wordt ‘genomica’ of ‘genomics’ genoemd. We kunnen op verschillende 
manieren kijken of genen aan of uit staan. Vroeger keken onderzoekers naar 
één enkel gen, tegenwoordig worden duizenden genen bestudeerd, b.v. met de 
microarray techniek. 
 
Genen kunnen in de cel worden vertaald tot eiwitten zoals antilichamen of 
sleutelmoleculen (zoals cytokinen) die een belangrijke rol spelen in de afweer 
tegen infecties, of in processen zoals ontstekingen. De studie naar de codering 
van het DNA zelf, dus Welke genen liggen waar op het genoom?, Wat is de 
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variatie in genen?, Waarin verschillen ze?, en Wat is de functie?, wordt 
‘genetica’ of ‘genetics’ genoemd. Ons uitgangspunt is dat het bestuderen van de 
afweer tegen kinkhoest met nieuwe technieken zoals genetics en genomics, 
nieuwe inzichten kan geven in het ziekteproces. Daarbij proberen we vragen te 
beantwoorden als: spelen genetische verschillen een rol bij het verschillende 
verloop van de ziekte? Kunnen we de daarvoor verantwoordelijke genen in kaart 
brengen en begrijpen we hoe deze het infectieproces kunnen beïnvloeden? En 
Kunnen we de verkregen inzichten ook toepassen, bijvoorbeeld in 
vaccinonderzoek? 
 
Deze nieuwe inzichten kunnen leiden tot een verbeterde behandeling of 
preventie van kinkhoest.  
 
In hoofdstuk 2 beschrijven we de identificatie van 3 nieuwe gevoeligheidsregio’s 
(loci). Een gevoeligheidsregio, is een stukje op het genoom dat tussen 
verschillende individuën in verschillende vormen voor kan komen. Individuën 
met de éne vorm kunnen vatbaarder zijn voor een ziekte dan individuën met 
een andere vorm. De regio’s (loci) die we hebben geïdentificeerd, hebben we 
Bordetella pertussis susceptibility loci-1, -2 and -3 (Bps-1, Bps-2 en Bps-3) 
genoemd. Deze loci zijn in kaart gebracht door speciale stammen laboratorium-
muizen (recombinant congene muizen)  waarvan het erfelijk materiaal bekend 
is, en die onderling een klein beetje genetisch verschillend zijn, te infecteren 
met exact hetzelfde aantal kinkhoest bacteriën. Een week na deze infectie is het 
aantal bacteriën in de long geteld als maat voor de ernst van de ziekte. Een 
gevoelige muis heeft meer bacteriën in de long vergeleken met een resistente 
muis.  Vervolgens is m.b.v. een statistisch model de relatie berekend tussen de 
genetische verschillen van deze muizen en het aantal bacteriën in de long. Met 
andere woorden, we hebben onderzocht welke genetische regio’s een rol spelen 
bij het verloop van infectie. Uit deze berekeningen bleek dat Bps-1, -2 en -3 
significant gecorreleerd zijn met de ernst van de ziekte. Deze correlatie was het 
meest duidelijk voor Bps-1. Zo’n gevoeligheidsregio is enkele miljoenen basen 
groot en er zitten honderden genen in. Om te bepalen welke van deze genen nu 
het verantwoordelijke ‘gevoeligheidsgen’ is, zijn vervolgstudies nodig. Een 
vervolgstudie is beschreven in hoofdstuk 4. 
  
Hoofdstuk 3 gaat over de gastheer genomics van kinkhoest.  Met deze studie 
wilden we laten zien wat er in een muizenlong gebeurt op gen-niveau nadat 
deze muis geïnfecteerd is met kinkhoest. Zoals hierboven beschreven is, kan 
een gen ‘aan’ of ‘uit’ staan in verschillende celtypes. Dit proces van aan en uit 
gaan verandert continu, omdat de functie van een cel kan veranderen, en zo  
Nederlandse Samenvatting 
 
 
 
241 
kan reageren op de omgeving. Het totaal aantal genen dat ‘aan’ of ‘uit’ staat in 
een bepaalde situatie wordt ‘expressieprofiel’ genoemd. Door het 
expressieprofiel van een cel of weefsel te vergelijken voor en na een infectie met 
kinkhoest, kunnen we die genen analyseren welke beïnvloed (gereguleerd) 
worden door een kinkhoest-infectie. In dit hoofdstuk hebben we muizen met 
kinkhoest geïnfecteerd en hebben we het expressieprofiel in de long bepaald 
vóór en één, drie en vijf dagen na de infectie. 1.841 Genen hebben een 
significant veranderde expressie vertoond na een kinkhoest-infectie. Met andere 
woorden, bijna 2.000 genen worden beïnvloed door infectie. 1.182 Genen 
gingen ‘aan’ (up-gereguleerd) en 659 genen gingen ‘uit’ (down-gereguleerd). De 
up-gereguleerde genen waren met name immunologische genen welke 
betrokken zijn bij de afweer tegen de bacterie, terwijl de down-gereguleerde 
genen vooral betrokken zijn bij niet-immunologische processen zoals 
ontwikkeling van de cel of spiercontractie. Van de 1.841 genen blijken er 9 in de 
gevoeligheidsregio Bps-1 te liggen,13 in Bps-2 en 62 in Bps-3.  
 
In hoofdstuk 4 wordt de in hoofdstuk 2 beschreven gevoeligheidsregio Bps-1 
beter beschreven met behulp van genomics technieken. Bps-1 is een grote regio 
waar 192 verschillende genen in liggen. In dit hoofdstuk willen we inzoomen in 
deze grote regio, en zo 1 of meerdere kandidaat gevoeligheidsgenen 
identificeren. Dit doen we door het expressieprofiel van de 2 muizenstammen 
waarmee we Bps-1 in kaart hebben gebracht met elkaar te vergelijken. 
Muizenstam 1 (C3H) heeft een andere variant van Bps-1 dan muizenstam 2 
(HcB). Door de expressieprofielen met elkaar te vergelijken (dus, welke genen 
binnen Bps-1 komen anders tot expressie in C3H muizen vergeleken met HcB 
muizen) kunnen we de functie van deze genen bestuderen, en wellicht een of 
meerdere kandidaat gevoeligheidsgenen aanwijzen. We hebben in totaal 206 
genen gevonden die verschillend tot expressie komen tussen de 2 
muizenstammen. 17 Hiervan liggen in de Bps-1 regio. 8 Hiervan clusteren 
samen op het immunoglobulin heavy chain complex (Igh). Dit Igh complex 
codeert voor verschillende vormen van een specifiek antilichaam IgG2a of 
IgG2c. Igh lijkt een voor de hand liggende kandidaat als gevoeligheidsgen 
binnen het Bps-1 locus.  
 
De afweer tegen micro-organismen zoals kinkhoest, wordt op verschillende 
manieren geïnitieerd. Één van de manieren is de niet-specifieke (innate) 
immuun respons. Activatie van immuuncellen van deze respons is een 
belangrijke eerste stap. Deze activatie vindt plaats door herkenning van 
structuren van micro-organismen (zoals bijvoorbeeld een membraanmolecuul  
van bacteriën zoals LPS) Herkenning van deze structuren gebeurt door 
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receptoren op de immuuncellen. Één van deze receptoren is de Toll-like receptor 
4 (Tlr4). Tlr4 is de receptor voor lipopolysaccharide (LPS), één van de 
componenten van de membraanstructuur van gram-negatieve bacteriën zoals 
Bordetella pertussis. Tlr4 bevindt zich op de membraan van cellen welke B. 
pertussis kunnen detecteren. In hoofdstuk 5 laten we zien dat Tlr4 een 
belangrijke rol speelt in het verloop van de infectie. Door muizen te infecteren 
die een defect hebben in Tlr4, en deze te vergelijken met muizen die een intact 
Tlr4 hebben, hebben we de functies van Tlr4 in kaart kunnen brengen. Muizen 
met een defect in Tlr4 blijken de bacterie slechter te kunnen klaren uit de long, 
hebben een hoger longgewicht (meer vocht in de long: ernstiger 
longontsteking), vallen meer af en hebben een vertraagde ontstekingsreactie, 
vergeleken met muizen welke een intact Tlr4 hebben.  
 
In Nederland wordt er sinds 1952 gevaccineerd tegen kinkhoest, dankzij deze 
vaccinatie sterven er bijna geen kinderen meer in Nederland door een 
kinkhoest-infectie. In de laatste decennia is er wel een stijging waargenomen in 
het aantal kinkhoestpatiënten. Door te onderzoeken hoe individuen reageren op 
vaccinatie, en waarom sommige individuen anders reageren op een vaccinatie, 
kan meer inzicht verkregen worden in de werking van het vaccin. Kennis die 
wellicht kan bijdragen aan de ontwikkeling van een beter vaccin, zodat het 
aantal kinkhoestpatiënten afneemt.   
In hoofdstuk 6 en hoofdstuk 7 wordt beschreven dat Tlr4 niet alleen een rol 
speelt in het verloop van de infectie met  B. pertussis, maar dat Tlr4 ook een 
belangrijke rol speelt in de respons op vaccinatie tegen kinkhoest. In hoofdstuk 
6 wordt dit voor muizen aangetoond, in hoofdstuk 7 voor mensen. In hoofdstuk 
6 zijn wederom muizen met elkaar vergeleken die een intacte of defecte Tlr4 
hebben. Deze muizen zijn gevaccineerd met whole-cell pertussis vaccin (wP)  of 
accelulair pertussis vaccin (aP). Whole-cell pertussis vaccin, het vaccin dat in 
Nederland van 1952 – 2005 aangeboden werd, bestaat uit hele gedode 
bacteriën. Hierdoor is de opgewekte imuunrespons gericht tegen de complete 
bacterie. Nadeel van dit vaccin is dat membraancomponenten zoals LPS meer 
bijwerkingen kunnen geven zoals koorts. Vanwege de grotere kans op 
bijwerkingen van het wP wordt in Nederland sinds begin 2005 het acellulair 
pertussis vaccin aangeboden. Dit vaccin bestaat uit 3-5 gezuiverde eiwitten die 
ook in de bacterie voorkomen. Hoewel de imuunrespons die wordt opgewekt 
tegen aP minder breed is, is de opgewekte bescherming goed, en zijn de 
bijwerkingen minder groot. Muizen met een defect in Tlr4 hebben over het 
algemeen een minder goed opgebouwde of vertraagde bescherming tegen 
kinkhoest. Tlr4 blijkt een belangrijke rol te hebben in het opwekken van een 
cellulaire immuun-respons, terwijl de antistoffen die opgewekt worden 
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vergelijkbaar zijn. Tlr4 speelt een belangrijke rol in de effectiviteit van de 
vaccinatie tegen kinkhoest. 
 
In hoofdstuk 7 hebben we onderzocht of  Tlr4 niet alleen in muizen, maar ook bij 
kinderen een belangrijke rol speelt. De hoogte van de antilichaamrespons na 
vaccinatie correleert met de mate van bescherming tegen de ziekte. De 
antilichaamrespons van 515 kinderen is gemeten 1 maand na de 4e vaccinatie. 
De hoeveelheid opgewekte antistoffen zijn vergeleken met verschillende 
genetische varianten van TLR4. Kinderen met een z.g. minor allel (de genetische 
variant die het minst voorkomt) van één van de variaties in TLR4, lijken vaker 
een lagere antistof titer te hebben. Hoewel deze kinderen nog steeds beschermd 
zijn, kan het zijn dat deze kinderen een sneller antilichaam-verval hebben. In 
vervolgstudies zal onderzocht moeten worden wat de rol van TLR4 is langer na 
de vaccinatie en of TLR4 ook een rol speelt in de infectie zelf bij kinderen.   
Toll-like receptor 4 speelt dus een belangrijke rol in zowel de respons na een 
kinkhoest infectie, als in de respons na vaccinatie tegen kinkhoest. De vraag is 
hoe we deze kennis kunnen gebruiken om te komen tot een verbeterde 
behandeling of preventie van kinkhoest. Een voorbeeld hiervan is 
gedemonstreerd in hoofdstuk 8. In dit hoofdstuk wordt beschreven dat het door 
Tlr4 gedetecteerde lipopolysaccharide (LPS) niet alleen ongewenste bijwerkingen 
heeft indien dit aanwezig is in een vaccin, maar dat het ook een versterkende 
werking heeft op de geïnduceerde bescherming tegen zowel de 
kinkhoestbacterie zelf als ook tegen andere bacteriën in het zelfde vaccin 
(difterie, tetanus en rode hond). In hoofdstuk 8 wordt een gedeelte van LPS (het 
niet toxische deel) toegevoegd aan het acelullaire pertussis vaccin. Muizen die 
gevaccineerd zijn tegen kinkhoest, met het toegevoegde LPS-analoog hebben 
minder bacteriën in de long (en zijn dus beter beschermd) en vertonen minder 
bijwerkingen. Het toevoegen van een LPS-analoog aan bestaande pertussis 
vaccins werkt dus via Tlr4, en lijkt een goede manier te zijn voor de verbetering 
van het pertussis vaccin.  
 
Samengevat onderzoekt dit proefschrift de rol van de gastheer en genetische 
verschillen tussen gastheren in het verloop van de ziekte kinkhoest. Het laat 
zien dat deze factoren ook een rol kunnen spelen in de vaccinatierespons. 
Fundamentele genetische studies beginnen vaak in proefdiermodellen (zoals de 
muis) en het is niet altijd eenvoudig om de gevonden resultaten te extrapoleren 
naar de mens. Wij laten zien dat Tlr4 niet alleen een rol speelt in de 
vaccinatierespons bij muizen, maar ook bij mensen. Deze kennis kan bijdragen 
in de ontwikkeling van een verbeterd kinkhoest vaccin, b.v. door de toevoeging 
van LPS-analogen aan bestaande vaccins.  
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Dankwoord 
 
Zo… het bier voor het promotiefeestje staat te gisten, mooie tijd om te beginnen 
aan het laatste hoofdstuk. Het hoofdstuk dat iedereen altijd als eerste leest… 
‘sta ik er wel in?’ Het is dus ook het hoofdstuk dat lastig is om te schrijven.. ‘ik 
zal toch niemand vergeten?’  
Sinds ik in september 1998 als stagiair het RIVM binnen kwam heb ik veel 
acroniemen achter mijn naam gehad… LIO, LTR, LEO, TOX, LIS. IMD, IMG… het 
wordt lastig om iedereen met naam en toenaam te noemen, maar ik ga toch een 
poging doen:  
Allereerst Tjeerd: Als ik terug denk aan hoeveel vertrouwen je altijd in me hebt 
gehad en wat je allemaal voor mij hebt gedaan, word ik best een beetje stil. 
Vanaf dag 1 (voorjaar 1999) heb je me veel verantwoording en zelfstandigheid 
geboden waardoor ik me heb kunnen ontplooien tot onderzoeker. Er zullen 
weinig AIO’s zijn die kunnen zeggen dat zijn/haar co-promotor elk manuscript 
binnen een week heeft nagekeken (soms zelfs binnen een dag!). Ik vond de 
samenwerking erg prettig, en heb met veel plezier ruim 8 jaar met je gewerkt!  
Rob: Officieel hebben we geloof ik geen enkel project samen gedaan, maar even 
een korte opsomming van de dingen die we afgelopen jaren wel samen hebben 
gedaan: Vele dierproeven tot een goed einde gebracht, 3 stagiairs begeleid, tal 
van experimenten uitgevoerd (we hebben samen heel wat miltjes geprakt), 6 
papers geschreven, 3 congressen bezocht en uren, vele uren (zowel op het RIVM 
als op het terras) over van alles gesproken, Bordetella, TLr4, Immunologie, 
maar natuurlijk ook luchtiger zaken… Rob, ik heb erg veel van je geleerd, en ik 
kijk met veel plezier terug op onze vruchtbare samenwerking.  
Ronald: Hoewel je pas in de laatste fase bij mijn promotie betrokken bent 
geweest en we elkaar weinig hebben gesproken, wil ik je bedanken voor het 
vertrouwen dat je in mijn werk hebt uitgesproken.  
Henk: Oorspronkelijk was er voor jou een veel prominentere rol in dit boekje 
gepland, maar helaas is het er door omstandigheden niet van gekomen. Bedankt 
voor het storten van de moleculaire fundering: ik heb veel van je geleerd. 
Verder vond ik het wekelijkse ICT-uurtje altijd erg gezellig.  
Frits, jammer dat je er 5 juni niet bij kan zijn, bedankt voor de leuke discussies, 
en al het werk dat ik op ‘jouw’ lab mocht doen. Han, Kees en Marjolein bedankt 
voor de afleiding  tijdens het longen prakken op het kinkhoest lab! 
Barbara, toen jij projectleider werd van het kinkhoestproject kwam het ineens in 
een sneltreinvaart. Mede door jouw kritische blik hebben we zoveel mogelijk een 
rechte lijn gehouden in het project en hebben we de doodlopende steegjes links 
laten liggen.  
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Peter Demant bedankt voor het meedenken met de muizenstudies, en bedankt 
voor al die muizen! Nico Nagelkerke, bedankt voor de uren statistiek, je wist me 
altijd te boeien, en je maakte de getallen weer levend.  
 
En dan mijn paranimfen: Mirjam, als de aquarioten die ’s ochtends altijd als 
eerste binnen waren, hebben we heel wat weekeind-voor-en-nabesprekingen 
gehad, en dat schept toch een band…. Leuk dat je mijn paranimf wilt zijn! 
Ewoud: Ik begrijp dat jij, na jouw eerste microbiologische ervaring (toen je mij 
eens kwam helpen op het kinkhoest lab), je volledig op het kankeronderzoek 
hebt gestort ! We hebben altijd veel gelachen en ik vind het leuk dat je mijn 
paranimf wilt zijn.  
Dan de overige aquarioten: Ed, Anuska, Petra, Wendy… erg leuk dat we na het 
uiteenvallen van ons clubje nog zo intensief contact hebben gehouden (ik denk 
dat we een gemeenschappelijk pepernoten trauma hebben)…Ik vond het een 
hele gezellige tijd met z’n 7-en op het aquarium! Sorry voor alle (a)mee-zing 
acties tijdens het werk.  
 
En de oud- en nieuw- aquariumbewoners Joost en Kris… Kris, leuk dat ik de 
promotieplechtigheid bij jou  alvast van dichtbij mocht meemaken.. en je 
paranimf mocht zijn. Joost bedankt voor het overnemen van de vrimima.  
En ik mag natuurlijk niet de hardwerkende stagiairs vergeten, die heel wat 
hoofdstukken van dit boekje bij elkaar gepipetteerd hebben: Marina, Hesther, 
Henke en Jihane; bedankt voor jullie inzet!  
Antoon, Hoewel ik me in die 8 jaar niet echt als ‘gast’ heb gedragen, wil ik je 
hartelijk danken voor de ‘gastvrijheid’.  
Gerard bedankt voor de ruimte en rust die je me hebt geboden om rustig het 
onderzoek af te ronden en te zoeken naar een nieuwe baan.  
Verder wil ik graag alle LEO/TOX-ers, LIO/LTR/LIS-ers bedanken voor de 
gezellige tijd, het assisteren bij grootschalige dierproeven, een kletsje op de 
gang, gezellige lunches etc.  
 
Alle colega’s van het CDF (Henk, Diana, Hans, Piet, Dirk, Christine) bedankt voor 
het meedenken en assisteren bij alle dierproeven, en voor het verzorgen van de 
muizen.  
 
Het welkom in mei bij IMD/IMG was allerhartelijkst… en dankzij de gezellige club 
collega’s ben ik me snel gaan thuis voelen. Jan, Marcel & Sally bedankt dat jullie 
me alle ruimte hebben geboden om mijn proefschrift rustig af te schrijven. 
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Werken op 3 afdelingen, betekent ook ondersteuning van 3 secretariaten. Nel, 
Carola, Willy, Marion, Janet, Ricky en Francien… in een woord “SUPER!”. 
 
Zo… met een biertje naast het toetsenbord op 10.000m hoogte boven de grote 
plas gaat het best goed zo’n dankwoord schrijven, ik ben zelfs aangekomen bij 
de allerbelangrijkste bron van kracht en inspiratie: Mijn familie en vrienden. 
Rieks en Mirjam, hoewel jullie altijd bang waren voor mijn zesjes-mentaliteit, 
hoop ik dat ik nu een keer wat anders heb laten zien. bedankt voor jullie 
onaflatende steun. Rieks, hopelijk zullen we samen nog veel biertjes brouwen in 
onze brouwerij QuattuorB… ik vind het altijd ‘oergezellig’. Caroline, dat kan geen 
toeval zijn dat je bijna ‘boven’  de feestlocatie woont….. kan ik blijven slapen??  
Joop en Lien bedankt voor alle steun en vertrouwen, bedankt voor alle oppas-
momenten zodat ik kon doorwerken aan dit boekje. 
 
Mijn sport- en mental coach Gert.. het wordt tijd dat we weer een balletje gaan 
slaan (en er daarna een biertje op drinken) … misschien dat we over 1,5 maand 
een avondje kunnen plannen?  
 
Verder wil ik graag alle vrienden bedanken voor de gezellige avonden en 
etentjes ! Komen jullie op mijn feestje? 
 
En dan tot slot: Lieve Dineke, bedankt dat je er altijd voor me bent, je bent mijn 
alles! Hopelijk kan ik jou de komende 4 jaar ook zo goed steunen. Ik besef nu 
dat met een baby en een kleuter op schoot, die doorgaans ‘kille’ 
epidemiologische cijfers ineens veel meer impact hebben. Lieve Anne en Chris… 
tegen de tijd dat jullie dit kunnen lezen zullen jullie ineens snappen dat ‘die 
hoestende muizen’ misschien wel nooit echt ‘beter’ zijn geworden. Hopelijk 
zullen jullie dan toch  snappen dat deze studie wellicht ooit hoestende kindjes 
kan helpen. Pappa heeft hierover een boekje geschreven, en dat is nu af. 
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